Fact-checked by Grok 2 weeks ago

Mental disorder

A mental disorder is a syndrome characterized by clinically significant disturbance in an individual's cognition, emotion regulation, or behavior that reflects a dysfunction in the psychological, biological, or developmental processes underlying mental function, typically associated with distress or disability in social, occupational, or other key activities.^[1] These conditions encompass diverse categories, including anxiety disorders, mood disorders, psychotic disorders, and neurodevelopmental disorders, classified primarily through symptom-based criteria in manuals such as the DSM-5-TR or ICD-11, though diagnostic reliability varies and lacks objective biomarkers for most.^[2] Globally, mental disorders affect over one billion people, representing about one in seven individuals, and constitute a leading cause of disability, with prevalence rising in recent decades amid debates over diagnostic expansion.^[3]^[4] The etiology of mental disorders involves multifactorial interactions between genetic vulnerabilities, neurobiological alterations (such as neurotransmitter imbalances or structural brain changes), and environmental stressors, including trauma, socioeconomic adversity, and substance exposure, rather than singular causes.^[5]^[6] Twin and adoption studies indicate heritability estimates ranging from 30-80% for conditions like schizophrenia or bipolar disorder, yet environmental triggers often determine expression, underscoring causal complexity over deterministic models.^[7] Empirical data reveal high comorbidity across disorders, challenging discrete categorical diagnoses and suggesting underlying dimensional traits like neuroticism or impulsivity.00395-3/fulltext) Historically, treatments evolved from institutionalization and rudimentary interventions like insulin shock therapy to pharmacotherapy, psychotherapy, and electroconvulsive therapy, with evidence supporting efficacy for severe cases but modest effect sizes for milder ones.^[8] Controversies persist regarding the biomedical framing of mental disorders as analogous to physical illnesses, with critics like Thomas Szasz contending that many represent "problems in living" or value judgments rather than verifiable pathologies, potentially enabling coercive psychiatry and undermining personal agency.^[9] Recent analyses highlight overdiagnosis risks, particularly for depression, ADHD, and bipolar spectrum conditions, driven by lowered thresholds, pharmaceutical influences, and cultural shifts toward pathologizing normal distress, leading to unnecessary labeling and interventions.^[10]^[11] Such issues, compounded by institutional biases in research favoring medicalization, call for rigorous, replicated evidence in refining diagnostic paradigms.01692-6/fulltext)

Definition

Biological and Neurological Foundations

Mental disorders exhibit substantial genetic underpinnings, as evidenced by twin and family studies estimating heritability at approximately 80% for schizophrenia and bipolar disorder, 40-50% for major depressive disorder, and up to 83% for autism spectrum disorders.^[12]^[13]^[14] These figures derive from comparisons of monozygotic and dizygotic twins, where concordance rates for monozygotic pairs significantly exceed those for dizygotic pairs, indicating a predominant genetic influence over shared environment alone.^[13] Genome-wide association studies further identify polygenic risk scores involving thousands of common variants, often in genes regulating synaptic plasticity, ion channels, and neurotransmitter receptors such as those for dopamine and serotonin.^[15] However, these genetic factors interact with environmental triggers, and no single gene accounts for disorder risk, underscoring a multifactorial etiology.^[15] Neurological evidence from structural and functional neuroimaging reinforces these foundations, revealing consistent brain alterations across disorders. In schizophrenia, magnetic resonance imaging (MRI) studies show reduced gray matter volume, cortical thinning, enlarged ventricles, and disrupted white matter integrity, with accelerated gray matter loss progressing over time.^[16]^[17] Functional MRI (fMRI) demonstrates aberrant connectivity in default mode and salience networks, correlating with positive and negative symptoms.^[16] For mood disorders like depression, fMRI indicates hypoactivity in the prefrontal cortex and hyperactivity in the amygdala, reflecting impaired emotion regulation circuits.^[18] Bipolar disorder similarly involves volumetric reductions in the hippocampus and prefrontal regions, alongside fluctuating activation patterns during manic and depressive episodes.^[18] These findings, replicated across large cohorts, suggest underlying neurodevelopmental disruptions rather than mere consequences of illness chronicity, though effect sizes remain moderate and overlap with subclinical traits.^[19] Neurotransmitter systems provide mechanistic links between genetics, brain structure, and symptomatology. Dopamine dysregulation, particularly hyperactivity in mesolimbic pathways, contributes to psychotic symptoms in schizophrenia, as supported by pharmacological evidence from antipsychotics blocking D2 receptors.^[20] Serotonin imbalances, often deficits in serotonergic transmission, associate with mood dysregulation in depression and anxiety, influencing circuits modulating affect and impulsivity.^[21] GABAergic inhibition deficits, evidenced by reduced GABA receptor density and interneuron dysfunction, underlie excitatory-inhibitory imbalances in disorders like schizophrenia and autism, exacerbating cognitive and sensory processing impairments.^[22] Glutamatergic abnormalities, particularly NMDA receptor hypofunction, further disrupt neural signaling, linking to working memory deficits across multiple conditions.^[23] These imbalances arise from genetic variants affecting synthesis, release, and reuptake, with empirical validation through positron emission tomography (PET) imaging of receptor binding.^[22] Despite therapeutic targeting of these systems yielding partial efficacy, they highlight causal pathways rooted in cellular and circuit-level biology.^[20]

Distinction from Adaptive Behaviors and Physical Illness

Mental disorders are distinguished from adaptive behaviors primarily by their association with clinically significant distress, impairment in social or occupational functioning, or dysfunction in underlying psychological processes, whereas adaptive behaviors promote survival, coping, or valued outcomes in response to environmental demands.^[24] ^[25] For instance, transient anxiety in the face of genuine threats, such as during combat or financial ruin, serves an evolutionary purpose by heightening vigilance and motivating escape or resolution, and thus does not qualify as a disorder unless it persists maladaptively beyond the stressor.^[24] Diagnostic frameworks explicitly exclude expectable cultural or situational responses, such as bereavement-related sadness, from classification as disorders, emphasizing that deviations must reflect intrinsic dysfunction rather than normative adjustments.^[26] This boundary is not always sharp, as behaviors initially adaptive—such as hypervigilance in trauma survivors—may become maladaptive when they generalize inappropriately, leading to avoidance that hinders daily life.^[27] In contrast to physical illnesses, which typically involve verifiable pathological lesions, infections, or physiological derangements identifiable through objective tests like blood assays or imaging, mental disorders are diagnosed syndromally based on observable behavioral, cognitive, or emotional patterns without routine biomarkers confirming etiology.^[28] ^[29] While some correlates exist, such as elevated inflammatory markers like C-reactive protein in subsets of patients with depression or schizophrenia, these lack diagnostic specificity and are not used clinically to confirm disorders, unlike glucose levels for diabetes or bacterial cultures for pneumonia.^[30] ^[31] This reliance on subjective reports and interrater judgment has prompted critiques, notably from Thomas Szasz, who argued in 1960 that labeling interpersonal or ethical conflicts as "mental illnesses" misleadingly equates them with bodily diseases, absent demonstrable brain pathology, framing them instead as problems in living amenable to social negotiation rather than medical intervention.^[32] ^[33] Empirical challenges persist: despite decades of research, no peripheral biomarkers achieve the sensitivity and validity needed for routine psychiatric diagnosis, underscoring a fundamental asymmetry with somatic medicine where etiology often guides classification.^[34] ^[35]

Conceptual Challenges and Harm-Based Criteria

Defining mental disorder encounters significant conceptual difficulties, primarily stemming from the lack of objective biological tests comparable to those in physical medicine, resulting in diagnoses based largely on observed behaviors and self-reports that may reflect cultural or situational norms rather than inherent pathology.^[36] Psychiatrist Thomas Szasz contended in his 1961 book The Myth of Mental Illness that psychiatric conditions represent metaphorical extensions of medical language to describe unwanted behaviors or "problems in living," devoid of the verifiable tissue damage or physiological dysfunction found in somatic diseases.^[9] This perspective highlights challenges in demarcating disorders from adaptive responses to adversity or moral conflicts, as evidenced by historical shifts in diagnostic criteria that have pathologized nonconformity, such as homosexuality's removal from the DSM in 1973 after value-based debates rather than new empirical data.^[37] A influential harm-based approach to resolving these issues is Jerome Wakefield's harmful dysfunction (HD) analysis, proposed in 1992, which defines a mental disorder as a condition involving both a failure of some internal psychological mechanism to perform its natural (evolutionary) function and a harm or negative value judgment imposed by the individual's culture or society.^[38] Under HD, mere statistical rarity or deviance does not suffice; for instance, bereavement following loss might cause distress without constituting dysfunction if mechanisms operate as designed evolutionarily.^[39] This dual criterion aims to ground psychiatry in naturalistic facts (dysfunction) while acknowledging evaluative elements (harm), distinguishing it from purely normative or statistical models.^[40] Criticisms of harm-based criteria emphasize their vulnerability to subjective interpretation, where "harm" risks incorporating cultural biases, potentially medicalizing benign variations or excluding conditions causing societal harm without clear internal failure, such as certain personality traits enabling exploitation.^[41] Empirical studies reveal inconsistent application, as lay judgments of disorder prioritize distress and impairment but overlook functional adaptations, complicating operationalization in diagnostic manuals like the DSM-5, which retains a distress-or-disability clause yet faces reliability issues in borderline cases.^[42] Proponents counter that omitting harm would equate any dysfunction—such as suboptimal vision—with disorder absent impairment, diluting medical specificity, though detractors argue for dysfunction-alone models to prioritize causal mechanisms over value-laden outcomes.^[43] These debates underscore ongoing tensions between empirical validation and normative influences in psychiatric nosology.^[44]

Classification Systems

Categorical Frameworks: DSM-5 and ICD-11

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), published by the American Psychiatric Association on May 22, 2013, establishes a categorical framework for classifying mental disorders through discrete diagnostic categories based on clusters of symptoms, impairment, and exclusion criteria.^[45] Disorders are grouped into 20 major sections, including neurodevelopmental disorders, schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, depressive disorders, anxiety disorders, and personality disorders, with diagnoses requiring that a specified number of symptoms from a checklist be met within defined time frames to distinguish pathological conditions from normal variations.^[46] This polythetic approach—allowing multiple symptom combinations to qualify—facilitates standardized clinical assessment, insurance reimbursement, and research but presumes clear boundaries between disorders and health.^[2] A text revision (DSM-5-TR) followed in March 2022, incorporating updated scientific literature, revised diagnostic criteria for select conditions, and expanded cultural considerations without altering the core categorical structure.^[2] The International Classification of Diseases, Eleventh Revision (ICD-11), endorsed by the World Health Assembly on May 25, 2019, and effective globally from January 1, 2022, features a dedicated chapter on mental, behavioural, or neurodevelopmental disorders that similarly adopts a categorical model but emphasizes prototypical descriptions over rigid checklists to enhance clinical utility across diverse settings.^[47]^[48] Key groupings encompass neurodevelopmental disorders, schizophrenia or other primary psychotic disorders, mood disorders, anxiety or fear-related disorders, obsessive-compulsive or related disorders, disorders specifically associated with stress, dissociative disorders, feeding or eating disorders, disorders of bodily distress or bodily experience, and disorders due to substance use or addictive behaviours, with diagnoses hinging on essential features causing distress or impairment while permitting cultural adaptations.^[49] ICD-11 streamlines categories—such as merging some personality disorders into a single "personality disorder" severity gradient with trait qualifiers—prioritizing simplicity for non-specialist use in primary care and global health statistics over DSM-5's granularity.^[50] While both frameworks promote categorical diagnoses to enable reliable identification and cross-system communication, DSM-5 offers more detailed, symptom-count-based criteria tailored to psychiatric expertise, whereas ICD-11 provides broader guidelines for international harmonization and public health applications, resulting in divergences like DSM-5's inclusion of disruptive mood dysregulation disorder (classified under oppositional defiant disorder in ICD-11) or differing thresholds for conditions such as prolonged grief.^[51] These systems underpin clinical practice worldwide—DSM-5 predominantly in the U.S. and ICD-11 as the WHO standard—yet their categorical nature assumes disorder boundaries verifiable by observable signs, a premise reliant on expert consensus amid ongoing empirical validation through field trials and longitudinal studies.^[52]

Criticisms of Reliability and Validity

The reliability of diagnoses in categorical systems like the DSM-5 remains a persistent concern, as evidenced by field trials conducted from 2009 to 2012 across clinical settings in the United States and Canada, which assessed inter-rater agreement using kappa statistics.^[53] Of the 23 disorders evaluated, only five achieved very good reliability (kappa 0.60–0.79), such as major depressive disorder at 0.75 and schizophrenia spectrum disorders around 0.70–0.78; nine fell in the good range (0.40–0.59); six were questionable (0.20–0.39), including borderline personality disorder at 0.39; and three were unacceptable (<0.20), notably complex somatic symptom disorder at 0.03 and mixed anxiety-depressive disorder at 0.19.^[54] These results indicate moderate agreement at best for many conditions, with critics arguing that kappas below 0.6 reflect insufficient consistency for guiding treatment or policy, far short of the high reliability seen in physical medicine diagnoses like myocardial infarction, where agreement often exceeds 0.8.^[55]^[56] Efforts to enhance reliability through operationalized criteria since DSM-III have yielded mixed outcomes, with personality disorders consistently showing low inter-rater agreement (kappas often 0.2–0.4) due to subjective interpretation of traits and behaviors.^[57] Allen Frances, chair of the DSM-IV task force, criticized the DSM-5 for accepting reliability thresholds as low as 0.2–0.4—barely above chance—as "acceptable," attributing this to methodological adjustments rather than true diagnostic stability, which risks inconsistent application in real-world settings.^[58] For the ICD-11, developmental field studies reported adequate inter-rater reliability for select disorders like depressive episode (kappa around 0.6–0.7), but overall consistency varies, with complex cases like personality disorders showing persistent variability across raters and cultures.^[59] These limitations stem partly from reliance on self-reported symptoms without objective biomarkers, amplifying observer bias and contextual influences. Validity critiques center on the syndromal nature of classifications, which group heterogeneous symptoms without establishing causal mechanisms, predictive power, or distinct biological correlates.^[60] Thomas Insel, then-director of the National Institute of Mental Health, highlighted in 2013 that DSM-5's core weakness lies in its invalidity, as categories represent consensus symptom clusters rather than validated etiologies, prompting NIMH to pivot toward research domain criteria (RDoC) focused on neural circuits and genetics over DSM constructs.^[61] High comorbidity rates further erode validity; for example, up to 58.7% of patients with five or more clinically significant symptoms fail to align neatly with any single DSM-5 disorder, while common overlaps like depression with anxiety disorders affect over 50% of cases, suggesting artificial boundaries rather than discrete entities.^[62]^[63] Frances warned that DSM-5 expansions, such as broadened autism spectrum criteria and attenuated psychosis thresholds, inflate prevalence without improving validity, exacerbating false positives and overmedicalization based on weak empirical support.^[64] ICD-11 addresses some issues by simplifying categories and emphasizing essential features over rigid symptom counts, yet it inherits similar validity gaps, including untested new entities and uncertain construct validity for core diagnoses like schizophrenia, where symptom profiles overlap substantially with other psychoses.^[65]^[66] Critics contend that both systems prioritize administrative utility and pharmaceutical alignment over etiological rigor, with institutional defenders like the American Psychiatric Association downplaying flaws amid evidence of diagnostic heterogeneity and poor separation of clinical profiles.^[67]^[68] This has fueled calls for dimensional alternatives, as categorical models fail to capture the continuous, multifaceted reality of mental distress grounded in empirical neuroscience.

Alternative Models: Dimensional, Transdiagnostic, and RDoC

Dimensional models conceptualize mental disorders as points along continuous spectra of psychological traits or symptom severity, rather than discrete categories. This approach posits that individual differences in psychopathology exist on gradients, such as varying levels of internalizing (e.g., anxiety, depression) or externalizing (e.g., impulsivity, aggression) tendencies, supported by factor analytic studies of symptom covariation across populations.^[69] For instance, the Hierarchical Taxonomy of Psychopathology (HiTOP) framework organizes disorders into spectra based on empirical data from large-scale assessments, revealing that traditional diagnostic boundaries often fail to capture subthreshold or comorbid presentations.^[70] Evidence from twin and genetic studies indicates higher heritability for dimensional traits than categorical diagnoses, suggesting a more biologically plausible structure, though challenges persist in establishing clinical thresholds for intervention.^[71] Transdiagnostic models emphasize shared etiological and maintenance processes across ostensibly distinct disorders, such as cognitive biases like rumination or avoidance behaviors that underpin both anxiety and mood disorders. This perspective arises from observations of high diagnostic instability and overlap in longitudinal studies, where patients frequently migrate between categories without corresponding changes in underlying mechanisms.^[72] Meta-analyses of transdiagnostic cognitive-behavioral therapies, which target these common factors, demonstrate moderate to large effect sizes in reducing symptoms across emotional disorders, outperforming disorder-specific treatments in heterogeneous samples.^[73] ^[74] However, empirical support varies by mechanism; while emotion dysregulation shows robust transdiagnostic links via neuroimaging and self-report data, not all processes (e.g., specific perceptual anomalies) generalize equally, limiting universality claims.^[75] The Research Domain Criteria (RDoC), initiated by the National Institute of Mental Health in 2009, proposes a framework for classifying psychopathology based on observable behavioral and neurobiological dimensions, organized into domains like negative valence systems (fear, loss), positive valence (reward responsiveness), and cognitive systems (attention, memory).^[76] RDoC integrates multi-level data from genetics to self-reports, aiming to identify dysfunctions in neural circuits rather than symptom clusters, with the goal of advancing precision medicine through biomarkers.^[77] Advantages include fostering hypothesis-driven research unencumbered by DSM/ICD assumptions, as evidenced by studies linking RDoC constructs to functional neuroimaging outcomes predictive of treatment response.^[78] Limitations encompass its preclinical focus, lacking validated clinical applications as of 2022, and potential oversight of subjective distress in favor of measurable constructs, with critics noting insufficient integration of social and environmental influences despite empirical calls for expansion.^[79]^[80]

Major Categories of Disorders

Neurodevelopmental Disorders

Neurodevelopmental disorders are characterized by onset during the developmental period, involving impairments in brain maturation that result in deficits across cognitive, social, communicative, behavioral, or motor functions, often evident before school entry and persisting into adulthood.^[81] In the DSM-5, the category encompasses autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), intellectual developmental disorder (IDD), specific learning disorder, communication disorders, developmental coordination disorder, and tic disorders, defined by clinically significant disturbances in personal, family, social, educational, or occupational functioning.^[81] The ICD-11 similarly groups these under neurodevelopmental disorders, emphasizing early-life deviations in neural growth and emphasizing functional impairments over symptom checklists alone.^[50] Prevalence data from U.S. national surveys indicate ADHD affects 8.5% of children aged 3-17 years, ASD 2.9%, and IDD 1.4%, with overall diagnosed developmental disabilities reaching 8.6% in 2021, up from 7.4% in 2019, potentially reflecting improved detection alongside true increases linked to causal factors.^[82]^[83] These rates vary by demographics, with higher ADHD and ASD diagnoses in males and certain ethnic groups, though underdiagnosis persists in underserved populations due to access barriers rather than biological differences alone.^[84] Causal evidence points to genetic factors as primary drivers, with heritability estimates of 80-90% for ASD, 76% for ADHD, and 33-65% for IDD (lower when comorbid with ASD), derived from twin and family studies showing shared polygenic risks across disorders.^[85]^[86]^[87] Environmental contributors, such as prenatal infections, toxin exposures, or advanced parental age, interact with genetic vulnerabilities but account for smaller variance portions, as meta-analyses confirm no single non-genetic factor exceeds modest effect sizes.^[88]^[89] Disruptions in core neurodevelopmental processes—like synaptic pruning, neuronal migration, or circuit formation—underlie these impairments, evidenced by converging findings from neuroimaging and postmortem brain studies.^[90] Diagnostic classification faces reliability issues, including high comorbidity (e.g., 50-70% overlap between ASD and ADHD) and porous boundaries, as categorical models fail to capture dimensional symptom gradients or shared etiologies, prompting calls for transdiagnostic approaches focused on underlying mechanisms over discrete labels.^[81]^[91] Empirical validation remains limited, with inter-rater agreement varying widely (kappa 0.4-0.8 for ASD) and cultural biases inflating diagnoses in high-resource settings without corresponding biological confirmation.^[81] Treatment emphasizes behavioral interventions and, where substantiated, pharmacotherapy for symptoms like ADHD inattention, though long-term efficacy data underscore genetic stability over environmental remediation for core deficits.^[92]

Psychotic Disorders

Psychotic disorders constitute a class of severe mental conditions marked by a detachment from reality, featuring core symptoms including delusions (fixed false beliefs resistant to contrary evidence), hallucinations (perceptual experiences without external stimuli, often auditory), disorganized speech (manifesting as derailment or incoherence), grossly disorganized or catatonic behavior, and negative symptoms such as diminished emotional expression or avolition.^[93]^[94] In the DSM-5 framework, these disorders require at least two of the specified symptoms (with delusions, hallucinations, or disorganized speech mandatory for some subtypes) persisting for a substantial duration—typically one month or more for schizophrenia—alongside social or occupational dysfunction, excluding cases primarily attributable to substances or medical conditions.^[93]^[95] Prominent subtypes within psychotic disorders include schizophrenia, schizoaffective disorder (combining psychosis with mood episodes), delusional disorder (isolated non-bizarre delusions without prominent hallucinations or disorganization), brief psychotic disorder (symptoms lasting one day to one month), schizophreniform disorder (symptoms akin to schizophrenia but shorter duration), and substance- or medication-induced psychotic disorder.^[96]^[97] Schizophrenia, the most studied exemplar, affects roughly 23 million individuals worldwide as of recent estimates, corresponding to a prevalence of approximately 0.3% (1 in 345 people), with lifetime risk around 0.33% to 0.75% in non-institutionalized populations; broader psychotic experiences occur in 4% to 17% of community samples, though not all meet disorder criteria.^[98]^[99]^[100] Etiologically, psychotic disorders arise from multifactorial interactions, with robust genetic contributions evidenced by concordance rates in monozygotic twins (up to 50% for schizophrenia) and adoption studies isolating hereditary effects from environment, yielding heritability estimates often exceeding 80%.^[101] The dopamine hypothesis, originating in the 1960s from observations of antipsychotic efficacy blocking D2 receptors, posits mesolimbic dopamine hyperactivity underlying positive symptoms like hallucinations and delusions, while prefrontal hypodopaminergia may account for negative and cognitive deficits; this model, though influential, remains a hypothesis requiring integration with evidence of glutamatergic and other neurotransmitter dysregulations.^[102]^[103] Environmental risks, including prenatal infections, urban rearing, and cannabis use in vulnerable individuals, interact with genetic liability to precipitate onset, typically in late adolescence or early adulthood.^[98]

Mood Disorders

Mood disorders encompass a group of psychiatric conditions characterized by persistent disturbances in emotional state, manifesting as episodes of severe depression (profound sadness, hopelessness, and loss of interest) or elevated mood (hypomania or mania, involving increased energy, irritability, and impulsivity).^[104] These disorders are primarily classified into depressive disorders, which include major depressive disorder (MDD) requiring at least five symptoms such as depressed mood or anhedonia nearly every day for two weeks, and bipolar and related disorders, featuring alternating depressive and manic/hypomanic episodes.^[105] The DSM-5 and ICD-11 definitions align closely, though ICD-11 permits mixed episodes without specifiers and broadens some bipolar criteria slightly compared to DSM-5.^[65]^[106] Prevalence data indicate mood disorders affect hundreds of millions globally. Lifetime risk for MDD stands at approximately 7.5% for males and 13.6% for females, with 1 in 5 men and 1 in 3 women experiencing major depression over their lifetimes; bipolar disorder affects about 1-2% of the population.^[107]^[108] In 2021, depressive disorders contributed significantly to the 1.1 billion people living with mental disorders worldwide, often comorbid with anxiety.^[26] U.S. annual prevalence for major depressive disorder is around 15.5% among adults with any mental illness.^[109] Etiological factors involve a interplay of genetic heritability, estimated at 40-50% for MDD based on twin studies, and environmental stressors such as trauma, chronic stress, or substance use, which can trigger or exacerbate episodes in vulnerable individuals.^[110]^[111] Neurobiological evidence points to dysregulation in monoamine neurotransmitters (e.g., serotonin, norepinephrine) and hypothalamic-pituitary-adrenal axis hyperactivity during depressive states.^[112] Diagnostic reliability remains challenged by subjective symptom reporting and overlap with other conditions, with inter-rater agreement for MDD at kappa values around 0.6-0.8 in structured assessments, though classifications like DSM-5 have faced critique for insufficiently addressing spectrum continuity between unipolar and bipolar forms.^[113]^[114] Course varies: MDD often recurs episodically, while bipolar disorder shows cyclical patterns with inter-episode recovery in milder cases, but chronicity increases with early onset or untreated mania.^[115] Anxiety disorders are characterized by excessive fear or anxiety that persists beyond adaptive responses, interfering with daily functioning and often involving avoidance behaviors. In the DSM-5 classification, these include separation anxiety disorder, selective mutism, specific phobia, social anxiety disorder, panic disorder, agoraphobia, and generalized anxiety disorder (GAD), among others such as substance/medication-induced anxiety disorder.^[116] Diagnostic criteria typically require symptoms lasting at least six months for GAD—such as excessive worry about multiple domains accompanied by restlessness, fatigue, or concentration difficulties—and marked fear disproportionate to the threat in phobias.^[117] Lifetime prevalence of anxiety disorders in the United States is approximately 33% among adolescents and adults, with social anxiety disorder affecting 13%, GAD 6.2%, and panic disorder 5.2%.^[118]^[119] These conditions show moderate heritability estimates of 30-50%, indicating genetic factors contribute alongside environmental influences like early adversity, though twin studies reveal shared genetic risks across specific anxiety subtypes and with traits like neuroticism.^[120]^[121] Comorbidity is common, particularly with mood disorders, and diagnostic reliability can vary by sex, with potential underreporting in males due to cultural factors affecting symptom endorsement.^[122] Trauma- and stressor-related disorders, distinct in DSM-5, require exposure to actual or threatened death, serious injury, or sexual violence, manifesting as intrusive memories, avoidance, negative alterations in cognition/mood, and hyperarousal. Primary examples include post-traumatic stress disorder (PTSD) and acute stress disorder (ASD), with PTSD requiring symptoms persisting beyond one month and ASD lasting 3 days to one month post-trauma.^[123]^[124] PTSD past-year prevalence in U.S. adults is 3.6%, higher among females (5.2%) than males (1.8%), while ASD prevalence averages 19% among trauma-exposed individuals, varying by trauma type such as combat or assault.^[125]^[126] Heritability for PTSD ranges from 20-40% following trauma exposure, with genetic overlap to anxiety and depression, but not all trauma-exposed individuals develop these disorders, pointing to predisposing vulnerabilities including prior mental health history.^[127]^[128] Criticisms of PTSD diagnosis include concerns over diagnostic validity influenced by subjective recall of trauma and potential inflation from broadened criteria, though empirical data support stressor exposure as a necessary but insufficient causal element.^[122]

Personality Disorders

Personality disorders encompass a group of conditions defined by rigid, pervasive patterns of perceiving, thinking, feeling, and relating to others that deviate significantly from cultural expectations, manifesting across diverse contexts and causing clinically significant distress or impairment in social, occupational, or other areas of functioning.^[129] In the DSM-5, published in 2013, these disorders require evidence of impairments in personality functioning—specifically in self-identity, self-direction, empathy, and intimacy—alongside one or more pathological personality traits that are stable over time and traceable to adolescence or early adulthood. Unlike transient states or axis I disorders, personality disorders reflect enduring traits rather than episodic symptoms, though they frequently comorbid with mood, anxiety, or substance use disorders, complicating differential diagnosis.^[130] The DSM-5 organizes the ten specific personality disorders into three clusters based on descriptive similarities. Cluster A disorders involve odd or eccentric patterns: paranoid personality disorder features pervasive distrust and suspiciousness of others' motives, interpreting actions as malevolent; schizoid personality disorder is marked by detachment from social relationships and a restricted range of emotional expression; and schizotypal personality disorder includes acute discomfort in close relationships, cognitive or perceptual distortions, and eccentric behavior.^[130] Cluster B disorders are characterized by dramatic, emotional, or erratic behaviors: antisocial personality disorder entails a disregard for and violation of others' rights, often with deceitfulness and impulsivity; borderline personality disorder involves instability in interpersonal relationships, self-image, and affects, with marked impulsivity; histrionic personality disorder displays excessive emotionality and attention-seeking; and narcissistic personality disorder shows grandiosity, need for admiration, and lack of empathy.^[130] Cluster C disorders reflect anxious or fearful tendencies: avoidant personality disorder involves social inhibition, feelings of inadequacy, and hypersensitivity to criticism; dependent personality disorder features submissive and clinging behavior with excessive need to be taken care of; and obsessive-compulsive personality disorder emphasizes preoccupation with orderliness, perfectionism, and control at the expense of flexibility and efficiency.^[130] Epidemiological data from the National Epidemiologic Survey on Alcohol and Related Conditions-III (NESARC-III), conducted between 2012 and 2013, estimate the 12-month prevalence of any personality disorder at 9.1% among U.S. adults, with borderline personality disorder at 1.4%; global meta-analyses report a pooled prevalence of 7.8%, higher in high-income countries.^[129] ^[131] These disorders predict poorer treatment outcomes in comorbid conditions and elevated risks of self-harm, with Cluster B types showing higher rates of suicidal behavior—up to 10% lifetime completion in borderline cases—supported by longitudinal studies tracking functional impairment over decades.^[129] Diagnostic assessments rely on structured interviews like the Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5-PD), though inter-rater reliability remains modest (kappa ≈ 0.4-0.6 for specific disorders), reflecting challenges in distinguishing enduring traits from situational responses or cultural variations.^[132] Empirical evidence from twin studies indicates moderate to high heritability (40-60% for most types), underscoring a biological basis beyond mere behavioral extremes, though environmental adversities like childhood trauma amplify expression in vulnerable individuals.^[133]

Substance Use and Addictive Disorders

Substance use disorders encompass a range of conditions involving the recurrent use of alcohol or other substances despite adverse consequences, as delineated in the DSM-5 by a cluster of at least two of eleven criteria within a 12-month period, including consumption in larger amounts or over longer durations than intended, persistent unsuccessful efforts to reduce or control use, excessive time devoted to obtaining, using, or recovering from the substance, cravings, failure to fulfill major role obligations, continued use despite social or interpersonal problems, abandonment of important social or occupational activities, recurrent use in hazardous situations, tolerance, and withdrawal symptoms.^[134]^[135] Severity is graded as mild (2-3 criteria), moderate (4-5 criteria), or severe (6 or more criteria), reflecting the continuum of impairment from neuroadaptations in the brain's reward circuitry, particularly involving dopamine release in the ventral tegmental area and nucleus accumbens, which substances hijack to produce reinforcing effects beyond natural rewards.^[136] These disorders apply to specific classes such as alcohol, cannabis, hallucinogens, inhalants, opioids, sedatives, hypnotics, anxiolytics, stimulants, and tobacco, with polysubstance use common and exacerbating risks.^[137] In the United States, the 2023 National Survey on Drug Use and Health estimated that 48.5 million individuals aged 12 or older—approximately 17% of this population—met criteria for a substance use disorder in the past year, with alcohol use disorder affecting 27.9 million (9.7%) and illicit drug use disorders including opioids impacting millions more, alongside high comorbidity rates with other mental disorders such as mood and anxiety conditions, which share genetic and neurobiological vulnerabilities.^[138]^[139] Heritability estimates for substance use disorders range from 40% to 60% across substances, interacting with environmental factors like early exposure and stress to drive progression, though longitudinal data indicate that many individuals remit spontaneously without formal treatment, challenging purely deterministic models. Addictive disorders extend beyond substances to behavioral patterns, with gambling disorder classified in DSM-5 as the sole non-substance example, characterized by persistent and recurrent problematic gambling behavior leading to clinically significant impairment or distress, evidenced by at least four of nine criteria such as preoccupation with gambling, needing to gamble with increasing amounts to achieve excitement, repeated unsuccessful efforts to control or stop, restlessness or irritability upon reduction, gambling to escape dysphoria, "chasing" losses, lying about gambling extent, jeopardizing relationships or opportunities, and relying on others for financial aid due to gambling.^[140] This reclassification from impulse-control disorders reflects shared neurobiological mechanisms with substance use, including dysregulated dopamine signaling in reward pathways, yet critics of the brain disease paradigm argue it overemphasizes irreversible pathology while underplaying volitional and learning-based elements, as evidenced by high recovery rates through behavioral interventions and the absence of uniform progression to chronicity.^[141]^[142] Emerging research explores other behavioral addictions like internet gaming, but these lack formal DSM-5 status pending further validation of diagnostic reliability.^[143]

Neurocognitive and Other Disorders

Neurocognitive disorders are characterized by acquired deficits in cognitive function, including impairments in attention, executive functions, learning and memory, language, perceptual-motor abilities, or social cognition, resulting from brain disease, injury, or physiological changes, distinct from developmental or psychiatric conditions.^[144] In the DSM-5, these include delirium, major neurocognitive disorder (NCD), and mild NCD, requiring evidence of decline from a prior level of functioning in at least one cognitive domain, confirmed by standardized testing or informant reports, with exclusion of primarily psychiatric causes.^[145] Major NCD involves marked interference with independence in everyday activities, whereas mild NCD causes minimal impairment; delirium features acute onset of fluctuating attention and cognition, often reversible.^[146] The ICD-11 similarly defines neurocognitive disorders as primary clinical deficits in cognitive functioning acquired later in life, encompassing mild neurocognitive disorder (equivalent to mild cognitive impairment) and dementia syndromes, with emphasis on etiological specifiers like Alzheimer's disease or vascular contributions.^[147] Subtypes of major NCD are specified by etiology, such as Alzheimer's disease (progressive memory loss with amyloid plaques and tau tangles), Lewy body disease (visual hallucinations, parkinsonism, fluctuating cognition), vascular (stepwise decline linked to cerebrovascular events), frontotemporal (behavioral changes or language deficits from lobar degeneration), or due to traumatic brain injury (post-concussive cognitive sequelae).^[145] Prevalence increases with age; globally, dementia affected 55 million people in 2020, projected to reach 78 million by 2030, with Alzheimer's comprising 60-70% of cases, disproportionately impacting low- and middle-income countries where over 60% of cases occur.^[148] In the U.S., nearly 10% of adults aged 65 and older have dementia, while mild cognitive impairment prevalence is 14-18% in those 70 and above, with annual conversion rates to dementia of 10-15%.^[149] Risk factors include advanced age, genetic variants like APOE ε4, cardiovascular disease, and head trauma, supported by longitudinal cohort studies showing heritability estimates of 40-80% for late-onset forms.^[150] Other disorders in mental health classifications encompass residual categories not captured by core diagnostic clusters, including medication-induced movement disorders (e.g., tardive dyskinesia from antipsychotics, with prevalence up to 20-50% in long-term users), other specified mental disorders due to another medical condition (e.g., cognitive deficits from hypothyroidism or HIV), and unspecified mental disorders where symptoms fail to meet full criteria but warrant attention.^[151] These often arise from physiological insults rather than primary psychopathology, emphasizing causal links to identifiable medical etiologies over psychosocial models alone; for instance, neuroleptic malignant syndrome presents with rigidity, fever, and autonomic instability in 0.01-0.02% of antipsychotic exposures, treatable via discontinuation and supportive care.^[152] Diagnostic validity relies on ruling out confounds like delirium or substance effects, with neuroimaging or biomarkers increasingly used to substantiate organic bases, countering historical overattribution to functional psychoses in biased institutional settings.^[153] Comorbidity with primary mental disorders occurs, but neurocognitive primacy is determined by temporal precedence and pathophysiological evidence, as in post-stroke apathy syndromes.^[154]

Etiology and Risk Factors

Genetic and Heritability Evidence

Twin and family studies have established that genetic factors contribute substantially to the liability for most mental disorders, with heritability estimates—the proportion of phenotypic variance attributable to genetic differences—ranging from moderate to high across diagnostic categories.^[13] These estimates derive from comparisons of monozygotic (identical) twins, who share nearly 100% of their genetic material, and dizygotic (fraternal) twins or siblings, who share about 50%, controlling for shared environments. Adoption studies further disentangle genetic from environmental influences by showing elevated risk in biological relatives separated early in life.^[155] While environmental factors interact with genetics, the consistency of elevated concordance in monozygotic twins supports a causal genetic component, independent of cultural or socioeconomic confounds often emphasized in non-genetic models.^[156] Heritability varies by disorder but is generally highest for neurodevelopmental and psychotic conditions. For schizophrenia, twin studies yield estimates of 41% to 87%, with meta-analyses converging around 80%, indicating strong genetic influence amid complex gene-environment interactions.^[155] Bipolar disorder shows similarly elevated heritability, often 70-90% from family and twin data, though population-based analyses using extended pedigrees report slightly lower figures around 60-80% due to diagnostic heterogeneity.^[157] Autism spectrum disorders exhibit meta-analytic heritability of 64-91%, with shared environmental effects emerging only at lower prevalence thresholds, underscoring predominantly additive genetic effects.^[158] Attention-deficit/hyperactivity disorder (ADHD) heritability hovers at 70-80%, while major depressive disorder is lower, at 36-51% in twin and sibling samples, reflecting greater environmental modulation.^[159]

Disorder	Heritability Estimate	Study Type	Source
Schizophrenia	41-87%	Twin studies	^[155]
Bipolar Disorder	60-90%	Twin/family/population	^[157]
Autism Spectrum	64-91%	Meta-analysis of twins	^[158]
ADHD	70-80%	Twin studies	^[13]
Major Depressive Disorder	36-51%	Twins/siblings	^[159]

At the molecular level, genome-wide association studies (GWAS) reveal that mental disorders are polygenic, involving thousands of common variants with small effect sizes rather than rare monogenic mutations predominant in some neurological conditions. Polygenic risk scores (PRS), aggregating these variants, predict disorder onset; for instance, individuals in the top 1% of schizophrenia PRS face a sixfold increased risk compared to the general population.^[160] Cross-disorder analyses identify shared genetic loci across conditions like schizophrenia, bipolar disorder, autism, ADHD, and depression, implicating pathways in synaptic function, brain development, and immune regulation.^[161] ^[162] A 2025 study pinpointed 683 variants influencing eight psychiatric disorders, highlighting pleiotropy where the same alleles elevate risk for multiple diagnoses, challenging strict categorical boundaries.^[163] These findings, drawn from large-scale consortia, affirm genetic causality while PRS utility remains limited for individual prediction due to environmental variance and population stratification effects.^[164]

Neurobiological Mechanisms

Neurobiological mechanisms underlying mental disorders encompass disruptions in neurotransmitter signaling, neural circuit integrity, stress response systems, and inflammatory processes, as evidenced by neuroimaging, postmortem analyses, and pharmacological studies. These alterations often manifest as imbalances in monoamine systems, such as reduced serotonin availability implicated in major depressive disorder and anxiety, where selective serotonin reuptake inhibitors alleviate symptoms by enhancing synaptic serotonin levels.^[21] Similarly, dopamine hyperactivity in mesolimbic pathways contributes to positive symptoms in schizophrenia, with antipsychotic efficacy correlating to D2 receptor blockade, though excess dopamine signaling fails to explain negative symptoms fully.^[165] Glutamate dysregulation, particularly NMDA receptor hypofunction, has been linked to cognitive deficits across psychotic and mood disorders, supported by ketamine-induced psychosis models mimicking schizophrenia-like states.^[165] Structural and functional brain imaging reveals consistent abnormalities, including reduced prefrontal cortex volume and hippocampal atrophy in schizophrenia and depression, observable via MRI in patients with chronic illness duration exceeding five years.^[166] Functional connectivity disruptions, such as hypoactivation in the default mode network during rest in major depressive disorder, correlate with rumination and anhedonia, while hyperconnectivity in salience networks appears in anxiety disorders.^[167] These findings, derived from meta-analyses of over 1,000 participants per disorder, indicate impaired executive control and emotional regulation, though causality remains inferred from longitudinal studies showing pre-onset deviations in high-risk cohorts rather than direct causation.^[168] The hypothalamic-pituitary-adrenal (HPA) axis exhibits hyperactivity in approximately 30-50% of individuals with major depression, characterized by elevated cortisol levels and dexamethasone non-suppression, reflecting impaired negative feedback that exacerbates neuronal vulnerability in the hippocampus.^[169] Chronic activation, often triggered by prolonged stress, leads to glucocorticoid receptor resistance and downstream effects like reduced neurogenesis in the dentate gyrus, as demonstrated in rodent models and human postmortem tissue.^[170] In bipolar disorder, HPA dysregulation fluctuates with mood states, with manic episodes showing blunted cortisol responses.^[171] Emerging evidence implicates neuroinflammation, involving microglial activation and elevated pro-inflammatory cytokines like IL-6 and TNF-α, in the pathogenesis of schizophrenia and depression, with meta-analyses reporting 20-30% higher peripheral cytokine levels in affected patients compared to controls.^[31] This process may arise from blood-brain barrier permeability or genetic predispositions affecting immune genes, contributing to synaptic pruning deficits in schizophrenia and reduced neuroplasticity in mood disorders, though anti-inflammatory trials yield mixed results, underscoring heterogeneity and the need for subtype-specific targeting.^[172] Overall, these mechanisms interact dynamically, with neurotransmitter imbalances often secondary to circuit-level changes, highlighting the brain's integrated vulnerability to genetic, developmental, and experiential insults.^[173]

Environmental and Psychosocial Contributors

Environmental factors, including prenatal exposures and urban living conditions, contribute to the risk of certain mental disorders, though establishing causality requires accounting for genetic confounders and reverse causation. Prenatal exposure to ambient air pollution, such as fine particulate matter (PM2.5), has been associated with altered neurodevelopment and behavioral issues in children, with cohort studies showing disruptions in brain structure and function persisting into later life.^[174] Maternal infections during pregnancy increase the odds of neurodevelopmental disorders like autism spectrum disorder (ASD) and schizophrenia in offspring, potentially through inflammatory mechanisms affecting fetal brain development.^[175] Urbanicity at birth or during upbringing elevates schizophrenia risk by approximately 2.37 times compared to rural environments, even after adjusting for familial genetic liability, suggesting social stressors like population density or pollution as mediators.^[176] ^[177] Psychosocial contributors, particularly early-life adversity and socioeconomic disadvantage, show robust associations with multiple psychiatric outcomes, supported by dose-response patterns and longitudinal data. Adverse childhood experiences (ACEs), such as abuse, neglect, or household dysfunction, dose-dependently predict adult mental disorders; individuals with four or more ACEs face 1.7–2.2 times higher odds of anxiety and depression, and up to 4.6 times for depression, with population-attributable fractions of 22–32% for psychiatric disorders overall.^[178] ^[179] ^[180] Low socioeconomic status (SES) causally influences mental health via mechanisms like chronic stress and limited access to resources, with Mendelian randomization studies confirming bidirectional effects where poverty predicts poorer outcomes independent of personality traits.^[181] ^[182] Social isolation and poor family dynamics exacerbate risks, while protective factors like strong peer relationships and optimism correlate with reduced incidence.^[183] ^[184] These effects persist after controlling for genetic risks, underscoring modifiable psychosocial pathways, though overemphasis in some academic reviews may underweight heritable factors.^[185]

Integrated Causal Models

Integrated causal models of mental disorders synthesize genetic predispositions, neurobiological vulnerabilities, and environmental stressors into frameworks that explain disorder onset as arising from probabilistic interactions rather than singular causes. The diathesis-stress model, formalized in the mid-20th century and refined through subsequent research, posits that inherent vulnerabilities—often genetic—confer susceptibility, which environmental adversities activate to precipitate psychopathology.^[186] Empirical support derives from twin studies indicating heritability estimates of 41-87% for psychotic disorders and 70-90% for bipolar disorder, suggesting a substantial genetic diathesis that environmental factors modulate.^[155] ^[13] These models reject monocausal explanations, emphasizing thresholds where cumulative liability exceeds resilience. Gene-environment interactions (G×E) provide mechanistic evidence for integration, demonstrating how specific genotypes amplify environmental risks. In depression, the BDNF Val66Met polymorphism interacts with childhood maltreatment or recent stressors to elevate symptom severity, with meta-analyses confirming moderated effects in longitudinal cohorts.^[187] For schizophrenia, variants in genes like AKT1 heighten psychosis risk under cannabis exposure, particularly during adolescence, as evidenced by case-control studies with odds ratios up to 6.9 for high-risk allele carriers using high-potency cannabis.^[188] Similarly, polygenic risk scores for schizophrenia and major depression correlate with psychosocial adversities in population samples, underscoring bidirectional influences where genetic liability draws individuals into adverse environments (gene-environment correlation).^[189] Genome-wide association studies (GWAS) explain 10-20% of heritability variance across disorders, with the remainder attributed to rare variants and interactions, highlighting the polygenic architecture underlying these dynamics.^[190] Developmental timing integrates these elements, as early-life stressors like prenatal infection or urban upbringing interact with genetic factors to disrupt neurodevelopmental trajectories, increasing schizophrenia liability by 2-3 fold in high-risk groups.^[191] Epigenetic modifications, such as DNA methylation changes from trauma, mediate G×E effects by altering gene expression without sequence alterations, though evidence remains correlational and requires causal validation.^[192] The biopsychosocial framework, proposed by Engel in 1977, attempts broad integration but faces criticism for conceptual vagueness, lack of falsifiability, and failure to prioritize empirical hierarchies, often resulting in eclectic rather than predictive applications.^[193] ^[194] More precise models, informed by causal inference methods like Mendelian randomization, affirm that genetic effects predominate but are contextually shaped, with environmental inputs acting as triggers rather than primary etiologies. Challenges persist in replication of specific G×E findings due to small effect sizes and phenotypic heterogeneity, yet converging evidence from large-scale consortia supports multifactorial causality over purely social or deterministic biological views.^[195] These models imply preventive potential through early intervention on modifiable risks in high-genetic-liability individuals, though overemphasis on psychosocial factors without biological grounding risks diluting etiological clarity.^[196]

Signs, Symptoms, and Course

Core Symptomatic Features

Mental disorders are characterized by clinically significant disturbances in an individual's cognition, emotional regulation, or behavior, which reflect dysfunction in underlying psychological, biological, or developmental processes and are associated with substantial distress or impairment in personal, family, social, educational, occupational, or other important activities.^[26] These disturbances manifest across heterogeneous conditions but share core symptomatic domains that deviate from normative functioning, as operationalized in diagnostic systems like the DSM-5 and ICD-11.^[197] ^[198] Cognitive symptoms represent a primary domain, encompassing abnormalities in perception, thought content, and thought processes. Delusions—fixed false beliefs resistant to evidence—hallucinations (perceptual experiences without external stimuli, such as auditory voices), and disorganized thinking (e.g., derailment or incoherence) are prevalent in psychotic spectrum disorders, affecting approximately 1-3% of the population lifetime.^[93] Obsessions (intrusive, persistent thoughts) and impaired attention or memory further exemplify cognitive disruptions in anxiety, obsessive-compulsive, and neurocognitive disorders, respectively.^[152] Empirical studies confirm these features' heritability and neurobiological correlates, distinguishing them from cultural norms or transient states.^[199] Affective or emotional symptoms involve dysregulated mood and emotional responses disproportionate to circumstances. Persistent low mood, anhedonia (inability to experience pleasure), or irritability underpin depressive disorders, while excessive fear, panic, or euphoria characterize anxiety and bipolar conditions; these affect over 20% of adults annually in high-income countries.^[200] Extreme mood lability or emotional numbing, as in trauma-related disorders, correlates with altered amygdala and prefrontal cortex activity, underscoring causal neural mechanisms beyond psychosocial stressors alone.^[201] ^[202] Behavioral symptoms include maladaptive actions or inactions stemming from cognitive-affective disturbances, such as social withdrawal, agitation, impulsivity, or repetitive compulsions that interfere with daily functioning.^[203] Risky behaviors (e.g., substance abuse or self-harm) and psychomotor changes (retardation or agitation) are documented in 10-15% of severe cases, often leading to measurable disability adjusted life years (DALYs) globally.^[26] These features, while varying by disorder, empirically predict poor outcomes when untreated, with longitudinal data showing persistence without intervention.^[204] Somatic symptoms frequently co-occur, including disrupted sleep, appetite, or energy levels, which serve as nonspecific but quantifiable indicators across disorders; for instance, insomnia affects 50-80% of individuals with mood or anxiety conditions.^[205] Such physiological correlates highlight the biopsychosocial integration of mental disorders, where symptoms like fatigue or psychomotor slowing reflect hypothalamic-pituitary-adrenal axis dysregulation rather than purely subjective complaints.^[199] Overall, these core features necessitate distress or impairment for diagnostic threshold, distinguishing pathological states from adaptive variations.^[206]

Variability, Comorbidity, and Progression

Mental disorders exhibit substantial heterogeneity in their symptomatic presentation among individuals sharing the same diagnostic label, arising from polythetic criteria in classification systems like the DSM, which permit diverse symptom combinations to meet diagnostic thresholds.^[207] For instance, depression manifests variably, with patients differing in core symptoms such as anhedonia, somatic disturbances, or melancholic features, alongside differing risk factors, treatment responses, and trajectories.^[208] This variability extends to neurobiological levels, including regional brain volume deviations and neural signal fluctuations, which differ across patients even within diagnostic categories.^[209] Cultural factors further modulate expression; for example, somatic complaints predominate in some non-Western presentations of distress compared to cognitive-affective symptoms in Western contexts.^[210] Such heterogeneity challenges uniform causal models and underscores the limitations of categorical diagnoses, as distinct etiological pathways may underlie superficially similar phenotypes.^[211] Comorbidity, the co-occurrence of multiple mental disorders in the same individual, is prevalent across populations, with approximately 31% of adults experiencing a past-year mental disorder also having at least one additional concurrent disorder.^[212] Epidemiological surveys indicate that mood disorders, such as major depression, frequently co-occur with anxiety disorders, while substance use disorders overlap with both, reflecting potential shared genetic, neurobiological, or environmental vulnerabilities rather than independent entities.^[213] In longitudinal cohorts, temporal sequencing reveals elevated risks for secondary disorders; for example, individuals with an initial anxiety disorder face heightened odds of subsequent mood disorder onset.^[214] High comorbidity rates—up to 57% in institutionalized samples—complicate attribution of causality and treatment, as overlapping symptoms may inflate diagnostic counts or mask primary mechanisms.^[215] This pattern persists across age groups, with youth showing comparable rates to adults, suggesting developmental continuity in poly-symptomatic profiles.^[216] The progression of mental disorders varies by type and individual factors, often following chronic, recurrent, or remitting courses documented in longitudinal studies spanning decades.^[217] Common disorders like anxiety and depression typically emerge in adolescence or early adulthood, with mean onset ages around 14-19 years for anxiety and 25-30 for mood disorders, progressing to persistence in 40-60% of cases without intervention.^[204] Cohort data from birth through midlife reveal that early-life disorders predict later comorbidity and functional decline, with only partial remission in many trajectories; for instance, childhood conduct problems evolve into adult antisocial patterns in up to 50% of cases.^[218] Schizophrenia and bipolar disorder often show episodic progression with cumulative neurocognitive deterioration, while neurodevelopmental conditions like autism display relative stability post-diagnosis.^[219] Factors influencing course include genetic loading and environmental stressors, with untreated cases exhibiting higher rates of chronicity—e.g., 30-50% persistence for major depression over 10 years—highlighting the value of early intervention to alter trajectories.^[220]

Functional Impairment and Disability

Functional impairment in mental disorders refers to the reduced ability to perform essential daily activities, fulfill social roles, or maintain occupational responsibilities due to symptomatic disturbances such as cognitive deficits, emotional dysregulation, or behavioral anomalies.^[221]^[222] This impairment manifests across domains including self-care, interpersonal relationships, and work performance, distinguishing it from mere symptom presence by emphasizing observable decrements in adaptive functioning.^[223] Unlike transient difficulties, persistent impairment often qualifies as disability when it substantially limits major life activities, as defined in frameworks like the World Health Organization's International Classification of Functioning, Disability and Health (ICF).^[224] Assessment of functional impairment typically employs standardized instruments to quantify severity and track changes. The World Health Organization Disability Assessment Schedule (WHODAS 2.0) evaluates limitations in six domains—cognition, mobility, self-care, getting along, life activities, and participation—across cultures and disorders.^[224] Other tools include the Global Assessment of Functioning (GAF) scale, which rates overall psychological, social, and occupational functioning on a 0-100 continuum, and the Sheehan Disability Scale, focusing on work, social, and family disruptions.^[225] These measures correlate with clinical outcomes, revealing that higher impairment scores predict poorer treatment adherence and relapse risk.^[226] Mental disorders impose substantial disability burdens globally, contributing 16% of total disability-adjusted life years (DALYs) in 2019, equivalent to 418 million DALYs, primarily through lost productivity and role incapacitation.^[227] In the United States, approximately 11.2 million adults experience significant psychiatric disability, with disorders like schizophrenia and bipolar disorder yielding unemployment rates exceeding 80% during acute episodes.^[228] Depression alone accounts for reduced workforce participation, with affected individuals reporting 20-30% more days of impaired occupational functioning annually compared to non-affected peers.^[229] Socially, impairments manifest as isolation or relational conflicts, exacerbating cycles of dependency; for instance, severe anxiety disorders correlate with 2-3 times higher rates of social withdrawal and caregiving burdens on families.^[230] Disability attribution requires evidence of causal linkage between disorder symptoms and functional deficits, often verified via longitudinal tracking to rule out confounds like comorbid physical conditions.^[231] Empirical data indicate that untreated or inadequately managed disorders amplify disability; early intervention can restore up to 50% of functioning in mood disorders, underscoring the reversibility in non-degenerative cases.^[229] However, chronic conditions like neurodevelopmental disorders frequently result in lifelong accommodations, with adaptive functioning deficits persisting despite symptom mitigation.^[232]

Diagnosis and Assessment

Clinical and Structured Methods

Clinical diagnosis of mental disorders primarily relies on the clinician's evaluation of a patient's reported symptoms, behavioral observations, and historical context, guided by standardized criteria in manuals such as the DSM-5-TR, published by the American Psychiatric Association in 2022, or the ICD-11 from the World Health Organization.^[46]^[197] These systems operationalize disorders as clusters of symptoms persisting for specified durations, such as at least two weeks for major depressive disorder in DSM-5-TR, excluding alternative explanations like substance use or medical conditions.^[46] Diagnosis begins with a comprehensive clinical interview assessing onset, duration, severity, and impact of symptoms, often supplemented by collateral information from family or records to mitigate patient recall biases.^[233] The mental status examination (MSE) forms a core structured component of this process, systematically evaluating domains including appearance, behavior, mood, affect, speech, thought content and process, perceptions (e.g., hallucinations), cognition (orientation, memory, attention), insight, and judgment.^[234] Conducted during the initial encounter, the MSE provides objective descriptors—such as "flight of ideas" in mania or "loose associations" in schizophrenia—facilitating differentiation from neurological or systemic conditions.^[235] While the MSE enhances descriptive accuracy, its interpretive subjectivity underscores the need for clinician training, as inter-rater variability can affect consistency without standardized probes.^[236] To improve diagnostic reliability over unstructured interviews, semi-structured tools like the Structured Clinical Interview for DSM-5 (SCID-5), introduced in 2016, guide clinicians through DSM criteria via scripted questions and follow-up probes for major disorders including mood, anxiety, psychotic, and substance use conditions.^[237] The SCID-5 demonstrates moderate to good inter-rater reliability (kappa values 0.6–0.8 for many diagnoses) and test-retest stability in community and clinical samples, outperforming free-form assessments by reducing omission of criteria and enhancing replicability.^[238]^[239] Similarly, the Mini-International Neuropsychiatric Interview (MINI) offers a briefer structured alternative aligned with both DSM and ICD, suitable for high-volume settings, with reliability coefficients around 0.7 for common disorders.^[239] Despite these advances, clinical and structured methods face inherent limitations, including syndromal heterogeneity where identical symptom profiles may arise from diverse etiologies, leading to potential misclassification rates of 10–20% in routine practice.^[240] Diagnostic reliability remains lower for complex or comorbid cases (e.g., kappa <0.5 for personality disorders), influenced by clinician experience and patient factors like poor insight or dissimulation.^[241] Empirical studies emphasize that while structured interviews mitigate bias, they do not resolve validity concerns, as categories lack biological validators and may pathologize normative distress, prompting calls for dimensional assessments in future frameworks.^[242]^[243]

Biomarkers, Imaging, and Objective Tests

Unlike many medical conditions, mental disorders lack validated biomarkers or imaging modalities that enable reliable, standalone diagnosis, with assessments relying predominantly on clinical interviews and symptom criteria. Efforts to identify objective indicators, such as peripheral blood markers or neuroimaging patterns, have yielded associations at the group level but fail to achieve sufficient sensitivity and specificity for individual-level diagnosis due to etiological heterogeneity, symptom overlap across disorders, and small effect sizes.^[244]^[29] For instance, no biomarker panel has been approved by regulatory bodies like the FDA for routine psychiatric use as of 2025, highlighting the field's reliance on subjective criteria amid calls for precision psychiatry.^[245] Peripheral biomarkers, including inflammatory markers like C-reactive protein (CRP), leukocytes, and haptoglobin, show associations with increased risk of subsequent psychiatric disorders in large cohort studies, with elevated levels predicting onset in up to 10-20% higher incidence rates for conditions like depression and schizophrenia.^[30] Metabolomic profiles, such as altered tricarboxylic acid cycle metabolites in bipolar disorder, have been validated in smaller studies but require replication across diverse populations to confirm diagnostic utility.^[246] Neuroendocrine measures, like dysregulated cortisol in post-traumatic stress disorder, correlate with symptom severity but do not distinguish it from other anxiety states reliably.^[247] These candidates, while promising for stratifying risk or monitoring treatment response, suffer from low predictive accuracy (often below 70% in cross-validated models) and are influenced by confounders like comorbidities and lifestyle factors.^[248] Neuroimaging techniques, including structural MRI and functional modalities like fMRI and PET, reveal average differences such as cortical thinning or altered connectivity in disorders like major depression and schizophrenia, but these findings do not meet clinical thresholds for diagnosis.^[249] For example, enlarged lateral ventricles observed in chronic schizophrenia cohorts via MRI occur in only about 20-30% of cases and overlap with normal aging or other neuropathologies.^[250] Functional imaging aids in research by identifying treatment predictors, such as prefrontal hypoactivity response to antidepressants, yet prospective validation trials report accuracies under 60% for individual prognosis.^[251] Clinically, neuroimaging is primarily employed to exclude organic mimics like tumors or strokes, which account for less than 1% of psychiatric presentations but necessitate ruling out in atypical cases.^[18] Limitations include high costs, variability in scanner protocols, and inability to capture dynamic symptom fluctuations.^[252] Objective tests beyond biomarkers and imaging, such as standardized neuropsychological batteries (e.g., assessing executive function deficits in ADHD), quantify cognitive impairments but serve as adjuncts rather than diagnostics, with test-retest reliability ranging from 0.7-0.9 yet poor specificity across disorders.^[253] Electrophysiological measures like EEG show promise for subtyping, such as reduced alpha asymmetry in depression, but lack standardization and are prone to artifacts.^[254] Digital biomarkers from wearables, tracking sleep or activity patterns, correlate with mood episode relapse in bipolar disorder (e.g., actigraphy detecting 80% of manic shifts in pilot studies), yet require algorithmic validation against gold-standard outcomes.^[255] Overall, these tools enhance research into mechanisms but underscore psychiatry's diagnostic challenges, where objective measures inform rather than supplant clinical judgment.^[256]

Diagnostic Pitfalls and Overdiagnosis

Psychiatric diagnosis relies heavily on subjective clinical interviews and behavioral checklists without validated biomarkers, contributing to frequent errors. A review of diagnostic errors in mental health identified common pitfalls such as inadequate history-taking, cognitive biases, and failure to consider alternative explanations, leading to missed or incorrect diagnoses that worsen patient outcomes.^[240] Misdiagnosis rates are notably high; for instance, up to 65.9% of major depression cases in primary care settings are misdiagnosed due to overlapping symptoms and lack of objective tests.^[257] In severe psychiatric disorders, over one-third of patients (39.16%) receive initial misdiagnoses, often confusing conditions like bipolar disorder with borderline personality disorder, where nearly 40% of borderline cases are erroneously labeled as bipolar.^[258]^[259] Overdiagnosis occurs when valid diagnostic criteria are applied to normal variations in emotion, cognition, or behavior, pathologizing distress without underlying dysfunction. The DSM-5's expansion of criteria has been criticized for diagnostic inflation, increasing the prevalence of disorders like ADHD and autism spectrum disorders by lowering thresholds, as evidenced by meta-analyses showing invalid broadening that captures non-clinical populations.^[260] In children and adolescents, systematic reviews confirm overdiagnosis of conditions such as ADHD and depression, driven by heightened awareness, screening pressures, and pharmaceutical marketing rather than rising true incidence.^[261] Adult ADHD and bipolar II exemplify this, with clinicians overapplying diagnoses amid comorbidity confusions, such as mistaking bipolar mood swings for ADHD inattention.^[262] Pharmaceutical industry influence exacerbates these issues, as undisclosed financial conflicts affected 60% of DSM-5-TR authors, biasing criteria toward conditions treatable by medications and incentivizing overdiagnosis for market expansion.^[263] Critics, including figures like Thomas Szasz, argue this medicalizes normative human experiences, such as grief as major depression or shyness as social anxiety, undermining causal realism by prioritizing symptom checklists over empirical validation of disorder constructs.^[264] Diagnostic stability remains low, with consistency rates as poor as 9.5% for unspecified mental disorders upon readmission, highlighting the unreliability of current paradigms absent biological markers.^[265] Addressing these pitfalls requires integrating longitudinal assessment and skepticism toward expansive nosology, particularly where academic and industry biases favor intervention over watchful waiting.^[256]

Prevention

Risk Factor Mitigation

Reducing exposure to adverse childhood experiences (ACEs), including physical abuse, sexual abuse, household dysfunction, and neglect, has been identified as a key strategy for mitigating the risk of developing mental disorders later in life, with longitudinal studies showing that high ACE scores correlate with up to a fivefold increase in psychopathology risk, and interventions like parenting programs can decrease these exposures by 20-40%.^[266]^[267] Prenatal and perinatal risk mitigation includes maternal nutrition optimization and avoidance of substance use; for instance, folic acid supplementation during pregnancy reduces the odds of autism spectrum disorders by approximately 40% in meta-analyses of randomized trials, while maternal smoking cessation lowers offspring schizophrenia risk by addressing neurodevelopmental disruptions.^[268]^[267] Lifestyle modifications targeting modifiable behavioral risks demonstrate preventive efficacy across disorders. Regular aerobic exercise, at levels of 150 minutes per week, is associated with a 20-30% reduction in incident depression in prospective cohort studies, mediated through neuroplasticity enhancements and inflammation reduction, as confirmed in meta-reviews of lifestyle psychiatry.^[269] Similarly, smoking cessation mitigates risks for anxiety disorders and cognitive decline, with quitters showing a 25% lower incidence of major depressive episodes compared to persistent smokers in population-based analyses, due to nicotine's interference with dopamine regulation.^[268]^[269] Dietary patterns rich in omega-3 fatty acids and whole foods correlate with lower schizophrenia and mood disorder onset, with intervention trials indicating a 15-25% risk attenuation via anti-inflammatory effects.^[269] Addressing social determinants offers broader leverage; higher educational attainment reduces overall mental disorder incidence by 15-20% through enhanced coping resources and economic stability, per global attributable fraction estimates.^[184] Preventing head trauma via protective measures in sports and occupational settings lowers dementia and PTSD risks, with epidemiological data linking even mild traumatic brain injuries to a 1.5-2-fold increase in psychiatric outcomes absent mitigation.^[268] Substance use avoidance, particularly cannabis in adolescence, prevents psychosis escalation, as daily use elevates risk odds by 2-4 times in genetically vulnerable youth, underscoring causal pathways from endocannabinoid disruption.^[270] These strategies collectively account for 30-50% of preventable mental disorder burden in population-attributable fraction models, prioritizing empirical interventions over less substantiated social narratives.^[270]^[184]

Early Screening and Intervention Programs

Early screening programs aim to identify individuals, particularly children and adolescents, at elevated risk for mental disorders through systematic assessments, enabling timely interventions to avert onset or severity. Universal screening in schools, for instance, has been implemented in various U.S. districts since the early 2000s, using tools like the Pediatric Symptom Checklist to detect emotional and behavioral issues. A 2021 randomized trial in high schools found that such screening increased identification of major depressive disorder symptoms by facilitating referrals, leading to higher treatment initiation rates among screened students compared to controls. However, logistical barriers, including resource constraints and follow-up gaps, limit widespread efficacy, with only about one-third of U.S. public schools mandating behavioral health screenings as of 2025.^[271]^[272] Intervention programs following screening often integrate psychosocial support, family involvement, and targeted therapies. For youth mental health, models like Child First, evaluated in randomized controlled trials since 2010, demonstrate reductions in aggressive behaviors by 42% among at-risk children through home-based coaching. In early psychosis, specialized services such as Early Intervention in Psychosis (EIP) programs, rolled out in the UK from 2002 and adapted globally, yield superior outcomes; a 2021 meta-analysis of 10 trials (n=2,176) showed EIP associated with better symptomatic remission and social functioning versus standard care, with effects persisting up to five years in U.S. RAISE-ETP trials. A 2024 meta-analysis further indicated a one-third reduction in suicide deaths linked to these interventions. Yet, disengagement rates hover around 30%, underscoring adherence challenges.^[273]^[274]^[275]^[276] Evidence for broader applications remains mixed, particularly in school settings where early interventions show limited impact on academic outcomes per a 2015 meta-analysis of programs targeting at-risk students. While early detection correlates with improved long-term functioning, as per NIH reviews emphasizing reduced chronicity through prompt linkage to care, causal claims require caution due to confounding factors like selection bias in observational data. Programs prioritizing indicated prevention—targeting subthreshold symptoms—appear more cost-effective than universal approaches, with national strategies like Healthy People 2030 advocating evidence-based models to mitigate risks without inflating false positives. Ongoing trials, such as those adapting EIP for diverse populations since 2021, continue to refine protocols for scalability.^[277]^[278]^[279]^[280]

Treatment Approaches

Pharmacological Interventions

Pharmacological interventions for mental disorders primarily target neurotransmitter systems to alleviate symptoms, though they do not address underlying causal factors and exhibit variable efficacy across conditions. Antidepressants, antipsychotics, mood stabilizers, stimulants, and anxiolytics constitute the main classes, with mechanisms involving modulation of serotonin, dopamine, norepinephrine, and other pathways.^[281] Meta-analyses indicate that effect sizes are often modest, frequently comparable to placebo responses of 30-40% in randomized trials, influenced by expectation and trial design factors like unblinding.^[282] Long-term use raises concerns including tolerance, withdrawal, and side effects such as weight gain, metabolic disturbances, and cognitive impairment, with industry-sponsored studies potentially inflating benefits due to selective reporting.^[283] Antidepressants, including selective serotonin reuptake inhibitors (SSRIs) like fluoxetine and serotonin-norepinephrine reuptake inhibitors (SNRIs), are prescribed for major depressive disorder, showing response rates of 40-60% in short-term trials, but a 2022 umbrella review found no consistent evidence linking low serotonin levels to depression, undermining the foundational hypothesis for their use.^[281] ^[284] Network meta-analyses from 2020-2025 confirm small advantages over placebo (effect size ~0.3), with higher doses not proportionally increasing benefits and risks of sexual dysfunction, emotional blunting, and discontinuation syndrome affecting up to 50% of users upon cessation.^[285] ^[286] In treatment-resistant cases, augmentation strategies yield limited gains, and critiques highlight publication bias in academic sources favoring positive outcomes despite null findings in raw data.^[287] For schizophrenia, antipsychotics such as olanzapine, aripiprazole, and paliperidone reduce relapse rates by 50-70% compared to placebo in maintenance therapy, with long-acting injectables improving adherence and outcomes in first-episode patients.^[288] Clozapine remains superior for treatment-resistant cases, lowering relapse risk when initiated after initial failure, though metabolic side effects like diabetes occur in 10-20% of long-term users.^[289] ^[290] Evidence from Cochrane reviews emphasizes relapse prevention over symptom resolution alone, but first-generation agents like haloperidol carry higher extrapyramidal risks, prompting shifts to atypicals despite comparable efficacy in preventing hospitalization.^[291] Mood stabilizers, notably lithium, demonstrate robust efficacy in bipolar disorder, reducing manic and depressive relapses by over 50% in meta-analyses of randomized trials spanning decades, with superiority to placebo in long-term prevention.^[292] Lithium's benefits extend to suicide prevention, halving rates in cohort studies, though monitoring for renal and thyroid toxicity is required, affecting 20-30% of patients after 10-20 years.^[293] Alternatives like valproate show acute mania efficacy but inferior maintenance effects and higher teratogenicity risks.^[294] Stimulants such as methylphenidate and amphetamines for attention-deficit/hyperactivity disorder (ADHD) produce short-term symptom reductions in 70-80% of children and adults per randomized trials, outperforming non-stimulants in core symptom control.^[295] Long-term data indicate sustained benefits without universal tolerance, though growth suppression (1-2 cm height reduction) and cardiovascular risks necessitate monitoring, with effect sizes diminishing in adults.^[296] ^[297] Benzodiazepines like lorazepam provide rapid anxiolysis for acute anxiety or agitation, but long-term use correlates with dependence in 15-44% of patients, cognitive decline, falls (especially in elderly), and increased mortality risks from overdose or accidents.^[298] ^[299] Guidelines restrict them to short-term (2-4 weeks) due to tolerance and rebound symptoms, favoring alternatives amid evidence of neurotoxicity in chronic users.^[300] Across classes, pharmacotherapy's role is adjunctive, with 20-30% non-response rates underscoring individual variability and the need for personalized dosing based on genetics or biomarkers, though overprescription in primary care—driven by diagnostic expansion—exceeds evidence-based indications.^[301] Relapse upon discontinuation highlights dependence on continuous treatment, prompting debates on deprescribing protocols to minimize harms.^[302]

Psychotherapeutic Methods

Psychotherapeutic methods encompass structured psychological interventions designed to alleviate symptoms of mental disorders by addressing cognitive, emotional, and behavioral patterns through verbal interaction between patient and therapist. These approaches, often termed "talk therapies," have been evaluated in numerous randomized controlled trials and meta-analyses, demonstrating moderate efficacy across disorders such as depression, anxiety, and posttraumatic stress disorder, though response rates typically range from 20-50% compared to control conditions.^[303] Overall effects are comparable to pharmacotherapy but may be inflated by methodological issues like publication bias and allegiance effects, where researchers favor therapies aligned with their training.^[304] Cognitive-behavioral therapy (CBT) represents the most empirically supported psychotherapeutic approach, focusing on identifying and modifying distorted thought patterns and maladaptive behaviors that contribute to psychopathology. In meta-analyses of over 400 trials, CBT yields effect sizes of 0.6-0.8 for major depressive disorder and generalized anxiety disorder, outperforming waitlist controls and showing small advantages over other therapies (g=0.06).^[305] For instance, a 2023 network meta-analysis confirmed CBT's superiority to psychodynamic therapy for depression, with sustained benefits post-treatment due to skill-building components like behavioral activation and exposure techniques.^[306] No other psychotherapy has demonstrated systematic superiority to CBT, which is designated as a first-line treatment in guidelines for multiple DSM-5 disorders, including obsessive-compulsive disorder and panic disorder.^[307] Dialectical behavior therapy (DBT), an adaptation of CBT emphasizing emotion regulation and mindfulness, shows robust evidence for borderline personality disorder, reducing self-harm by 50% in randomized trials compared to usual care.^[308] Interpersonal therapy (IPT), which targets relational patterns, achieves effect sizes similar to CBT for depression (g≈0.5), particularly in cases with interpersonal triggers, as evidenced by 20-year follow-up data indicating lower relapse rates.^[309] In contrast, psychodynamic therapies, rooted in unconscious conflicts, exhibit weaker empirical support, with meta-analyses revealing smaller effects (g=0.3-0.5) and higher dropout rates than CBT, partly attributable to longer durations and less focus on measurable outcomes.^[305] Combination of psychotherapy with pharmacotherapy often enhances outcomes, yielding small but significant improvements (g=0.2-0.3) over monotherapy for severe depression and schizophrenia spectrum disorders, as per umbrella reviews of 60+ meta-analyses.^[310] However, access barriers persist, with only 20-30% of patients receiving evidence-based psychotherapies due to therapist shortages and insurance limitations. Emerging formats like internet-delivered CBT maintain efficacy comparable to in-person sessions (moderate-certainty evidence), broadening reach but requiring guided support to match acceptability.^[311] Limitations include modest absolute improvements—many patients remain symptomatic—and potential overestimation from industry-funded studies or selective reporting, underscoring the need for replication in diverse populations.^[312]

Neuromodulation and Emerging Biological Therapies

Neuromodulation encompasses techniques that alter neural activity through electrical, magnetic, or mechanical means to treat mental disorders, particularly in cases resistant to pharmacological or psychotherapeutic interventions. Established methods include electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), deep brain stimulation (DBS), and vagus nerve stimulation (VNS), which target dysregulated brain circuits implicated in conditions like major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). These approaches demonstrate empirical efficacy in clinical trials, though outcomes vary by disorder severity and patient selection, with response rates often ranging from 50% to 90% in treatment-refractory populations.^[313]^[314] ECT induces controlled seizures via electrical currents under anesthesia, yielding response rates of 70-90% in severe, treatment-resistant depression, with rapid symptom reduction often within days.^[315]^[316] Despite historical associations with cognitive side effects, modern protocols using brief-pulse stimuli and unilateral electrode placement minimize amnesia, though relapse occurs in up to 85% of cases without maintenance therapy.^[317] ECT also reduces suicidality, with a 34% decrease in odds of suicide post-treatment in large cohorts.^[318] rTMS delivers magnetic pulses to cortical regions, such as the dorsolateral prefrontal cortex, and is FDA-approved for MDD since 2008, showing moderate to large effect sizes in meta-analyses of over 100 trials, with 50% of responders maintaining benefits for up to one year.^[319]^[320] Accelerated protocols, delivering multiple sessions daily, enhance short- and long-term efficacy without increased adverse events.^[321] Non-invasive and well-tolerated, rTMS outperforms sham in reducing depressive severity, though placebo responses can inflate perceived benefits in some analyses.^[322]^[323] Invasive options like DBS involve implanting electrodes in subcortical targets, such as the ventral capsule/ventral striatum for OCD, achieving 35-60% response rates (defined as ≥35% reduction in Yale-Brown Obsessive Compulsive Scale scores) in refractory cases, with sustained effects over years in open-label follow-ups.^[314]^[324] For chronic depression, DBS yields approximately 60% response across targets like the nucleus accumbens, particularly in patients with comorbid anxiety.^[325] Risks include surgical complications and transient mood fluctuations, but long-term data indicate safety and symptom stability.^[326] VNS, via implanted devices stimulating the vagus nerve, is FDA-approved for treatment-resistant depression, producing gradual improvements in depressive symptoms over months, with brain imaging linking effects to modulated limbic activity.^[327]^[328] Systematic reviews confirm modest efficacy in psychiatric applications, including potential benefits for PTSD via anti-inflammatory pathways, though evidence remains limited compared to rTMS or ECT.^[329]^[330] Emerging neuromodulation includes intermittent theta-burst stimulation (iTBS), a faster rTMS variant with comparable efficacy and safety to standard protocols in depression trials.^[331] Focused ultrasound (FUS), non-invasively disrupting deep brain targets, shows preliminary promise in early-stage trials for depression, schizophrenia, and anxiety, bypassing skull barriers without incisions.^[332] Biological therapies under investigation, such as preclinical gene therapies targeting rare genetic variants in disorders like schizophrenia, aim to address underlying neurobiology but lack large-scale clinical validation as of 2025.^[333] Psychedelic-assisted interventions, leveraging compounds like psilocybin to induce neuroplasticity, represent another frontier, though integration with neuromodulation protocols requires further causal evidence beyond small trials.^[334] Overall, these modalities prioritize circuit-level interventions, with ongoing research emphasizing biomarkers for patient stratification to optimize outcomes.^[245]

Lifestyle and Self-Management Strategies

Lifestyle and self-management strategies encompass behavioral modifications that individuals with mental disorders can adopt to alleviate symptoms, enhance functioning, and prevent relapse, often as adjuncts to clinical treatments. Systematic reviews indicate that self-management interventions, including education on symptom monitoring and coping skills, reduce psychiatric symptoms and hospital admissions while improving quality of life in those with severe mental illnesses.^[335] Multidimensional approaches targeting multiple domains yield superior outcomes compared to single-focus strategies.^[336] Physical activity stands out as one of the most robustly supported strategies, with meta-analyses demonstrating that regular exercise lowers the risk of depression by up to 26% and reduces symptoms of anxiety and distress across diverse populations.^[337] ^[338] Even modest doses, such as 30-60 minutes weekly of moderate activity, confer significant mental health benefits, comparable to pharmacological effects in mild to moderate cases.^[339] Mechanisms include neuroplasticity enhancements via BDNF upregulation and reduced inflammation, though adherence remains a challenge in clinical populations.^[340] Adequate sleep hygiene—practices like consistent bedtimes, limiting screen exposure, and avoiding stimulants—directly impacts psychiatric outcomes, as poor sleep exacerbates depression and anxiety, with insomniacs facing 10-fold higher depression risk.^[341] Interventions improving sleep quality yield medium-sized reductions in depressive (g=−0.63) and anxiety symptoms (g=−0.51).^[342] Causal links are evident from longitudinal data showing sleep disturbances preceding disorder onset.^[343] Nutritional patterns influence brain function through gut-brain axis modulation and neurotransmitter synthesis; adherence to Mediterranean-style diets correlates with 28% lower neurological disorder risk, including depression.^[344] Randomized trials report significant symptom reductions, such as 20.6-point drops on depression scales, from dietary interventions emphasizing whole foods over processed items.^[345] Evidence is stronger for prevention than acute treatment, with Western diets high in sugars linked to worsened mood via oxidative stress.^[346] Social support networks facilitate self-management by buffering stress and enhancing resilience; scoping reviews link robust support to faster recovery from mental health crises.^[347] Perceived support mediates reductions in anxiety and depression via lowered perceived stress.^[348] Peer-led programs integrating social elements improve coping in severe cases.^[349] Mindfulness practices, such as meditation, show small to moderate efficacy in diminishing stress, anxiety, and depressive symptoms, per meta-analyses of randomized trials, though effects vary by individual and program fidelity.^[350] ^[351] Benefits stem from altered default mode network activity, but long-term maintenance requires structured self-practice.^[352] Avoidance of alcohol, tobacco, and illicit substances is critical, as substance use disorders co-occur with mental illness in over 50% of cases and undermine self-management efforts; abstinence supports symptom stability.^[353] Overall, these strategies empower autonomy but demand personalized application, with empirical monitoring to track efficacy amid heterogeneous responses.^[354]

Prognosis and Outcomes

Recovery Trajectories and Relapse Rates

Recovery trajectories for mental disorders exhibit significant heterogeneity, influenced by disorder type, treatment adherence, and individual factors such as comorbidity and social support. Longitudinal studies indicate that while acute episodes often remit with intervention, full symptomatic and functional recovery remains elusive for many, with chronic or recurrent courses predominant in severe cases. For instance, a two-year prospective study of 177 individuals with serious mental illnesses identified four distinct recovery patterns: rapid symptom resolution with sustained gains (25%), gradual improvement (31%), initial gains followed by deterioration (22%), and minimal change (22%), underscoring that deterioration is not inevitable but relapse disrupts progress in a substantial minority.^[355]^[356] In mood disorders, relapse rates are notably high, reflecting an episodic yet progressive nature. For major depressive disorder, the risk of recurrence following a first episode approximates 50%, escalating to 70% or higher after multiple prior episodes due to kindling effects where subsequent episodes onset more rapidly and respond less robustly to treatment. Continuation of antidepressants post-remission halves the relapse risk within months (23% versus 49% for discontinuation), though long-term recurrence accumulates, with up to 33% experiencing severe relapse over three years in naturalistic cohorts. Bipolar disorder follows a similar recurrent pattern, with annual relapse rates of 39-52% despite maintenance therapy, and 65.9% of patients relapsing within 2.5 years, often alternating between manic (47.8%) and depressive (44.3%) episodes; syndromal recovery from mania reaches 84% at one year, but only 62% achieve symptomatic recovery, with recurrence median time around 40 months in monitored samples.^[357]^[358]^[359]^[360]^[361] Psychotic disorders like schizophrenia typically feature a more unremitting trajectory, with multiple relapses characterizing the illness course in most patients; meta-analyses confirm that discontinuation of antipsychotics precipitates relapse in over 70% within one year, while even adherent patients face 10-20% annual relapse under optimal conditions, exacerbated by high expressed emotion in family environments (relative risk increase of 2-4 fold). Long-term outcomes reveal 20-30% achieving functional recovery, but 50-80% experience chronic impairment with episodic decompensation, as evidenced by systematic reviews of longitudinal data showing persistent positive and negative symptoms despite pharmacotherapy. Family interventions, including psychoeducation, reduce relapse by 20-50% over 1-2 years compared to standard care.^[362]^[363]^[364] For anxiety and trauma-related disorders, trajectories often involve partial remission with residual symptoms, though evidence for sustained recovery is stronger with targeted therapies. Generalized anxiety disorder and specific phobias show favorable long-term outcomes post-cognitive behavioral therapy (CBT), with meta-analyses of 69 trials demonstrating enduring symptom reduction at 3-12 months follow-up versus control conditions, yet 20-40% experience recurrence linked to untreated comorbidities like depression. In PTSD, one-third of cases remit spontaneously within three months, but 39% follow a chronic course, with recurrence post-remission reported at 14-34% over 7 years in civilian cohorts; prolonged exposure therapy yields 50-70% response rates, but relapse occurs in 10-20% upon stressor re-exposure, highlighting vulnerability to environmental triggers over inherent disorder progression.^[365]^[366]^[367]^[368]

Disorder Category	Approximate First-Episode Recovery Rate	Relapse Risk (Annual/Short-Term)	Key Modifiers
Major Depression	70-80% remission with treatment	20-50% within 1-2 years post-remission	Episode history, medication adherence^[358]
Bipolar Disorder	80-85% syndromal recovery from acute phase	39-52% within 1 year	Mood stabilizer compliance, episode polarity^[360]
Schizophrenia	50-70% acute symptom control	10-20% with adherence; >70% with discontinuation	Family dynamics, substance use^[362]
Anxiety Disorders (e.g., GAD)	60-80% with CBT	20-40% long-term recurrence	Comorbidity resolution^[365]
PTSD	30-50% natural remission	14-34% post-recovery over years	Trauma re-exposure, therapy type^[367]

Overall, relapse prevention hinges on sustained multimodal interventions, as discontinuation markedly elevates risks across disorders, though biological vulnerabilities and external stressors limit universal recovery; empirical data from randomized trials emphasize that optimistic portrayals of inevitable improvement overlook the probabilistic, often deteriorating long-term realities for subsets with poor prognostic indicators.^[369]^[370]

Predictors of Treatment Response

Predictors of treatment response in mental disorders encompass clinical, biological, and psychosocial factors, with evidence indicating modest predictive power overall, often necessitating trial-and-error approaches in clinical practice.^[371] Across disorders such as major depressive disorder (MDD) and schizophrenia, baseline symptom severity consistently influences outcomes; higher pretreatment severity is associated with lower remission rates in both anxiety and depressive conditions.^[372] Early symptomatic improvement, particularly within the first two weeks of antidepressant therapy, robustly forecasts later response, as demonstrated in individual patient data meta-analyses of MDD trials.^[373] Conversely, persistent non-response signals treatment resistance, affecting 20-60% of patients and linked to elevated healthcare costs.^[374] Biological markers show promise but limited clinical utility to date. Electroencephalography (EEG) patterns, such as frontal alpha asymmetry, predict antidepressant response with accuracies up to 80% in some studies, though validation remains inconsistent.^[375] Genetic factors, including polygenic scores for depression, bipolar disorder, ADHD, and PTSD, correlate with treatment-resistant depression (TRD), alongside cytochrome P450 metabolizer status influencing drug efficacy.^[376] In schizophrenia, younger age at onset emerges as the strongest predictor of treatment resistance, with neurobiological evidence pointing to dopamine-glutamate dysregulation in resistant cases.^[377]^[378] Biomarkers like brain-derived neurotrophic factor (BDNF) levels normalize more in responders than non-responders to antidepressants, per meta-analytic findings.^[379] Psychosocial and treatment-related factors also modulate response. In psychotherapy for personality disorders like borderline personality disorder, a strong therapeutic alliance predicts better outcomes across modalities.^[380] Homework completion and adherence consistently forecast positive results in psychological therapies for youth mental health issues.^[381] Comorbidities, such as greater anxiety or suicidality, heighten TRD risk, while employment and lower anxiety predict response to adjunctive esketamine in TRD.^[382]^[383] Premorbid functioning and education level inversely predict resistance in first-episode psychosis.^[384] Demographic variables like recurrent depression episodes increase resistance odds, underscoring the interplay of chronicity and mixed features across unipolar and bipolar subtypes.^[385]

Factor Category	Examples	Associated Outcomes	Evidence Strength
Clinical	High baseline severity, early non-improvement, comorbidities (e.g., anxiety, suicidality)	Poorer response/remission	Strong (meta-analyses)^[372]^[373]
Biological	Younger onset (schizophrenia), EEG patterns, genetic polygenic scores, BDNF levels	Resistance or response prediction	Moderate (emerging, needs validation)^[377]^[375]^[376]
Psychosocial/Treatment	Therapeutic alliance, adherence/homework, employment	Better outcomes	Consistent in specific contexts^[380]^[381]

Multimodal models integrating these predictors, such as machine learning approaches using EEG, genetics, and clinical data, achieve higher accuracy for MDD response than single factors, though real-world generalizability varies.^[386] Lower premorbid adjustment and negative symptoms further elevate resistance risk in psychosis, highlighting causal roles of neurodevelopmental insults over purely environmental explanations.^[384] Despite advances, no single predictor reliably guides precision psychiatry, with response rates hovering at 42-53% for first-line antidepressants.^[371]

Epidemiology

Global Prevalence and Demographic Patterns

In 2021, approximately 1 in 7 individuals worldwide, or 1.1 billion people, were living with a mental disorder, with anxiety and depressive disorders comprising the majority of cases.^[26] This equates to a global point prevalence of about 13.9%, based on estimates from the Institute for Health Metrics and Evaluation (IHME) drawing from representative surveys and health data across regions.^[8] Lifetime prevalence varies by study methodology but indicates substantial cumulative risk; cross-national analyses estimate that around 29% of adults experience at least one mental disorder over their lifetime, with morbid risk reaching approximately 50% by age 75 for common disorders like mood, anxiety, and substance use conditions.00193-1/abstract) These figures derive from Global Burden of Disease (GBD) models and meta-analyses of epidemiological surveys, which emphasize underreporting in low-resource settings due to diagnostic access barriers rather than true absence.00395-3/fulltext) Demographic patterns reveal consistent sex differences: females exhibit higher rates of internalizing disorders such as depression (prevalence roughly 1.5-2 times that of males in young adulthood) and anxiety, while males show elevated prevalence for externalizing disorders like substance use and conduct issues, particularly before age 14.^[387]00272-2/fulltext) Age gradients peak in early adulthood; serious mental illness affects 11.6% of individuals aged 18-25, compared to lower rates in children and older adults, with onset of the first disorder occurring before age 14 in about one-third of cases globally.^[387]^[204] Socioeconomic status correlates inversely with prevalence in many high-income contexts, where lower-income groups face 1.5-2 times higher odds of common mental disorders, potentially linked to chronic stressors like poverty and instability, though reporting biases may inflate figures in aware populations.^[388] Regional variations persist despite universal presence; prevalence of anxiety and depression concentrates in higher human development index (HDI) countries, possibly reflecting better detection rather than etiology, while low- and middle-income countries bear disproportionate disability-adjusted life years (DALYs) due to untreated cases and comorbidities.^[389] Income inequality exacerbates patterns within nations: studies across OECD countries link greater Gini coefficients to 20% higher disorder rates among lower strata, with cross-national data showing elevated common mental disorder prevalence in unequal rich societies like the US and UK.^[390]^[391] Urban-rural divides also emerge, with urban dwellers reporting 10-20% higher rates in global surveys, attributable to factors like social disconnection and environmental stressors, though causal inference remains challenged by confounding variables in observational data.^[392] These patterns underscore that while mental disorders affect all demographics, vulnerability amplifies under adverse social and economic conditions, independent of cultural diagnostic norms.

Trends in Incidence and Rising Burdens

In the United States, the prevalence of any mental illness among adults rose from approximately 17.7% in 2008 to 23% in 2021, reflecting a sustained upward trend in reported cases.^[393] Among youth, diagnoses of anxiety in adolescents increased by 61% and depression by 45% between recent survey periods, with 11% of children aged 3-17 receiving an anxiety diagnosis and 8% a depression diagnosis as of 2023 data.^[394]^[395] For young adults specifically, depression and anxiety diagnoses surged 63% from 2005 to 2017, coinciding with broader epidemiological shifts.^[396] Globally, age-standardized prevalence rates of mental disorders have shown relative stability or slight declines from 1990 to 2019, yet absolute numbers have escalated, with over 970 million people affected in 2019 and exceeding 1 billion by 2025 estimates from the World Health Organization.^[3]^[397] The Institute for Health Metrics and Evaluation reported 13.9% of the world's population experiencing mental disorders in 2021, contributing to a rising disability-adjusted life years (DALYs) burden, particularly from anxiety and depressive disorders.^[8] Projections indicate continued absolute burden growth through 2050, driven by population expansion and aging demographics, despite per-capita rate reductions in some models.^[398] These trends have amplified societal burdens, including heightened treatment demands—52.1% of U.S. adults with mental illness received care in 2024—and economic costs from lost productivity and healthcare expenditures.^[109] In youth populations, the share diagnosed with mental health conditions rose 18% between 2020-2021 and 2022-2023 surveys, straining educational and family systems.^[399] While improved screening may contribute to higher detection, longitudinal data on symptom severity and self-reported distress, such as elevated anxiety disorder prevalence (23.4% lifetime in U.S. females), suggest substantive increases beyond diagnostic expansion alone.^[400]^[108]

History

Pre-Modern Conceptions

In ancient Mesopotamian and Egyptian societies, mental disturbances were frequently attributed to supernatural forces such as demons, sorcery, or divine displeasure, with treatments involving incantations, exorcisms, and herbal remedies to expel malevolent entities. Mesopotamian texts described conditions akin to mental illness as afflictions of the "libbu" (inner self) caused by evil spirits or witchcraft, often addressed through ritual purification and appeals to deities. Egyptian medical papyri, such as those from around 1550 BCE, documented symptoms resembling depression and anxiety, sometimes linking them to heart afflictions or magical influences, yet also prescribed practical interventions like rest and incantations without uniformly invoking possession.^[401]^[402]^[403] In Classical Greece, around the 5th century BCE, Hippocrates of Kos advanced a naturalistic explanation, rejecting divine or demonic causation in favor of imbalances in the four bodily humors—blood, phlegm, yellow bile, and black bile—which he posited affected the brain and produced melancholia, mania, or phrenitis depending on the excess. This humoral theory framed mental disorders as physiological imbalances treatable through diet, purgatives, bloodletting, and lifestyle adjustments to restore equilibrium, marking an early somatogenic shift from purely supernatural models. Roman physician Galen, in the 2nd century CE, refined this framework, emphasizing empirical observation of symptoms and humoral pathology, which dominated Western medical thought for centuries.^[404]^[405]^[406] Biblical accounts from the Hebrew scriptures, compiled between the 8th and 2nd centuries BCE, often portrayed insanity as divine punishment, prophetic ecstasy, or torment by evil spirits, as in the case of King Saul afflicted by an "evil spirit from the Lord" in 1 Samuel 16:14, treated through music rather than medical means. New Testament narratives, circa 1st century CE, depicted demon possession manifesting as muteness, seizures, or self-harm, with Jesus expelling spirits as the remedy, distinguishing such cases from physical ailments like epilepsy in some instances.^[407]^[408] During Europe's Middle Ages (circa 500–1500 CE), Christian theology reinstated supernatural interpretations, viewing madness as demonic possession, sin, or satanic influence, leading to widespread exorcisms, pilgrimages to saints' shrines, and occasional trephination or confinement. Chroniclers documented cases of "madness" intertwined with epilepsy or alcoholism as divine affliction, with treatments prioritizing spiritual intervention over humoral methods, though family custody remained the norm for lunatics, and English common law from the 13th century protected "congenital idiots" via guardianship. Islamic scholars in the same era, drawing on Galen, maintained humoral explanations in texts like Avicenna's Canon of Medicine (1025 CE), advocating baths, music, and ethical counsel for melancholics, blending Greek rationalism with religious caution against sorcery.^[409]^[410]^[411]

19th-Century Institutionalization and Early Theories

The 19th century marked a pivotal expansion in the institutionalization of individuals diagnosed with mental disorders, driven by reform movements advocating dedicated asylums over confinement in prisons or workhouses. In France, Philippe Pinel's work at Bicêtre and Salpêtrière hospitals from the late 18th century into the early 19th influenced this shift, promoting the removal of chains and restraints in 1793 and emphasizing environmental and psychological interventions.^[412] His approach, termed moral treatment, prioritized humane care, structured daily routines, occupational activities, and physician-patient rapport to restore rationality, viewing mental disorders as disruptions amenable to non-physical therapies rather than demonic possession or mere humoral imbalances.^[413] This method spread across Europe, with Samuel Tuke's 1813 description of his grandfather William Tuke's York Retreat—established in 1796—detailing a Quaker-inspired model of seclusion from societal stressors, moral discipline, and community labor to foster self-control.^[414] In Britain, the 1845 Lunacy Act compelled counties to fund asylums for pauper lunatics, replacing ad hoc poor law provisions and leading to over 100 institutions by century's end, though initial optimism for curative isolation waned amid overcrowding.^[415] Across the Atlantic, American reformer Dorothea Dix, beginning her advocacy in 1841, lobbied state legislatures with exposés of inhumane conditions, resulting in the founding or enlargement of more than 30 public mental hospitals by 1880, explicitly modeled on Pinel and Tuke's principles of early intervention in serene, rural settings.^[416] ^[417] The first U.S. asylum dedicated to moral treatment, the Friends Asylum in Frankford, Pennsylvania, opened in 1814 under Quaker auspices, featuring patient labor and minimal coercion.^[418] Early theories coalesced around a nascent medical framework, with alienists—specialists in "mental alienation"—emerging mid-century to classify disorders as brain-based pathologies distinct from neurology or general medicine.^[419] Figures like Étienne-Jean Georget posited hysteria and other conditions as somatic in origin, advocating asylum sequestration for observation and treatment, though empirical evidence for organic lesions remained elusive.^[420] Moral treatment's optimism, rooted in psychosocial causation, contrasted with deterministic views of heredity and degeneration gaining traction later, yet asylums increasingly filled with chronic cases, exposing limits in curative claims by the 1870s.^[421] Professional bodies, such as the Association of Medical Officers of Asylums in Britain (founded 1841), formalized alienist expertise, prioritizing empirical classification over speculative etiology.^[422]

20th-Century Shifts: Psychoanalysis to Biological Psychiatry

In the early 20th century, Sigmund Freud's psychoanalytic theory, emphasizing unconscious conflicts, childhood experiences, and intrapsychic dynamics, became the prevailing framework in psychiatry, particularly for outpatient treatment.^[423] Psychoanalysis dominated American and European psychiatric training and practice through the mid-century, influencing diagnoses and therapies by prioritizing interpretive talk therapy over biological or behavioral interventions.^[423] However, by the 1940s and 1950s, criticisms mounted regarding its lack of empirical validation, with core concepts like the Oedipus complex and repression proving difficult to falsify or test scientifically, leading to perceptions of it as pseudoscientific. ^[424] The shift accelerated post-World War II amid demands for more reliable, evidence-based treatments, particularly for returning veterans with severe psychoses, where psychoanalytic methods showed limited efficacy. A pivotal development occurred in 1952 with the introduction of chlorpromazine, the first antipsychotic medication, synthesized by Paul Charpentier and tested by Henri Laborit; it demonstrated rapid symptom reduction in schizophrenia without heavy sedation, enabling patient discharge from asylums and sparking deinstitutionalization movements across Europe and the U.S. by the late 1950s.^[425] ^[426] This pharmacotherapeutic success underscored brain chemistry's role—targeting dopamine pathways—contrasting psychoanalysis's etiological focus on nurture over nature, and fueled the rise of neuropsychopharmacology as a discipline.^[427] By the 1960s, biological psychiatry gained traction through advances in neurochemistry, such as identifying neurotransmitter imbalances in mood disorders, and genetic studies suggesting heritability in conditions like schizophrenia (concordance rates of 40-50% in monozygotic twins). Psychoanalytic influence waned as randomized controlled trials highlighted psychotherapy's modest outcomes compared to medications; for instance, tricyclic antidepressants introduced in the 1950s outperformed talk therapy in empirical comparisons for depression. Institutional resistance persisted in some academic circles, but funding shifts toward biomedical research—exemplified by the U.S. National Institute of Mental Health's pivot in the 1970s—marginalized Freudian orthodoxy.^[428] The paradigm crystallized with the American Psychiatric Association's DSM-III in 1980, which abandoned psychoanalytic etiologies for a descriptive, symptom-based system with explicit, operationalized criteria, enabling reliability coefficients above 0.7 in inter-rater studies and facilitating biological research.^[429] ^[430] This "neo-Kraepelinian" approach, led by Robert Spitzer, prioritized observable phenomena over inferred psychodynamics, aligning psychiatry with medicine's evidence standards and diminishing psychoanalysis to a niche therapy.^[431] While biological models advanced causal understanding through brain imaging and pharmacology, debates persisted on their reductionism, as not all disorders yielded to somatic interventions alone.^[432]

Post-1980 Developments and Classification Evolutions

The publication of the Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM-III) in 1980 by the American Psychiatric Association represented a paradigm shift toward operationalized, symptom-based criteria for psychiatric diagnoses, replacing earlier psychoanalytic frameworks with an atheoretical, descriptive approach intended to enhance diagnostic reliability across clinicians and researchers.^[430] This edition introduced a multiaxial system assessing clinical disorders (Axis I), personality disorders and intellectual disabilities (Axis II), medical conditions (Axis III), psychosocial stressors (Axis IV), and global functioning (Axis V), while emphasizing observable behaviors over inferred etiologies.^[433] The changes responded to criticisms of prior editions' vagueness and low inter-rater agreement, drawing on field trials to refine criteria, though subsequent analyses indicated only modest gains in validity beyond reliability.^[431] Subsequent revisions refined this framework amid growing scrutiny. The DSM-III-R (1987) adjusted criteria based on emerging data but retained the core structure; DSM-IV (1994) expanded to 297 disorders across 886 pages, incorporating cultural considerations and evidence from longitudinal studies.^[64] The DSM-5 (2013) eliminated the multiaxial system in favor of integrated assessments, introduced dimensional ratings for severity in conditions like autism spectrum disorder, and added entities such as disruptive mood dysregulation disorder and hoarding disorder, while reclassifying bereavement-related grief under major depressive disorder with qualifiers.^[430] These evolutions aligned partially with the World Health Organization's International Classification of Diseases (ICD), with ICD-10 (endorsed 1990, implemented variably from 1994) standardizing mental disorder categories globally through alphanumeric codes and emphasizing clinical utility over etiology.^[434] ICD-11 (adopted 2019, effective 2022) further harmonized with DSM-5 by introducing disorders like gaming disorder, complex post-traumatic stress disorder, and prolonged grief disorder, while restructuring neurodevelopmental conditions to reflect evidence from genetics and neuroimaging, reducing categorical silos.^[435] Critics have highlighted diagnostic inflation as a persistent issue, with the proliferation of categories— from 106 in DSM-III to over 300 in DSM-5—potentially pathologizing normative variations in behavior, such as mild anxiety or grief, thereby expanding treatment markets amid pharmaceutical industry ties to task force members.^[64] ^[436] Empirical reviews post-1980 found that while reliability improved via structured criteria, predictive validity for outcomes remained limited, questioning the categorical model's alignment with underlying biological continua evidenced by twin studies and brain imaging.^[437] Institutional biases in academic psychiatry, including underrepresentation of dissenting views on overdiagnosis, have compounded these concerns, as field trials prioritized consensus over rigorous causal validation.^[438] Internationally, ICD revisions faced analogous debates, with ICD-11's additions criticized for insufficient cross-cultural testing despite WHO's global mandate.^[65]

Controversies and Debates

The medical model of mental disorders conceptualizes them as brain diseases characterized by biological abnormalities, akin to physical illnesses, with treatment focused on correcting pathophysiological processes through interventions like pharmacotherapy.^[439] This approach relies on empirical evidence from genetics, neuroimaging, and clinical trials to identify underlying mechanisms. For instance, twin studies have estimated the heritability of schizophrenia at approximately 81%, indicating a strong genetic component independent of environmental influences.^[440] Similarly, heritability for bipolar disorder ranges from 60% to 83%, supporting the view that genetic factors play a predominant role in these conditions.^[441] Neuroimaging research further bolsters the medical model by revealing consistent structural and functional brain differences in affected individuals. In schizophrenia, longitudinal MRI studies show accelerated grey matter volume loss compared to healthy controls, suggesting progressive neuropathology.^[16] For major depressive disorder, comparative analyses indicate reduced hippocampal volumes, distinct from patterns observed in schizophrenia, pointing to disorder-specific neural alterations.^[442] Clinical efficacy data align with this framework; a 2018 meta-analysis of 522 trials found all 21 examined antidepressants more effective than placebo for adults with major depressive disorder, with effect sizes varying by drug but consistently favoring active treatment.32802-7/fulltext) In contrast, social constructionism posits that mental disorders are not objective pathologies but socially constructed labels shaped by cultural, historical, and power dynamics, lacking inherent biological validity.^[443] Thomas Szasz's 1961 book The Myth of Mental Illness exemplifies this perspective, arguing that psychiatric diagnoses medicalize "problems in living" rather than identifying true diseases, as no demonstrable brain pathology akin to somatic illnesses exists for most conditions labeled mental disorders.^[9] Szasz contended that such classifications serve social control functions, equating involuntary psychiatric interventions with rights violations, and urged viewing deviant behaviors as moral or ethical issues rather than medical ones.^[444] Critiques of social constructionism highlight its tendency to overlook accumulating biological evidence, such as genetic and neuroanatomical findings, in favor of interpretive frameworks that emphasize societal labeling over causal mechanisms.^[445] While acknowledging that diagnostic criteria can reflect cultural influences and that stigma arises from social processes, proponents of the medical model argue that constructionist denials of empirical data undermine effective treatment and ignore replicated findings of heritability and treatment responsiveness.^[37] For example, the superior outcomes of pharmacotherapy over placebo in randomized trials challenge claims that mental disorders are merely metaphorical or invented entities, as biological interventions would not yield consistent advantages absent underlying physiological substrates.32802-7/fulltext) This debate underscores tensions between reductionist biomedical explanations and holistic social analyses, with the former gaining traction through verifiable scientific advancements despite persistent philosophical objections.^[446]

Diagnostic Inflation and Pathologization of Normality

Diagnostic inflation describes the progressive broadening of psychiatric diagnostic criteria, resulting in higher reported prevalence rates of mental disorders and the classification of normative emotional and behavioral variations as pathological. This phenomenon has been documented across multiple editions of the Diagnostic and Statistical Manual of Mental Disorders (DSM), where criteria expansions for conditions such as attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, and major depressive disorder have incorporated milder or more common symptoms, thereby increasing diagnostic inclusivity.^[260] For instance, ADHD diagnoses in U.S. children aged 3–17 years reached 11.4% (approximately 7 million) by 2022, up from earlier estimates of around 6–7% in the 1990s, with evidence suggesting factors beyond improved detection, including loosened thresholds in DSM revisions.^[447]^[448] The pathologization of normality involves reinterpreting everyday experiences—such as grief, shyness, or academic underperformance—as indicators of disorder, often driven by cultural shifts toward medicalization and pharmaceutical marketing. Allen Frances, former chair of the DSM-IV task force, argued in his 2013 book Saving Normal that such expansions, particularly in DSM-5 (published 2013), risk labeling transient sadness or mild anxiety as clinical depression or generalized anxiety disorder, potentially affecting up to 50% of adults by age 32 with an anxiety diagnosis due to inflated boundaries.^[449]^[64] Frances highlighted how DSM-5's lowering of bereavement exclusion for depression and broadening of ADHD criteria could pathologize normal responses to loss or childhood distractibility, leading to unnecessary pharmacotherapy and lifelong labeling.^[450] This critique is supported by observations of tripling ADHD rates over recent decades, uncorrelated solely with awareness campaigns.^[64]^[451] Empirical studies provide mixed but concerning evidence: a 2025 analysis found expanded depression concepts prevalent among younger cohorts, supporting diagnostic creep rather than pure epidemiological shifts, while a meta-analysis of DSM changes from III to 5 identified inflation in ADHD and autism without uniform deflation elsewhere.^[452]^[260] Counterclaims attributing rises to destigmatization or better screening overlook inconsistencies, such as stable or lower rates in less medicalized contexts, and fail to account for iatrogenic effects like self-diagnosis fueled by online awareness efforts.^[453] Critics like Frances emphasize that academic and pharmaceutical incentives—evident in industry-funded research—may systematically bias toward expansion, eroding distinctions between distress and disorder without robust biological validation.^[454] This process not only escalates treatment burdens but also risks stigmatizing adaptive traits, as seen in the subsumption of eccentricities under autism spectrum criteria post-DSM-5, where prevalence surged from 1 in 150 children in 2000 to over 1 in 36 by 2023.^[152]^[455]

Pharmaceutical Influence and Treatment Efficacy

The pharmaceutical industry exerts significant influence over psychiatric diagnosis and treatment through funding of research, development of diagnostic criteria, and marketing practices. A substantial portion of randomized controlled trials (RCTs) evaluating psychiatric medications are financed by pharmaceutical companies, which has been associated with biased reporting of efficacy outcomes favoring sponsored drugs. ^[456] ^[457] Industry-sponsored studies in psychiatry report psychiatric drugs as approximately 50% more effective compared to independently funded trials of the same medications. ^[458] This funding bias extends to the Diagnostic and Statistical Manual of Mental Disorders (DSM), where nearly 70% of task force members for DSM-V had financial ties to the pharmaceutical industry, potentially shaping diagnostic categories to align with marketable treatments. ^[459] Similarly, clinical practice guidelines and journal publications often reflect undisclosed conflicts, with industry influence contributing to expanded indications for drugs like antidepressants and antipsychotics. ^[460] ^[461] Marketing strategies further amplify this influence, promoting off-label use and contributing to overprescription. Direct-to-consumer advertising, physician detailing visits, free samples, and sponsored educational events correlate with higher prescribing rates for psychotropics, including stimulants for ADHD and antidepressants for mild conditions. ^[462] ^[463] In the United States, such practices have driven a rise in antidepressant prescriptions, with evidence indicating overprescription for non-severe depression where benefits may not outweigh risks. ^[464] Ghostwriting and selective publication of positive trial data exacerbate this, as negative industry-sponsored results are often suppressed, distorting the evidence base available to clinicians. ^[465] These dynamics, rooted in profit motives, have led to diagnostic expansion—termed "disease mongering"—where normal variations in mood or behavior are pathologized to create markets for pharmacotherapy. ^[466] Regarding treatment efficacy, psychiatric medications demonstrate modest short-term benefits over placebo in meta-analyses, but effect sizes are often small and diminish for milder cases. For antidepressants in major depressive disorder, a 2018 network meta-analysis of 522 trials found all 21 studied drugs superior to placebo, with odds ratios for response ranging from 1.37 to 2.13; however, the absolute improvement on standardized scales like the Hamilton Depression Rating Scale averaged only 1.8-2 points beyond placebo, below thresholds for clinical significance in many guidelines. ^[467] ^[468] Placebo response rates in antidepressant trials frequently exceed 30-40%, driven by expectation effects, with no greater variability in individual responses to active drugs versus placebo. ^[469] ^[470] Long-term efficacy remains uncertain due to sparse data; while relapse prevention is observed, sustained use often yields diminishing returns, and up to 25% of placebo remitters in trials maintain remission without drugs. ^[282] Antipsychotics for schizophrenia show robust short-term reductions in positive symptoms, with relapse rates lower on medication (e.g., 20-30% vs. 60-80% off), but long-term outcomes are complicated by side effects and adherence issues. ^[471] Meta-analyses indicate atypical antipsychotics like olanzapine or risperidone prevent relapse more effectively than placebo over 1-2 years, yet prolonged use correlates with metabolic disturbances, tardive dyskinesia, and cognitive blunting, with some observational data suggesting dose minimization or intermittent strategies may preserve functioning without full discontinuation risks. ^[472] ^[473] Industry bias inflates reported advantages, as independent trials reveal smaller differences between agents and highlight high discontinuation rates (up to 50% in first year) due to adverse effects. ^[474] Discontinuation challenges underscore limitations in long-term utility. Abrupt or rapid withdrawal from antidepressants, antipsychotics, or benzodiazepines frequently induces severe syndromes—including rebound anxiety, psychosis-like states, or protracted symptoms lasting months—due to neuroadaptations from chronic exposure. ^[475] Surveys of long-term users report that 52% successfully taper off after years of use, often citing inefficacy or side effects, but 72% experience withdrawal difficulties, with duration of prior use predicting severity. ^[476] These effects, underemphasized in industry trials, suggest that while medications aid acute management, evidence for indefinite use is weak, and non-pharmacological interventions like cognitive behavioral therapy may offer comparable or superior durability for many conditions without dependency risks. ^[477] Overall, efficacy claims must account for publication bias and funding sources, as independent analyses consistently reveal smaller, context-dependent benefits than promotional narratives imply. ^[478]

Specific Disputes: Declassifications and Emerging Conditions

One prominent declassification occurred with homosexuality, listed in DSM-I (1952) as a sociopathic personality disturbance and in DSM-II (1968) as a sexual deviation.^[479] In December 1973, the American Psychiatric Association (APA) board voted to remove it as a disorder, a decision ratified by a subsequent referendum where 5,854 psychiatrists voted in favor and 3,810 opposed, amid protests by gay activists at APA meetings.^[480] ^[481] Critics, including some psychiatrists, contended that the change reflected social and political pressures rather than compelling new empirical evidence demonstrating homosexuality's normality or lack of association with distress and dysfunction, noting the APA's prior reliance on clinical observations of comorbidity with other pathologies.^[482] The replacement category, "sexual orientation disturbance" (later ego-dystonic homosexuality), addressed distress over orientation but was itself eliminated in DSM-III-R (1987).^[483] Other declassifications include the removal of broad neurotic categories in DSM-III (1980), which shifted to specific anxiety and mood disorders to emphasize observable symptoms over psychoanalytic theory, though this reclassification faced disputes for potentially inflating discrete diagnoses without proportional gains in validity.^[430] From DSM-IV to DSM-5 (2013), diagnoses like somatization disorder, hypochondriasis, and undifferentiated somatoform disorder were consolidated into somatic symptom disorder, sparking debate over whether this broadened criteria to encompass milder, non-pathological somatic concerns, contributing to diagnostic expansion rather than refinement. Emerging conditions have similarly provoked contention, exemplified by prolonged grief disorder (PGD), introduced in DSM-5-TR (2022) for persistent bereavement symptoms exceeding 12 months in adults (6 months in children), requiring intense yearning, emotional pain, and functional impairment.^[484] Proponents cite empirical studies showing distinct neurobiological markers and treatment responsiveness, but critics argue the criteria pathologize normal adaptive grief—prevalent in 10-20% of bereaved individuals—based on insufficient evidence of categorical distinction from uncomplicated bereavement, potentially driven by diagnostic inflation to justify interventions like antidepressants.00150-X/fulltext) ^[485] A 2023 analysis highlighted challenges in cross-cultural applicability and risk of overdiagnosis, given grief's variability.^[486] Gender dysphoria, reclassified in DSM-5 (2013) from gender identity disorder to emphasize clinically significant distress over identity incongruence, aimed to reduce stigma but ignited disputes over its validity as a disorder amid rising youth referrals—up 4,000% in some clinics since 2009—and high overlap with autism spectrum disorder (ASD; up to 20-26% comorbidity) and ADHD (prevalent in 75% of some cohorts).^[487] ^[488] Skeptics question whether expansions reflect true prevalence increases or social contagion and broadened criteria, noting limited long-term outcome data for interventions and potential iatrogenic harms, while APA sources maintain focus on distress differentiates it from non-clinical variations.^[489] Expansions in neurodevelopmental disorders, such as merging Asperger's into ASD and easing ADHD persistence criteria beyond age 12 in DSM-5, correlate with diagnosis rates doubling in the U.S. from 2003-2011, fueling arguments of overpathologization of normative behavioral variations influenced by educational and pharmaceutical incentives rather than etiological advances.^[152]^[490] These shifts underscore broader critiques that DSM revisions, often committee-driven with modest reliability (kappa ~0.4-0.6 for many categories), prioritize consensus over falsifiable biomarkers, enabling both declassifications under activist pressure and emergences via threshold lowering.^[491]

Societal and Cultural Dimensions

Stigma, Discrimination, and Public Perception

Public stigma toward mental disorders manifests as negative stereotypes, prejudice, and discrimination, while self-stigma involves the internalization of these views by affected individuals, leading to diminished self-esteem and avoidance of help-seeking. Surveys indicate that over half of individuals with mental illness forgo treatment due to fears of stigma and discrimination.^[492] In the United States, a 2019 American Psychological Association survey found that 33% of respondents agreed that "people with mental health disorders scare me," and 39% reported they would view a family member or close friend differently if diagnosed with a mental illness.^[493] These attitudes contribute to social exclusion, with public perceptions often linking mental disorders to unpredictability or violence, though empirical data shows such risks are elevated primarily in untreated severe cases involving substance abuse or specific conditions like schizophrenia.^[494] Discrimination in employment remains prevalent, with field experiments demonstrating that job applicants disclosing mental health histories receive fewer callbacks and offers compared to those without such disclosures.^[495] Employment rates for individuals with disabling mental illnesses range from 22% to 40%, far below general population figures, exacerbated by employer biases and lack of accommodations under laws like the Americans with Disabilities Act.^[496]^[228] In housing, a 2017 pilot study revealed that applicants with mental disabilities faced higher denial rates and less favorable treatment during rental processes, with stigma portraying such individuals as unreliable tenants.^[497] Structural barriers, including overrepresentation in homeless populations, perpetuate cycles of instability, as inadequate housing correlates with worsened symptoms and recidivism.^[498]^[499] Temporal trends in stigma are mixed. U.S. public stigma toward mental illness declined modestly from 1996 to 2018, with reduced endorsement of stereotypes like weakness of character, though persistent gaps remain in willingness for social contact.^[500] In contrast, global self-stigma has risen across dimensions of the Internalized Stigma of Mental Illness scale from 2005 to 2023, based on meta-analysis of 179 studies involving 33,046 participants, potentially reflecting diagnostic expansion and cultural shifts.^[501] European data from 2001 to 2020 show decreases in emotional responses like anger (-0.14) and lack of understanding (-0.19), yet uneasiness persists.^[502] Anti-stigma interventions, including campaigns and education, yield short-term reductions in youth stigma, with meta-analyses confirming small to moderate effects on knowledge and attitudes.^[503]^[504] However, evidence for sustained public change is limited, and some messaging risks unintended effects, such as reinforcing separation between "normal" and "disordered" by overemphasizing biological determinism without addressing behavioral accountability.^[505] Academic sources, often institutionally aligned with advocacy, may overestimate campaign efficacy while underemphasizing causal factors like comorbidity with antisocial traits that underpin valid public wariness.^[506]

Legal Frameworks and Coercive Treatment

Legal frameworks governing mental disorders primarily address civil commitment and capacity determinations, balancing individual autonomy with public safety. In the United States, state laws permit involuntary hospitalization when an individual, due to mental illness, poses an imminent danger to themselves or others, or is unable to care for basic needs, as established by the Supreme Court's ruling in O'Connor v. Donaldson (1975), which held that confinement solely for benevolent treatment violates due process if the person is not dangerous.^[507] Procedures typically require emergency petitions by family or professionals, followed by judicial hearings within days, with rights to counsel and periodic reviews to prevent indefinite detention.^[508] In the United Kingdom, the Mental Health Act 1983 authorizes detention for assessment (up to 28 days) or treatment (renewable periods) if a person suffers from a mental disorder necessitating hospital care for their health, safety, or protection of others, assessed by approved medical practitioners.^[509] Coercive treatment, including medication without consent, is permitted during initial detention phases, subject to second opinions for neuroleptics after three months, though physical restraints like seclusion require justification and documentation to mitigate abuse risks.^[510] Internationally, criteria vary, with many nations requiring evidence of severe impairment and risk, but implementation shows wide disparities; for instance, annual involuntary hospitalization rates differ significantly across Europe, influenced by resource availability and cultural attitudes toward coercion.^[511] The United Nations Convention on the Rights of Persons with Disabilities (2006) emphasizes supported decision-making and critiques substituted judgment leading to coercion, prompting calls from WHO and OHCHR in 2023 for laws prioritizing free and informed consent over forced interventions.^[512] ^[513] Yet, empirical reviews indicate coercive inpatient measures correlate with short-term risk reduction in acute psychosis but also heightened patient trauma and rehospitalization, underscoring tensions between harm prevention and civil liberties.^[514]^[515] Safeguards include appeals to tribunals or courts, with data from jurisdictions like England showing rising detentions—over 50,000 under the Act in recent years—amid debates on overreach, particularly for non-violent cases where alternatives like community treatment orders have mixed efficacy in sustaining compliance without eroding trust.^[516] Critics argue these frameworks, rooted in paternalism, enable diagnostic overreach, while proponents cite reduced suicides in treated cohorts as causal evidence for necessity in grave disability scenarios.^[517]

Cross-Cultural Variations and Biases

The prevalence and symptomatic presentation of mental disorders vary substantially across cultures, reflecting differences in etiology, expression, and detection. Empirical studies indicate that anxiety disorders, including generalized anxiety disorder and panic disorder, exhibit pronounced cross-cultural disparities in rates, with higher reported incidences in Western populations compared to others.^[518] Similarly, depression often manifests somatically—through physical complaints like pain or fatigue—in many non-Western cultures, such as among Asian and Latin American groups, rather than via cognitive or emotional descriptors emphasized in individualistic societies, potentially leading to underrecognition when applying universal diagnostic tools.^[519]^[520] These variations arise from cultural norms shaping help-seeking behaviors and symptom idioms, where collectivist orientations prioritize relational harmony over individual introspection, altering both perceived burden and clinical identification.^[210] Psychiatric classification systems like the DSM have historically imposed Western-centric frameworks, biasing diagnoses toward ethnocentric interpretations and marginalizing culture-specific syndromes such as amok in Southeast Asia or susto in Latin America, which involve acute dissociative states tied to local explanatory models.^[521] While DSM-5 introduced a Cultural Formulation Interview to mitigate this by assessing cultural influences on phenomenology, critics argue it insufficiently addresses how such adaptations risk diluting biological universals, as evidenced by consistent neurobiological markers across groups despite symptomatic divergence.^[522]^[523] For schizophrenia, core psychotic features show cross-cultural stability, but prognostic outcomes are reportedly better in developing nations, with lower chronicity rates potentially linked to family support structures rather than inherent pathology differences.^[524] Stigma levels also differ, with North African samples exhibiting less social rejection of schizophrenia than Central European ones, underscoring how cultural values modulate public response without altering disorder essence.^[525] Biases in cross-cultural research stem from overreliance on Western samples and clinicians, inflating perceived relativism while underemphasizing empirical consistencies in heritability and pathophysiology; institutions like academia, prone to ideological skews favoring constructionist views, often amplify these through selective emphasis on variability over invariants.^[526]^[527] For instance, mental health literacy surveys reveal Europeans outperforming non-Western groups in recognizing depression and schizophrenia via biomedical lenses, yet this gap reflects diagnostic acculturation more than true prevalence shifts.^[528] Rigorous assessment demands triangulating self-reports, biomarkers, and longitudinal data to distinguish causal cultural modulators from artifacts of biased instrumentation, ensuring classifications prioritize observable pathology over interpretive overlays.^[529]

Economic Impacts and Policy Responses

Mental disorders generate significant economic costs worldwide, encompassing direct expenditures on healthcare services, medications, and hospitalizations, as well as indirect losses from reduced workforce participation, absenteeism, presenteeism, and premature mortality. Globally, the economic burden of depression and anxiety disorders alone equates to approximately US$1 trillion annually in lost productivity, a figure that has remained consistent in assessments through 2025. Broader estimates attribute up to US$5 trillion in annual economic value losses to mental disorders, representing 4-5% of gross domestic product in affected regions, with projections indicating a rise to US$6 trillion by 2030 if unaddressed. In the United States, mental illness imposes an annual cost of $282 billion as of 2024, comparable to the impact of an average economic recession, driven largely by untreated cases among working-age adults that result in $477.5 billion in productivity deficits. These burdens disproportionately affect lower-income groups and exacerbate inequalities, potentially adding US$14 trillion in excess U.S. costs by 2040 without interventions targeting disparities.^[3]^[227]^[530]^[531]^[532]^[533] Indirect costs dominate, with studies indicating that productivity losses from unemployment and reduced output account for 60-80% of totals in high-income countries, while direct treatment costs—such as for schizophrenia, estimated at $343 billion annually in the U.S.—comprise a smaller share but have risen with increased service utilization post-pandemic. Suicide, often linked to untreated disorders, contributes substantially; for instance, it accounts for billions in foregone earnings yearly. These figures rely on disability-adjusted life years (DALYs) and willingness-to-pay valuations, which, while empirically grounded, may understate intangible societal costs like caregiver burdens or overstate through assumptions of full economic replacement value.^[109]^[534] Policy responses have centered on expanding access to mitigate these costs, though implementation varies and effectiveness remains debated. In the U.S., the Mental Health Parity and Addiction Equity Act (MHPAEA) of 2008 mandates equivalent coverage for mental health services in employer-sponsored insurance, leading to a 10-20% increase in utilization from 2008-2013 without proportionally higher premiums in many plans, potentially yielding net savings through reduced long-term disability claims. However, enforcement challenges and recent rules have drawn criticism for raising administrative costs and risking reduced network adequacy, with some analyses projecting premium hikes of up to 4% and unintended barriers to care. Globally, governments allocate a median of 2% of health budgets to mental health as of 2025, unchanged since 2017, prompting calls from bodies like the World Health Organization for scaled-up investments in community-based services to avert productivity losses.^[535]^[536]^[537]^[538]^[3] Additional measures include state-level funding increases for crisis intervention and workplace accommodations under laws like the Americans with Disabilities Act, which have correlated with modest reductions in absenteeism in pilot programs. Federal initiatives, such as expanded Medicaid coverage for behavioral health, have covered $280 billion in services annually, though unmet needs persist due to provider shortages. Prevention-focused policies, emphasizing early screening in schools and employment, show promise in lowering lifetime costs by 20-30% per case in modeled scenarios, but adoption lags amid fiscal constraints and skepticism over diagnostic overreach inflating intervention demands. Critics argue that without addressing root causes like economic inequality—linked to higher prevalence in unequal societies—such policies yield diminishing returns, as evidenced by stagnant spending efficacy in high-disparity regions.^[539]^[540]^[541]

Evolutionary and Biological Perspectives

Animal Models and Behavioral Homologies

Animal models in psychiatric research involve inducing behavioral, neurobiological, or genetic alterations in non-human species, primarily rodents, to recapitulate aspects of human mental disorders, enabling causal investigations into mechanisms inaccessible in human studies. These models aim to identify homologies—shared behavioral phenotypes and underlying neural circuits—such as avoidance behaviors analogous to anxiety or reduced reward sensitivity mirroring anhedonia in depression. For instance, rodents exhibit conserved fear responses mediated by the amygdala, paralleling human anxiety circuits, though human cognitive overlays like anticipatory worry lack direct equivalents.^[542]^[543] Validity of these models is assessed via three criteria: face validity (phenotypic similarity to disorder symptoms), predictive validity (response to known human treatments), and construct validity (etiological resemblance). In depression models, chronic mild stress in rats induces anhedonia, measured by decreased sucrose preference, which reverses with chronic antidepressant administration, demonstrating predictive validity for selective serotonin reuptake inhibitors (SSRIs) effective in humans since their introduction in the 1980s. Schizophrenia models, such as neonatal ventral hippocampal lesions in rats, produce enduring deficits in prepulse inhibition—a sensory gating measure disrupted in 70-80% of schizophrenia patients—and social interaction, homologous to human positive and negative symptoms.^[544]^[545]^[546] Anxiety models leverage innate fear responses; the elevated plus-maze test in mice quantifies avoidance of open arms, reduced by benzodiazepines that alleviate human anxiety, supporting predictive validity. Genetic models enhance construct validity, as in serotonin transporter knockout mice displaying heightened anxiety-like behaviors and altered stress responses akin to human polymorphisms linked to anxiety disorders since identified in 1996. Behavioral homologies extend to primates, where rhesus monkeys show cortisol dysregulation and withdrawal behaviors post-social isolation, echoing human attachment disruptions in disorders like autism.^[547]^[548]^[549] Despite these parallels, limitations persist: animal behaviors often reflect adaptive responses rather than pathological states, with poor translation for novel therapies, as evidenced by over 90% failure rates of preclinical candidates in human trials for psychiatric drugs. Rodent brains lack human prefrontal cortex complexity, undermining homology for executive dysfunction in disorders like ADHD, where models like spontaneously hypertensive rats capture hyperactivity but not full syndromal features. Ethical constraints and variability in model induction further challenge reproducibility, with meta-analyses scarce and questioning overall empirical robustness.^[550]^[551]^[550]

Evolutionary Theories of Vulnerability

Evolutionary theories of mental disorder vulnerability emphasize that natural selection shapes psychological mechanisms for survival and reproduction, but leaves individuals susceptible to dysfunction when these mechanisms misfire, encounter novel environments, or trade off benefits against costs. Randolph Nesse, a foundational figure in evolutionary psychiatry, argues that defenses such as anxiety and low mood evolved to prioritize avoiding threats over accuracy, as the fitness cost of failing to detect real dangers exceeds that of false alarms—a concept known as the smoke detector principle.^[552]^[553] This principle, articulated by Nesse in 2001, explains why anxiety disorders persist: systems tuned for quick activation in ancestral environments, where predators or social rivals posed immediate risks, overreact in modern contexts with chronic stressors like urban noise or job insecurity, leading to prevalence rates of anxiety disorders around 18% lifetime in the U.S. population.^[554]^[555] The mismatch hypothesis posits that many vulnerabilities arise from discrepancies between Pleistocene-era adaptations and contemporary conditions, rendering once-adaptive traits maladaptive. For instance, human psychology evolved in small hunter-gatherer groups with high physical activity, varied diets, and tight kin networks, but modern lifestyles featuring isolation, sedentary behavior, and nutrient-poor processed foods disrupt serotonin regulation and social bonding mechanisms, contributing to depression rates that have risen sharply since the 1980s in industrialized nations.^[556]^[557] Empirical support includes twin studies showing heritability of major depressive disorder at 40-50%, yet expression modulated by environmental novelty, as urban dwellers exhibit 20-40% higher incidence than rural counterparts, suggesting evolutionary calibration to ancestral ecologies.^[558] Nesse extends this to argue that vulnerability persists because selection favors flexible defenses over rigid perfection, as hyper-accurate systems would be metabolically costly and slow to respond.^[559] Additional frameworks include frequency-dependent selection and pleiotropy, where rare alleles for disorders like schizophrenia (affecting ~1% globally) confer advantages at low frequencies, such as enhanced creativity or kin recognition in social groups, but become deleterious when common.^[560] Life history theory integrates this by viewing disorders as accelerated or slowed strategies mismatched to cues of environmental harshness; for example, early adversity signals unpredictable futures, prompting fast reproduction over investment, which correlates with higher impulsivity and substance use vulnerability in longitudinal cohorts.^[561] These theories do not negate proximate causes like genetics or trauma but reframe why selection tolerates vulnerability: disorders often represent the downside of adaptive variability, with evidence from genomic studies revealing polygenic risks shared across traits like neuroticism, which aids vigilance but heightens disorder risk by 2-3 fold in high-score individuals.^[555] Critics note limited direct fossil or cross-species data, yet the persistence of these mechanisms across primates supports their deep evolutionary roots.

References

[1]
What is Mental Illness? - American Psychiatric Association
Mental illnesses are health conditions involving changes in emotion, thinking or behavior (or a combination of these).
[2]
About DSM-5-TR - American Psychiatric Association
Learn about the development and criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR).
[3]
Over a billion people living with mental health conditions – services ...
Sep 2, 2025 · The global median number of mental health workers stands at 13 per 100 000 people, with extreme shortages in low- and middle-income countries.
[4]
Global burden of mental disorders in 204 countries and territories ...
May 15, 2025 · It was estimated that by 2019, approximately 12% of the global population suffered from mental disorders, accounting for about 5% of the global ...
[5]
The roots of mental illness - American Psychological Association
Jun 1, 2012 · Often, McNally notes, mental illnesses are likely to have multiple causes, including genetic, biological and environmental factors. Of ...
[6]
Environmental Connections: A Deeper Look into Mental Illness - NIH
Scientists have long known that these potentially devastating conditions arise from combinations of genes and environmental factors.
[7]
Biological, Psychological, and Environmental Causes of Mental Illness
Jul 31, 2024 · Research consistently shows that most mental disorders result from a combination of genetic vulnerability and environmental stressors – neither ...
[8]
Mental health - Institute for Health Metrics and Evaluation
13.9% of the world's population experienced mental disorders in 2021. 71% of global anxiety disorder burden could be avoided if all people with anxiety ...
[9]
The Myth of Mental Illness: 50 years after publication - PubMed
In 1960, Thomas Szasz published The Myth of Mental Illness, arguing that mental illness was a harmful myth without a demonstrated basis in biological pathology.
[10]
How Modern Psychiatry Lost Its Way While Creating a Diagnosis for ...
May 15, 2018 · Paris argues that major depression is seriously overdiagnosed. He notes that the term dates back to the DSM, Third Edition (DSM-III).
[11]
Overdiagnosis of mental disorders in children and adolescents (in ...
Jan 17, 2017 · This study found significant evidence of overdiagnosis of attention-deficit/hyperactivity disorder. In the second part of this paper, we ...Missing: empirical | Show results with:empirical
[12]
Genetics in psychiatry: Methods, clinical applications and future ...
Apr 7, 2022 · They have confirmed that psychiatric disorders are heritable, with heritability of about 80% for SCZ and BP, while around 40%–50% for MDD.
[13]
Genetic influences on eight psychiatric disorders based on family ...
Sep 17, 2018 · Twin studies showed that genetic factors play an important role in the etiology of psychiatric traits. Heritability estimates (h2, i.e. the ...
[14]
Genetic and environmental factors of schizophrenia and autism ...
Apr 13, 2020 · They found that the heritability rate for ASD was 83% (95% CI 79–87%) and the ASD heritability rate from twin studies alone was 87% (95% CI 68– ...
[15]
New insights from the last decade of research in psychiatric genetics
Genes linked to ion channels, neurotransmitter receptors and synaptic proteins have also been implicated in GWAS on bipolar disorder65, 136 and depression .
[16]
Neuroimaging in schizophrenia: an overview of findings and their ...
Sep 2, 2022 · These studies show that schizophrenia is associated with lower grey matter volumes and cortical thickness, accelerated grey matter loss over time, abnormal ...
[17]
Neuroimaging in schizophrenia: A review article - Frontiers
Due to the high resolution of MRI, various brain abnormalities in schizophrenia such as increased volume of cerebrospinal fluid (CSF) and decreased volume of ...
[18]
Diagnostic Brain Imaging in Psychiatry: Current Uses and Future ...
Abnormalities of amygdala activation also have been reported consistently in neuroimaging studies of depression [5], bipolar disorder [6], schizophrenia (a ...
[19]
Neuroimaging in Psychiatric Disorders - PMC - NIH
It is used to detect structural lesions causing psychosis and to differentiate depression from neurodegenerative disorders or brain tumors.
[20]
Neurotransmitters and Their Influence on Mental Health Disorders
Excessive dopamine activity is linked to schizophrenia, where patients may experience hallucinations, delusions, and disordered thinking.
[21]
Neurotransmitters: What They Are, Functions & Types
Mar 14, 2022 · Diseases associated with serotonin imbalance include seasonal affective disorder, anxiety, depression, fibromyalgia and chronic pain.
[22]
Neurotransmitters—Key Factors in Neurological and ...
Explicitly, impaired GABA homeostasis has been linked to various neurological disorders (e.g., autism spectrum disorders [36,37], schizophrenia [38], epilepsy [ ...
[23]
The Underlying Neurobiological Mechanisms of Psychosis
Jun 12, 2024 · Abnormalities in GABA neurotransmission are also linked to the effects of hypoactive NMDARs on GABA interneurons, leading to E/I imbalance as a ...
[24]
Depression and anxiety: maladaptive byproducts of adaptive ... - NIH
The behaviors associated with mood disorders and anxiety disorders are not themselves adaptive, but may arise from adaptive mechanisms that have become ...
[25]
On Adaptive and Maladaptive Patterns - Psychology Today
Jun 4, 2020 · A positive adaptive pattern is where an individual adjusts to the situation in a way that results in valued outcomes, such that they are nourished and growing.
[26]
Mental disorders - World Health Organization (WHO)
Sep 30, 2025 · A mental disorder is characterized by a clinically significant disturbance in an individual's cognition, emotional regulation, or behaviour.
[27]
The Differences Among Mental, Developmental, and Behavioral ...
The primary difference between a behavior disorder and another type of psychiatric disorder is the presence of choice.
[28]
Biomarkers in Psychiatry: Concept, Definition, Types and Relevance ...
This review provides an overview about the current state of biomarkers in neuropsychiatry, with the ultimate aim of remarking some goals achieved up to date and ...
[29]
Rethinking the studies of diagnostic biomarkers for mental disorders
For mental disorders, the identification of biomarkers with high specificity, sensitivity, and validity remains a major challenge due to their heterogeneity ...
[30]
Inflammatory Biomarkers and Risk of Psychiatric Disorders
Aug 21, 2024 · In this cohort study, inflammatory biomarkers including leukocytes, haptoglobin, CRP, and IgG were associated with a subsequent risk of psychiatric disorders.
[31]
Inflammation-related biomarkers in major psychiatric disorders
Sep 18, 2019 · The relevance of inflammation to psychiatric disorders suggests its potential as a suitable biomarker. A biomarker is defined as “any substance, ...
[32]
[PDF] THE MYTH OF MENTAL ILLNESS
The crux of the matter is that a disease of the brain, analogous to a disease of the skin or bone, is a neurological defect, and not a problem in living. For ...
[33]
Mental Illness vs Brain Disorders: From Szasz to DSM-5
Feb 28, 2014 · He argues that the concept of mental illness undermines the principle of personal responsibility, which is the ground on which all free ...
[34]
Biomarkers in psychiatric disorders: status quo, impediments and ...
May 9, 2023 · Biomarkers have diverse potential roles: there may be biomarkers of risk, of diagnosis/trait, of state or acuity, of stage, of treatment response, and of ...
[35]
Candidate biomarkers in psychiatric disorders: state of the field
May 9, 2023 · The search for biomarkers in psychiatry is motivated by the need for objective measures to inform diagnosis, prognosis, and treatment choices.Biomarkers In Autism... · Biomarkers In Mood Disorders · Biomarkers In Substance Use...
[36]
No such thing as mental illness? Critical reflections on the major ...
Szasz did not deny that humans have difficulties but he preferred to conceptualise them not as mental illnesses or as diseases, but as 'problems in living'. Nor ...
[37]
“The Myth of Mental Illness:” Continuing controversies and their ...
Since the publication of “The Myth of Mental Illness” in 1960, there has been an ongoing debate about Thomas Szasz's ideas concerning mental illness.
[38]
Disorder as harmful dysfunction: A conceptual critique of DSM-III-R's ...
This definition is an attempt to operationalize 2 basic principles: that a disorder is harmful and that a disorder is a dysfunction.
[39]
The concept of mental disorder: diagnostic implications of the ...
According to the HD analysis, a condition is a disorder if it is negatively valued ("harmful") and it is in fact due to a failure of some internal mechanism.
[40]
Defining Mental Disorder: Jerome Wakefield and His Critics
Philosophers discuss Jerome Wakefield's influential view of mental disorder as “harmful dysfunction,” with detailed responses from Wakefield himself.<|separator|>
[41]
Harm should not be a necessary criterion for mental disorder
However, we believe that the harm requirement can be (provisionally) maintained among the specific diagnostic criteria of certain individual mental disorders.
[42]
What is a mental disorder? Evaluating the lay concept of Mental Ill ...
Apr 3, 2023 · Findings indicated that concepts of mental disorder were primarily based on judgments that a condition is associated with emotional distress and ...
[43]
[PDF] Harm as a Necessary Component of the Concept of Medical Disorder
May 23, 2020 · Wakefield's harmful dysfunction analysis asserts that the concept of medical disorder includes a naturalistic component of dysfunction.
[44]
What is a mental disorder? An exemplar-focused approach - PMC
Apr 12, 2021 · Many previous attempts have applied a conceptual approach to the definition of mental disorder. These have produced limited progress, ...
[45]
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
May 22, 2013 · Publisher: American Psychiatric Publishing ; Copyright Year: 2013 ; Print Date: May 22, 2013 ; Online Date: September 18, 2014 ; ISBN: 978-0-89042- ...
[46]
Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR)
The manual will help clinicians and researchers define and classify mental disorders, which can improve diagnoses, treatment, and research.Fact Sheets · About DSM-5-TR · Online Assessment Measures · Proposed Changes
[47]
WHO releases new International Classification of Diseases (ICD 11)
Jun 18, 2018 · ICD-11 will be presented at the World Health Assembly in May 2019 for adoption by Member States, and will come into effect on 1 January 2022.
[48]
The ICD‐11 has been adopted by the World Health Assembly - PMC
The endorsement of the new classification will not come into effect until January 1, 2022. Until that date, the Member States of the World Health Organization ( ...
[49]
11 has been adopted by the World Health Assembly
Oct 3, 2019 · This latter chapter includes the following groupings: neurodevelopmen- tal disorders, schizophrenia and other pri- mary psychotic disorders, ...
[50]
Mental, behavioral and neurodevelopmental disorders in the ICD-11
Jan 27, 2020 · This Forum brings together a broad range of experts to reflect on key changes and controversies in the ICD-11 classification of mental disorders.
[51]
Major Diagnostic Differences Between DSM-5 and ICD-11
May 22, 2022 · DSM-5 classifies severe childhood irritability and anger as disruptive mood dysregulation disorder, while ICD-11 classifies it as oppositional defiant disorder ...
[52]
7 DSM-5 and ICD-11 classifications - Oxford Academic
The diagnostic guidelines in the CDDG differed from DSM diagnostic criteria in offering more flexible, prototypic guidance intended to allow for clinical ...DSM-I to DSM-IV and ICD-10... · DSM-5 and ICD-11... · Mental and behavioural...
[53]
DSM-5 Field Trials in the United States and Canada, Part II: Test ...
Overall, five diagnoses were in the very good range (kappa=0.60–0.79), nine in the good range (kappa=0.40–0.59), six in the questionable range (kappa=0.20–0.39) ...
[54]
DSM-5 field trials in the United States and Canada, Part II - PubMed
Overall, five diagnoses were in the very good range(kappa=0.60–0.79), nine in the good range(kappa=0.40–0.59), six in the questionable range (kappa = 0.20–0.39) ...
[55]
DSM 5 Field Trials Discredit APA - Psychology Today
Oct 30, 2012 · According to the authors, 14 of the 23 disorders had “very good” or “good” reliability; 6 had questionable, but 'acceptable' levels; and just ...
[56]
DSM-5: How Reliable Is Reliable Enough? - Psychiatry Online
Jan 1, 2012 · It is unrealistic to expect that the quality of psychiatric diagnoses can be much greater than that of diagnoses in other areas of medicine, ...
[57]
Method Matters: Understanding Diagnostic Reliability in DSM-IV and ...
Given this situation, it is not surprising that the DSM-5 Field Trials—which resulted in lower kappa reliability estimates than past field trials and the ...
[58]
DSM-5: How Reliable Is Reliable Enough? - Psychology Today
Jan 18, 2012 · For DSM 5, 'acceptable' reliability has been reduced to a startling 0.2-0.4. This barely exceeds the level of agreement you might expect to get ...Missing: criticisms | Show results with:criticisms
[59]
The ICD‐11 developmental field study of reliability of diagnoses of ...
This paper describes the EIFS results concerning reliability of the proposed ICD‐11 CDDG among adult patients in 13 countries.
[60]
Debating DSM-5: diagnosis and the sociology of critique - PMC - NIH
Dec 10, 2013 · The weakness is its lack of validity. Unlike our definitions of ischemic heart disease, lymphoma, or AIDS, the DSM diagnoses are based on a ...
[61]
Director of top research organization for mental health criticizes ...
May 8, 2013 · “The weakness is its lack of validity.” The problem, Insel said, was that “DSM diagnoses are based on a consensus about clusters of clinical ...
[62]
Poor Separation of Clinical Symptom Profiles by DSM-5 Disorder ...
While 58.7% of those with 5 or more clinically significant symptoms did not map to the diagnostic criteria of any of the 10 DSM-5 disorders studied, those with ...
[63]
Psychiatric comorbidity: fact or artifact? - PMC - PubMed Central - NIH
This article investigates the nature of comorbidity among psychiatric diseases, and considers how this reflects on psychiatric disease classification.
[64]
The perils of diagnostic inflation - PMC - NIH
Allen Frances, appears no less aghast. “Most of the changes made to the DSM-V are based on limited data, the evidence is remarkably weak for changing anything,” ...
[65]
ICD-11 and mental disorders: important changes, controversies, and ...
Sep 25, 2023 · One major change is the avoidance of arbitrary cut-offs for diagnostic symptoms but description of essential features that occur nearly in all ...
[66]
Validity, reliability and clinical utility of mental disorders
ICD-11 schizophrenia demonstrates adequate reliability and clinical utility, but its validity remains uncertain.
[67]
ICD-11 should not repeat the mistakes made by DSM-5
Jan 2, 2018 · It has included a number of new and untested mental disorders without sufficient data on prevalence, reliability, validity, treatment response, ...Background · Problems With Dsm-5 · Sensitivity V. Specificity<|separator|>
[68]
Poor DSM-5—So Misunderstood! - Psychiatric Times
Mar 23, 2021 · Critics' claims of DSM-5's biomedical focus are unfounded; it lacks emphasis on genetics or neurochemistry. DSM-5 acknowledges fluid boundaries ...
[69]
A dimensional model for common mental disorders - PubMed
A more parsimonious representation of symptomatology can be obtained by using a dimensional model for symptoms-with two correlated axes corresponding to ...
[70]
Review What is a psychopathology dimension? - ScienceDirect.com
The first possible meaning of “dimension” is that the sum or average of symptoms or indicators of a disorder category can be thought of or treated as continuous ...
[71]
Dimensional models of personality disorders - PubMed Central - NIH
This review focuses on challenges and the related opportunities of moving toward dimensional models in personality disorder research and practice.
[72]
Transdiagnostic Approaches to Mental Health Problems
We propose that 'transdiagnostic' approaches have the potential to better represent the clinical and scientific reality of mental health problems.
[73]
Effectiveness of Transdiagnostic Cognitive-Behavioral ...
Dec 23, 2020 · A transdiagnostic modular cognitive-behavioral therapy (CBT) program outperform management as usual for youth with emotional and behavioral problems.
[74]
A systematic review and meta-analysis of transdiagnostic cognitive ...
Jan 16, 2024 · This review and meta-analysis strengthens the evidence for TD-CBT as an efficacious treatment for emotional disorders in different settings.
[75]
Transdiagnostic psychiatry: a systematic review - PMC - NIH
Therefore, a transdiagnostic approach in psychiatry is expected to cut across existing categorical diagnoses and go beyond them, to produce a better ...
[76]
Research Domain Criteria (RDoC) - National Institute of Mental Health
RDoC is a research framework for new approaches to investigating mental disorders, integrating many levels of information (from genomics and circuits to ...RDoC MatrixAbout RDoCNew NIMH initiativeDefinitions of the RDoC ...RDoC Domains and Constructs
[77]
The NIMH Research Domain Criteria (RDoC) Project: Precision ...
Apr 1, 2014 · RDoC's ultimate goal is precision medicine for psychiatry—a diagnostic system based on a deeper understanding of the biological and psychosocial ...
[78]
Revisiting the seven pillars of RDoC | BMC Medicine | Full Text
Jun 30, 2022 · More than a decade has passed since the National Institute of Mental Health (NIMH) Research Domain Criteria (RDoC) project was initiated, and ...
[79]
The Utility of Research Domain Criteria in Diagnosis and ... - Frontiers
Notably, using the RDoC framework, the risk of developing a disorder was found to be significantly elevated, as much as 67%, at levels of temper loss that are ...
[80]
Research Domain Criteria: Strengths, Weaknesses, and Potential ...
Aug 13, 2019 · RDoC conceptualizes normal human behavior, emotion, and cognition as dimensional, with mental illnesses as dimensional extremes. We suggest that ...
[81]
Neurodevelopmental disorders—the history and future of a ... - NIH
In DSM-5, NDDs include intellectual disability (ID), autism spectrum disorder (ASD), and attention-deficit/hyperactivity disorder (ADHD).
[82]
Prevalence of neurodevelopmental disorders among US children ...
Nov 24, 2022 · The weighted prevalence of currently had NDDs was 8.5% (95% CI: 7.9–9.2%) for ADHD, 2.9% (95% CI: 2.6–3.4%) for ASD, 1.4% (95% CI: 1.2–1.7%) for ...
[83]
Diagnosed Developmental Disabilities in Children Aged 3–17 Years
Jul 13, 2023 · The prevalence of any developmental disability was similar across age groups: 8.42% in children aged 3–7, 8.05% in children aged 8–12, and 7.84% ...
[84]
[PDF] NCHS Data Brief, Number 473, July 2023 - CDC
NCHS Data Brief ■ No. 6.06% in 2021. The prevalence of any developmental disability varied by sex and race and Hispanic origin but not age group. (10.76%) than ...
[85]
What do we know about genes and environmental factors in autism?
Jun 25, 2025 · "In the case of autism, heritability is estimated at around 80–90 per cent. ... In cases of autism accompanied by intellectual disability, rare ...
[86]
Shared heritability of attention-deficit/hyperactivity disorder and ...
In ADHD, approximately 76% of the phenotypic variance is explained by heritable factors [29]; in ASD, heritability has been estimated as >90% for the narrow ...Missing: intellectual disability
[87]
The Familial Risk of Autism Spectrum Disorder with and without ...
Oct 26, 2020 · The broad-sense heritability (95% CI) for ASD − ID and ASD+ID were 64.6% (46.0–100.0%) and 33.4% (14.4–58.4%), respectively. Familial risk and ...
[88]
Early environmental risk factors for neurodevelopmental disorders
This genetically informed review showed evidence for a range of environmental factors of potential casual significance in NDDs.
[89]
A meta-analysis of genetic effects associated with ... - Nature
Feb 20, 2023 · This meta-analysis provides a holistic view of genetic and environmental contributions to all NDDs and commonly co-occurring developmental ...
[90]
Neurodevelopmental Disorders: From Genetics to Functional ...
Feb 27, 2020 · NDDs are caused by the disruption of essential neurodevelopmental processes. Many genes and mutations are associated with NDDs, pointing to ...
[91]
Neurodevelopmental disorders: mechanisms and boundary ... - NIH
Dec 3, 2013 · Neurodevelopmental disorders such as intellectual disability, autism spectrum disorder and schizophrenia lack precise boundaries in their clinical definitions.Missing: criticisms | Show results with:criticisms
[92]
[PDF] Neurodevelopmental Disorders - EPA
Examples of neurodevelopmental disorders in children include attention-deficit/hyperactivity disorder (ADHD), autism, learning disabilities, intellectual.
[93]
Table 3.20, DSM-IV to DSM-5 Psychotic Disorders - NCBI
At least one of these must be (1), (2), or (3):. delusions. hallucinations. disorganized speech (e.g., frequent derailment or incoherence). grossly disorganized ...Missing: prevalence | Show results with:prevalence
[94]
Structure of the Psychotic Disorders Classification in DSM-5 | Focus
There are five such domains: hallucinations, delusions, disorganized thought (speech), disorganized or abnormal motor behavior (including catatonia), and ...
[95]
Acute Psychosis: Differential Diagnosis, Evaluation, and Management
Mar 23, 2023 · Specifically, the DSM-5 diagnosis of brief psychotic disorder requires the presence of psychotic symptoms for between 1 day and 1 month and ...
[96]
Psychotic Disorders: Types, Symptoms, Diagnosis, Treatment
Aug 20, 2024 · Types of Psychotic Disorders · Schizophreniform disorder · Schizoaffective disorder · Delusional disorder · Brief psychotic disorder.
[97]
Psychotic Disorders: List of Types, Symptoms, Causes
Types of Psychotic Disorders · Schizophreniform disorder · Delusional disorder · Brief psychotic disorder · Substance/medication-induced psychotic disorder ...Types · Symptoms · Diagnosis · Treatment
[98]
Schizophrenia - World Health Organization (WHO)
Oct 6, 2025 · Schizophrenia affects approximately 23 million people or 1 in 345 people (0.29%) worldwide. The rate is 1 in 233 people (0.43%) among adults (2) ...
[99]
Schizophrenia - National Institute of Mental Health (NIMH) - NIH
Estimates of the international prevalence of schizophrenia among non-institutionalized persons is 0.33% to 0.75%.Definition · Prevalence of Schizophrenia
[100]
Prevalence of Psychotic Disorder and Community ... - JAMA Network
The prevalence of psychotic symptoms broadly defined was 17.5% (n = 1237), and the prevalence of psychotic symptoms narrowly defined was 4.2% (n = 295).
[101]
New genetic findings in schizophrenia: is there still room ... - Frontiers
Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. ... The G72/G30 gene locus in psychiatric disorders: a challenge to diagnostic ...
[102]
Dopamine and Psychosis: Theory, Pathomechanisms and ...
The dopamine hypothesis is the oldest neurochemical theory of the pathophysiology of psychosis. ... genetic mechanisms of psychiatric disorders. Nat Rev ...
[103]
Dopamine Hypothesis of Schizophrenia: Version III—The Final ...
Mar 26, 2009 · Striatal dopamine elevation is not seen in mania, depression, or other psychiatric disorders without psychosis142–147 and not related to ...
[104]
Mood Disorder - StatPearls - NCBI Bookshelf
Mood disorders are described by marked disruptions in emotions (severe lows called depression or highs called hypomania or mania).
[105]
An organization‐ and category‐level comparison of diagnostic ...
The ICD‐11 and DSM‐5 definitions of a (major) depressive episode are nearly the same: at least five symptoms persisting nearly every day for at least 2 weeks, ...
[106]
Bipolar disorder in the International Classification of Diseases ...
Dec 19, 2022 · There are only minor differences between the two classifications. Nevertheless, the ICD-11 definitions are somewhat broader than the DSM-5 ones.
[107]
Global, regional, and national burden of major depressive disorders ...
According to a recent cross-national study, the average lifetime prevalence of MDD is 7.5 % for males and 13.6 % for females, and the projected cumulative ...
[108]
Mental Health - Our World in Data
It's estimated that 1 in 3 women and 1 in 5 men will experience major depression in their lives. Other conditions, such as schizophrenia and bipolar disorder, ...How do researchers study the... · What is the lifetime risk of...
[109]
Mental Health By the Numbers
Schizophrenia Spectrum Disorders: 1.2% ; Posttraumatic Stress Disorder: 4.1% ; Co-occurring Substance Use Disorder and Mental Illness: 8.1% ; Major Depressive ...<|separator|>
[110]
Major Depression and Genetics - Stanford Medicine
In most cases of depression, around 50% of the cause is genetic, and around 50% is unrelated to genes (psychological or physical factors).<|separator|>
[111]
A Scientometric Review of the Genetic Basis of Mood Disorders
Jan 30, 2023 · Specifically, twin and adoption studies indicate the strong contribution of genetic factors in the risk for these psychiatric disorders [8,9].
[112]
Mood disorders - Symptoms and causes - Mayo Clinic
Jan 31, 2024 · Mood disorders are caused by traits passed down to you, as well as environmental factors and life events. Environmental factors can include, for ...Missing: genetic | Show results with:genetic
[113]
[PDF] Reliability of DSM-IV Anxiety and Mood Disorders - Boston University
The reliability of current and lifetime Diagnostic and Statistical Manual of Mental Disorders (4th ed.;. DSM-IV; American Psychiatric Association, ...
[114]
The Classification of Mood Disorders and the Unipolar/Bipolar ...
May 16, 2024 · A long-standing debate in the field of mood disorders classification is the continuity or spectrum concept of mood disorders, which includes ...
[115]
Environmental factors, life events, and trauma in the course of ... - NIH
The etiology and clinical course of bipolar disorder are considered to be determined by genetic and environmental factors. Although the kindling hypothesis ...
[116]
What are Anxiety Disorders? - American Psychiatric Association
Generalized anxiety disorder involves persistent and excessive worry that interferes with daily activities. This ongoing worry and tension may be accompanied by ...Types of Anxiety Disorders · How Common Are Anxiety...
[117]
Table 3.15, DSM-IV to DSM-5 Generalized Anxiety Disorder ... - NCBI
A. Excessive anxiety and worry (apprehensive expectation), occurring more days than not for at least 6 months, about a number of events or activities (such as ...
[118]
Anxiety Disorders - National Institute of Mental Health (NIMH) - NIH
About a third of U.S. adolescents and adults experience an anxiety disorder at some point in their lives. Anxiety disorder symptoms can interfere with daily ...
[119]
Anxiety Disorders: A Review - PubMed - NIH
Dec 27, 2022 · Generalized anxiety disorder (6.2% lifetime prevalence), social anxiety disorder (13% lifetime prevalence), and panic disorder (5.2% lifetime ...
[120]
Genetics of anxiety disorders: Genetic epidemiological and ...
Mar 12, 2015 · Genetic epidemiological studies report a moderate level of familial aggregation (odds ratio: 4–6) and heritability estimates are about 30–50%.
[121]
A Review and Meta-Analysis of the Genetic Epidemiology of Anxiety ...
OBJECTIVE: The authors conducted meta-analyses of data from family and twin studies of panic disorder, generalized anxiety disorder, phobias, ...
[122]
Genome-wide Association Study Confirms PTSD Is in Part ...
Jun 14, 2019 · The reliability and/or validity of PTSD diagnosis may differ by sex (e.g., cultural factors may discourage men from complaining of PTSD symptoms) ...Missing: criticisms | Show results with:criticisms
[123]
PTSD and DSM-5 - PTSD: National Center for PTSD - VA.gov
PTSD was included in a new category in DSM-5, Trauma- and Stressor-Related Disorders. All conditions included in this classification require exposure to a ...
[124]
Posttraumatic Stress Disorder - StatPearls - NCBI Bookshelf - NIH
Feb 25, 2024 · Posttraumatic stress disorder (PTSD) is a prevalent and complex psychiatric condition that arises in response to exposure to traumatic events.Etiology · History and Physical · Evaluation · Treatment / Management
[125]
Post-Traumatic Stress Disorder (PTSD)
An estimated 3.6% of U.S. adults had PTSD in the past year. · Past year prevalence of PTSD among adults was higher for females (5.2%) than for males (1.8%).Missing: acute | Show results with:acute
[126]
Acute Stress Disorder - PTSD
ASD prevalence rates vary in trauma exposed populations across studies and across different trauma types, with an average of 19% (1). Some trauma types are ...
[127]
[PDF] Genomic Perspectives on PTSD
It is part genetic, with 20-40% risk heritability for. PTSD following trauma; and in part depends on past personal history, including adult and childhood trauma ...<|separator|>
[128]
The Genetics of Stress-Related Disorders: PTSD, Depression, and ...
This review focuses on the genetic basis of three disorder categories—posttraumatic stress disorder (PTSD), major depressive disorder (MDD), and the anxiety ...
[129]
Personality Disorders - National Institute of Mental Health (NIMH)
Personality disorders represent “an enduring pattern of inner experience and behavior that deviates markedly from the expectations of the individual's culture” ...Definitions · Prevalence of Personality... · Co-morbidity with Other Mental...
[130]
Overview of Personality Disorders - Merck Manuals
Personality disorders in general are pervasive, enduring patterns of thinking, perceiving, reacting, and relating that cause significant distress or functional ...
[131]
The prevalence of personality disorders in the community: a global ...
Jul 12, 2019 · The global pooled prevalence of any personality disorder was 7.8% (95% CI 6.1–9.5%). This figure exceeds the WHO World Mental Health personality ...
[132]
Diagnosing Personality Disorders: A Review of Issues and ...
First, I review studies of diagnostic reliability and stability, because studies of the above questions can only be interpreted in the context of the ...
[133]
Personality disorder: a disease in disguise - PMC - PubMed Central
Overwhelming evidence supports the idea that an interaction between genetic and environmental factors is necessary for the development of human personality. The ...Classification Of... · General Description Of... · Dimensions Of Personality...
[134]
What Is a Substance Use Disorder? - Psychiatry.org
Substance use disorder (SUD) is a complex condition in which there is uncontrolled use of a substance despite harmful consequences.
[135]
Substance Use Disorders - Impact of the DSM-IV to ... - NCBI - NIH
The DSM-5 combines the abuse and dependence criteria under the new rubric substance use disorder, which requires 2 out of 11 criteria in a 12-month period for ...
[136]
[PDF] The Neurobiology of Drug Addiction - NIDA
The neurons of the VTA contain the neurotransmitter dopamine, which is released in the nucleus accumbens and in the prefrontal cortex (point to each of these ...
[137]
DSM 5 Criteria for Substance Use Disorders - Verywell Mind
The 11 criteria outlined in the DSM-5-TR can be grouped into four primary categories: physical dependence, risky use, social problems, and impaired control.The DSM 5 Criteria · Substances · Substance-Induced Disorders
[138]
Alcohol and Drug Abuse Statistics (Facts About Addiction)
Mar 26, 2025 · In 2023, 48.5 million Americans had a substance use disorder, 10.2% had alcohol use disorder, 9.7% had drug use disorder, and 7.5 million had ...Statistics for Substance Use in... · Substance Abuse · Am I A Drug Addict Quiz
[139]
2023 National Survey on Drug Use and Health (NSDUH) Releases
Feb 13, 2025 · The 2023 NSDUH Detailed Tables present national estimates of substance use, mental health, and treatment in the United States.Key Substance Use and... · 2021, 2022, and 2023... · Table of Contents
[140]
What is Gambling Disorder? - American Psychiatric Association
Gambling disorder is identified by a pattern of repeated and ongoing betting and wagering that continues despite creating multiple problems in several areas of ...
[141]
Addiction: Current Criticism of the Brain Disease Paradigm - NIH
Jul 8, 2013 · Many argue that framing addiction as a disease will enhance therapeutic outcomes and allay moral stigma. We conclude that it is not necessary, and may be ...
[142]
Addiction as a brain disease revised: why it still matters, and the ...
Feb 22, 2021 · A common criticism of the notion that addiction is a brain disease is that it is reductionist and in the end therefore deterministic [81, 82].
[143]
The co-morbidity of DSM-V Gambling with DSM-V mental disorders ...
Apr 10, 2023 · There is evidence that gambling disorder shares similarities with other types of addictive behavior, such as occurs in substance abuse.
[144]
Classification of Neurocognitive Disorders in DSM-5: A Work in ... - NIH
Having listed these (complex attention, learning and memory, executive ability, language, visuoconstructional-perceptual ability, and social cognition), we ...
[145]
DSM-5-TR Neurocognitive Disorders Supplement - Psychiatry Online
Oct 1, 2022 · The criteria for the various NCDs are based on defined cognitive domains. Table 1 pro- vides for each of the key domains a working definition, ...
[146]
DSM-5 and Neurocognitive Disorders
Jun 1, 2014 · Those disorders that do not cause sufficient impairment to qualify for a diagnosis of dementia are now defined as neurocognitive disorders and ...
[147]
Neurocognitive disorders in ICD‐11: the debate and its outcome - NIH
In the ICD‐11, the chapters “06. Mental, behavioural or neurodevelopmental disorders” and “08. Diseases of the nervous system” are going to include, ...
[148]
Dementia statistics | Alzheimer's Disease International (ADI)
There are over 55 million people worldwide living with dementia in 2020. This number will almost double every 20 years, reaching 78 million in 2030 and 139 ...
[149]
One in 10 Older Americans Has Dementia
Oct 24, 2022 · In a nationally representative study of cognitive impairment prevalence, Columbia researchers found almost 10% of older adults have dementia ...
[150]
Time Trends in the Prevalence of Neurocognitive Disorders and ...
The prevalence of AD increased from 1.87% in 1998 to 2.96% in 2010 with an annual percentage change (APC) of 4.08% (5.08% for males; 3.78% for females). After ...
[151]
[PDF] DSM-5 Table of Contents - American Psychiatric Association
Other Specified Mental Disorder Due to Another Medical Condition. Unspecified Mental Disorder Due to Another Medical Condition. Other Specified Mental Disorder.
[152]
The DSM-5: Classification and criteria changes - PubMed Central
Under the DSM-IV, individuals exhibiting symptoms of major depressive disorder were excluded from diagnosis if also bereaved within the past 2 months. The ...
[153]
Classifying neurocognitive disorders: the DSM-5 approach
Neurocognitive disorders--including delirium, mild cognitive impairment and dementia--are characterized by decline from a previously attained level of ...
[154]
[PDF] DSM-5 NEUROCOGNITIVE DISORDERS (
The criteria for the various NCDs are all based on defined cognitive domains. Table 1 provides for each of the key domains a working definition, examples of ...
[155]
Heritability Estimates for Psychotic Disorders: The Maudsley Twin ...
Studies of schizophrenia using clinical diagnoses have consistently suggested an important genetic component, with heritability estimates from 41% to 87%.
[156]
Twin Studies of Heritability | Psychiatric Epidemiology
Findings from heritability studies of twins have been interpreted to mean that shared family environment has only weak effects on mental traits and disorders ( ...
[157]
A population-based heritability estimate of bipolar disorder
Twin- and family studies have shown variations in the heritability estimates of bipolar disorder (BPD). The current study uses an updated statistical ...
[158]
Heritability of autism spectrum disorders: a meta‐analysis of twin ...
Dec 27, 2015 · The meta-analytic heritability estimates were substantial: 64–91%. Shared environmental effects became significant as the prevalence rate ...<|separator|>
[159]
Population-Based Estimates of Heritability Shed New Light on ...
Nov 1, 2018 · The results showed moderate heritability for major depression. Estimates were around 41%−49% in twins and 36%−51% in the sibling sample, very ...
[160]
Polygenic Scores in Psychiatry: On the Road From Discovery to ...
Nov 1, 2022 · Across ancestries, those with a polygenic score in the top 1% of the distribution were at a sixfold increased risk of schizophrenia compared ...
[161]
Eight Psychiatric Disorders Share the Same Genetic Causes, Study ...
Jan 23, 2025 · A new study identifies specific genetic variants that have significant impacts on brain development and are shared across eight different psychiatric disorders.Missing: 2023-2025 | Show results with:2023-2025
[162]
Genetic variants associated with psychiatric disorders are enriched ...
Oct 15, 2022 · Multiple psychiatric disorders have been associated with abnormalities in both the innate and adaptive immune systems.
[163]
Several Psychiatric Disorders Share The Same Root Cause, Study ...
Jun 10, 2025 · Researchers recently discovered that eight different psychiatric conditions share a common genetic basis.What Is ADHD? · What Is Schizophrenia? · What Is Autism Spectrum...Missing: 2023-2025 | Show results with:2023-2025
[164]
Polygenic risk scores: from research tools to clinical instruments
May 18, 2020 · Polygenic risk scores may be used to estimate an individual's lifetime genetic risk of disease, but the current discriminative ability is low in the general ...
[165]
Information about Mental Illness and the Brain - NCBI - NIH
Scientists believe that there may be disruptions in the neurotransmitters dopamine, glutamate, and norepinephrine in individuals who have schizophrenia. One ...Mental Illness in the Population2 · Mental Illness and the Brain4
[166]
Neuroimaging in schizophrenia: A review article - PMC
Nov 15, 2022 · Although CT is often the first study performed in new onset psychosis, MRI and functional imaging have proved the mainstay for schizophrenia ...
[167]
A systematic review of structural and functional magnetic resonance ...
Jul 4, 2024 · We conducted a systematic review to provide an overview of studies that investigated the neural correlates of depressive symptoms in SSDs using neuroimaging ...
[168]
Brain Imaging Reveals Patterns That Foreshadow Schizophrenia's ...
Jul 5, 2020 · For people at risk of schizophrenia, these variants might push them over a tipping point, triggering psychosis. Treatment Options for ...<|separator|>
[169]
HPA Axis in Major Depression: Cortisol, Clinical Symptomatology ...
The Hypothalamic Pituitary Adrenal (HPA) axis has been implicated in the pathophysiology of a variety of mood and cognitive disorders.
[170]
Childhood Trauma, the HPA Axis and Psychiatric Illnesses - Frontiers
In this review we synthesize current understandings and hypotheses concerning the neurobiological link between childhood trauma, the HPA axis, and adult ...Abstract · Early Life Stress and Trauma · The HPA Axis, Early Life... · Conclusion
[171]
The HPA axis dysregulation in severe mental illness: Can we shift ...
The HPA axis dysregulation is widely observed in patients with severe mental illness and it is likely that it occurs as a consequence of exposure to various ...
[172]
Neuroinflammation in psychiatric disorders: An introductory primer
There is strong evidence linking neuroinflammation to neurodegenerative conditions such as Alzheimer's disease and multiple sclerosis.
[173]
An Overview of Psychological and Neurobiological Mechanisms by ...
Alterations in brain structure and function in limbic and prefrontal cortical regions have been linked to early negative experiences and to mood disorders.
[174]
Prenatal exposure to ambient air pollution is associated with ...
Jan 24, 2023 · Higher prenatal ambient air pollution exposure has been associated with impaired neurodevelopment in preschoolers and school-aged children.
[175]
Prenatal environmental risk factors for autism spectrum disorder and ...
Sep 16, 2024 · Infection during pregnancy, gestational diabetes, and maternal obesity are established risk factors for ASD. Emerging areas of research include ...
[176]
Meta-Analysis of the Association of Urbanicity With Schizophrenia
The risk for schizophrenia at the most urban environment was estimated to be 2.37 times higher than in the most rural environment.
[177]
The role of genetic liability in the association of urbanicity at birth ...
Compared to birth in rural areas, birth at higher levels of urbanicity was associated with greater risk of schizophrenia, with the exception of birth in ...
[178]
The Association of Adverse Childhood Experiences with Anxiety and ...
Children exposed to four or more ACEs had higher odds of anxiety (aOR:1.7; 95% CI 1.4-2.1) and depression (aOR: 2.2; 95% CI 1.7-2.9) than children with exposure ...
[179]
Population Attributable Fractions of Psychiatric Disorders and ...
Oct 10, 2011 · The estimated attributable fractions for psychiatric disorders attributable to having experienced any adverse childhood event ranged from 22% to 32% among ...
[180]
The association between adverse childhood experiences and ...
In fact, adults who experience four or more ACEs were 4.6 times (95 % CI: 3.8–5.6) more likely to report being depressed in the previous year compared to adults ...
[181]
Socioeconomic status, personality, and major mental disorders
Apr 27, 2024 · Our Mendelian randomization (MR) study aims to explore the bidirectional causality between SES and mental disorders, as well as to evaluate the potential ...
[182]
New Study Confirms Causal Link Between Poverty and Mental Illness
Jul 10, 2024 · Clinical relevance: New research confirms that poverty and mental illness are causally linked, with each exerting influence on the other.
[183]
Psychosocial factors associated with the mental health of ...
Aug 23, 2017 · Positive family and peer relationships, high self-esteem and optimism were associated with increased positive mental health outcomes.<|separator|>
[184]
The social determinants of mental health and disorder: evidence ...
Jan 12, 2024 · In this paper we provide a roadmap to address the social determinants that cause mental ill health.
[185]
The reciprocal relationships between economic status and mental ...
Dec 1, 2024 · According to the social causation theory, lower levels of socioeconomic conditions would predict lower levels of mental health (Hypothesis 1).
[186]
Gene-Environment Interactions in Psychiatry: Recent Evidence and ...
The stress-diathesis model suggests that individuals are born genetically vulnerable to psychiatric disorders and that those disorders manifest only if an ...
[187]
Gene–Environment Interactions in Severe Mental Illness - PMC
A functional polymorphism (Val66Met) in the brain-derived neurotrophic factor (BDNF) gene has been reported to interact with stressful life events and childhood ...
[188]
Gene-Environment Interactions in Schizophrenia: A Literature Review
Nov 23, 2021 · We provide a brief review of studies reporting evidence of such interactions, exploring genes and variants that moderate the effect of the environment to ...
[189]
Polygenic scores for schizophrenia and major depression are ...
Jul 4, 2022 · Polygenic scores for schizophrenia and major depression are associated with psychosocial risk factors in children: evidence of gene–environment ...
[190]
Genetic and phenotypic similarity across major psychiatric disorders
Mar 30, 2024 · ... heritability of human traits based on fifty years of twin studies. ... bipolar disorder, schizophrenia, and autism spectrum disorder. Biol ...
[191]
Gene × Environment Interactions in Schizophrenia: Evidence from ...
Sep 20, 2016 · Interactions between genetic risk and environmental stressors at various stages of life appear important in the development of schizophrenia ...Mutant Models of G × E... · Infection and Schizophrenia · Cannabis Use and...<|separator|>
[192]
Epigenetics of Stress-Related Psychiatric Disorders and Gene ...
Jun 17, 2015 · Here, we review epigenetic mechanisms associated with the response to stress and trauma exposure and the development of stress-related psychiatric disorders.
[193]
The Biopsychosocial Model and Its Limitations - Psychology Today
Oct 30, 2015 · In the next post, I explain why we should move from the ambiguous biopsychosocial model offered by Engel for medicine to the physical-bio-psycho ...
[194]
The biopsychosocial model: Its use and abuse
Apr 17, 2023 · The biopsychosocial model (BPSM) is increasingly influential in medical research and practice. Several philosophers and scholars of health have criticized the ...
[195]
[PDF] Gene–environment interactions in psychiatry
Mental disorders have known environmental causes, but there is heterogeneity in the response to each causal factor, which gene– environment findings ...
[196]
Defining the Environment in Gene–Environment Research: Lessons ...
Sep 10, 2013 · As shown in Figure 1, a diathesis-stress model implies increasing heritability in negative environments, and an allelic divergence as adversity ...
[197]
DSM-5: What It Is & What It Diagnoses - Cleveland Clinic
The Diagnostic and Statistical Manual of Mental Disorders, often known as the “DSM,” is a reference book on mental health and brain-related conditions and ...Missing: adaptive exclusion
[198]
ICD-11
International Classification of Diseases 11th Revision. The global standard for diagnostic health information. Use ICD‑11. ICD-11 Browser; for seeing the ...WHO-FIC Maintenance Platform · Coding Tool · ICD-11 Training Package · ICD-API
[199]
The latent structure of psychiatric symptoms across mental disorders ...
Aug 9, 2016 · Raw data were used from five studies of adults with mental illnesses (N=4,480) in an attempt to identify a psychiatric symptoms factor ...
[200]
Mental Illness Surveillance Among Adults in the United States - CDC
Sep 2, 2011 · The most common mental illnesses in adults are anxiety and mood disorders (4). The effects of mental illness range from minor disruptions in ...
[201]
Mental illness - Symptoms and causes - Mayo Clinic
Dec 13, 2022 · Excessive fears or worries, or extreme feelings of guilt; Extreme mood changes of highs and lows; Withdrawal from friends and activities ...
[202]
Innovations and changes in the ICD‐11 classification of mental ...
The ICD‐11 guidelines explicitly state that gender variant behaviour and preferences alone are not sufficient for making a diagnosis. NEW MENTAL, BEHAVIOURAL ...
[203]
Warning Signs of Mental Illness - Psychiatry.org
Dramatic sleep and appetite changes. · Decline in personal care – Difficulty caring for oneself including bathing. · Mood changes — ...
[204]
Age at onset of mental disorders worldwide: large-scale meta ...
Jun 2, 2021 · Descriptively, the earliest median age of onset was observed for phobias/separation anxiety, ASD, ADHD, social anxiety disorders (8-13 years), ...
[205]
Avoiding the pitfalls of the DSM-5: A primer for health professionals
The purpose of this primer is to assist health professionals in avoiding pitfalls by presenting five key considerations applicable to the DSM.
[206]
Clinical descriptions and diagnostic requirements for ICD-11 mental ...
Mar 8, 2024 · CDDR is a comprehensive diagnostic manual designed to support the accurate and reliable identification and diagnosis of these disorders in clinical settings ...
[207]
Unveiling the Structure in Mental Disorder Presentations | Guidelines
Aug 7, 2024 · Importance DSM criteria are polythetic, allowing for heterogeneity of symptoms among individuals with the same disorder. In empirical research, ...
[208]
The Heterogeneity of Depression | American Journal of Psychiatry
Oct 1, 2023 · Clinicians are familiar with the heterogeneous nature of depression. Two patients rarely share the same symptoms, risk factors, treatments, or outcome.
[209]
Regional, circuit and network heterogeneity of brain abnormalities in ...
Aug 14, 2023 · We showed that heterogeneity between individuals in regional GMV deviations is a general feature of psychiatric illness, but that these ...
[210]
The Influence of Culture and Society on Mental Health - NCBI - NIH
There are some well recognized differences in symptom presentation across cultures. The previous chapter described ethnic variation in symptoms of ...Missing: variability | Show results with:variability
[211]
The Heterogeneity problem: Approaches to identify psychiatric ...
One issue is the 'heterogeneity problem': different causal mechanisms may relate to the same disorder, and multiple outcomes of interest can occur within one ...
[212]
Comorbid mental disorders among adults in the mental health ...
Approximately one-third of adults (31.1%, or more than 15 million) with a past-year mental disorder had a co-occurring mental disorder.
[213]
Comorbidity within mental disorders: a comprehensive analysis ...
Survey data from a range of sites confirms that comorbidity between mental disorders is common. Understanding the risks of temporally secondary disorders ...
[214]
Exploring Comorbidity Within Mental Disorders Among a Danish ...
Jan 16, 2019 · Some disorders were associated with substantial absolute risks of developing specific later disorders (eg, 30.6% [95% CI, 29.3%-32.0%] of men ...Missing: empirical | Show results with:empirical
[215]
The prevalence of mental disorders and patterns of comorbidity ...
Jun 11, 2020 · The results of this study revealed high levels of comorbidity within a sample of mentally ill prisoners. Taken together, 56.9% of the patients ...
[216]
Prevalence and comorbidity of mental disorders among young ...
Apr 27, 2025 · We found a very high prevalence of mental disorders and a high rate of comorbidity comparable to the prevalence at baseline.
[217]
Longitudinal Assessment of Mental Health Disorders and ...
Apr 21, 2020 · This cohort study describes mental disorder life histories across 4 decades among participants in the Dunedin Study.
[218]
Longitudinal Assessment of Mental Health Disorders and ... - NIH
Apr 21, 2020 · This study demonstrates how much novel information can be learned by taking a longitudinal, life-course view of mental disorders.
[219]
Longitudinal studies of child mental disorders in the general ...
Aug 11, 2023 · Longitudinal studies of child mental disorders in the general population have advanced our understanding of trends in prevalence and incidence ...
[220]
Persistence and course of mental health problems from childhood ...
Feb 27, 2021 · This longitudinal study analyzed the prevalence, course, and persistence of MHP over 10 years from childhood into adolescence based on a sample from the Future ...
[221]
Functional impairment - Definition and Explanation
Functional impairment refers to the limitation or loss of an individual's ability to perform tasks or activities necessary for daily living.
[222]
Functional Impairment - (Abnormal Psychology) - Fiveable
Functional impairment refers to the reduction in an individual's ability to perform everyday tasks and activities due to psychological or physical conditions.
[223]
The importance of functional impairment to mental health outcomes
1. Introduction. Mental disorders create societal problems because they produce functional impairment.
[224]
Measuring Specific Mental Illness Diagnoses with Functional ...
The WHODAS corresponds to the disability domains of the International Classification of Functioning, Disability and Health, is developed for use in all clinical ...
[225]
The assessment of functional impairment. - APA PsycNet
The assessment of functional impairment has become increasingly important in the ascertainment of psychopathology in clinical practice, ...
[226]
Assessing the severity of functional impairment of psychiatric disorders
Nov 19, 2019 · Measures. The Clinical Global Impression (CGI) scale is a brief, easy to use and pragmatic tool for the assessment of psychiatric illness ...
[227]
Quantifying the global burden of mental disorders and their ...
We estimate that 418 million disability-adjusted life years (DALYs) could be attributable to mental disorders in 2019 (16% of global DALYs)—a more than three- ...<|separator|>
[228]
Research Brief: Mental Health, Employment, and the ADA
Over 46 million adults in the United States have some kind of mental health condition, and 11.2 million adults have a significant psychiatric disability1.
[229]
Long-Term Effects of Mental disorders on Employment In the ... - NIH
Conclusions. Expanded access to treatment among current employees and students with mental disorders might lead to improved employment outcomes in these ...
[230]
Occupational performance problems in people with depression and ...
Many people suffer from permanent problems with a reduced engagement in the performance of occupations as well as in relationships in their everyday life ...
[231]
12.00 Mental Disorders - Adult | Disability | SSA - Social Security
The listings for mental disorders are arranged in 11 categories: neurocognitive disorders (12.02); schizophrenia spectrum and other psychotic disorders (12.03); ...20 CFR 404.1512(a) · 404.1535 · Drug Addiction and Alcoholism<|separator|>
[232]
Predictors of functional impairment at assessment and functional ...
Mental disorders are associated with impairment to daily functioning, which affects both the individual and society. Despite this, most research on treatment ...
[233]
Mental illness - Diagnosis and treatment - Mayo Clinic
Dec 13, 2022 · A psychological evaluation. A doctor or mental health professional talks to you about your symptoms, thoughts, feelings and behavior patterns.
[234]
Mental Status Examination - StatPearls - NCBI Bookshelf - NIH
The mental status examination is essential for psychiatrists to assess a patient during initial and subsequent encounters and for clinicians across various ...Continuing Education Activity · Function · Enhancing Healthcare Team...
[235]
The Mental Status Examination | AAFP
Oct 15, 2016 · The mental status examination is useful in helping differentiate between a variety of systemic conditions, as well as neurologic and psychiatric ...
[236]
The Mental Status Examination - Clinical Methods - NCBI Bookshelf
The mental status examination is a structured assessment of the patient's behavioral and cognitive functioning. It includes descriptions of the patient's ...
[237]
The Structured Clinical Interview for DSM-5 - APA
The Structured Clinical Interview for DSM-5 (SCID-5) is a semistructured interview guide for making the major DSM-5 diagnoses.
[238]
Clinical validity and intrarater and test-retest reliability of ... - PubMed
Aim: The Structured Clinical Interview for the DSM is one of the most used diagnostic instruments in clinical research worldwide. The current Clinician Version ...
[239]
Methods to Improve Diagnostic Accuracy in a Community Mental ...
Structured diagnostic interviews are superior to less-structured clinical interviews in deriving reliable psychiatric diagnoses (4–12) because they facilitate ...
[240]
Diagnostic error in mental health: a review - PMC - NIH
Apr 4, 2024 · Missed, delayed or wrong diagnosis of mental disorders can lead to poorer patient outcomes and can waste time and resources. For example, ...
[241]
Reliability and validity of severity dimensions of psychopathology ...
This study examined whether the Structured Clinical Interview for DSM (SCID), a widely used semistructured interview designed to assess psychopathology ...
[242]
How to Overcome the Limitations of Diagnosis in Psychiatry
May 27, 2021 · The fundamental problem for psychiatry is that diagnosis remains largely syndromal. Syndromes inevitably are produced by a range of causal ...
[243]
Psychiatric diagnosis and treatment in the 21st century: paradigm ...
The 3rd edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM‐III) was paramount, providing an approach that attempted to eschew different ...
[244]
Candidate biomarkers in psychiatric disorders: state of the field - PMC
May 9, 2023 · The field of psychiatry is hampered by a lack of robust, reliable and valid biomarkers that can aid in objectively diagnosing patients and ...
[245]
towards a biology-informed framework for mental disorders - Nature
Jun 19, 2025 · Biomarkers are essential tools for building a biology-informed framework for mental disorders that encompasses biological evidence in the ...
[246]
Validated metabolomic biomarkers in psychiatric disorders - NIH
Jul 9, 2025 · In this article we provide a comprehensive review of validated metabolomics research, focusing on both the specific psychiatric conditions and the types of ...
[247]
Biomarkers in psychiatry: drawbacks and potential for misuse - PMC
One needs to closely weigh the costs against the benefits because currently there are no reliable biomarkers that can consistently predict mental illness. In ...
[248]
Biomarkers and Mental Disorders: A Relevance Analysis Using a ...
May 29, 2025 · This study utilized the Random Forest machine learning algorithm along with cross-validation to assess the importance of various biomarkers.
[249]
Neuroimaging in psychiatry: toward mechanistic insights and clinical ...
Oct 11, 2024 · Neuroimaging continues to advance our understanding of developmental processes in psychiatry, particularly the importance of plasticity early in ...
[250]
Clinical Applications of Neuroimaging in Psychiatric Disorders - NIH
Brain imaging has maintained a well-established but narrow place in the diagnostic evaluation of patients with psychiatric disorders.
[251]
Functional Neuroimaging in Psychiatry—Aiding in Diagnosis and ...
The APA's claim that neuroimaging has not had a significant impact on the diagnosis and treatment of psychiatric illnesses seems to assume that functional ...Abstract · Neuroimaging Could Guide... · The Incongruity Between DSM...
[252]
Neuroimaging in psychiatry: Potentials and pitfalls - The Hospitalist
Dec 2, 2019 · Currently, neuroimaging is used in psychiatry to rule out neurologic disorders such as seizures, tumors, or infectious illness that might be ...<|separator|>
[253]
Relevance of Objective Measures in Psychiatric Disorders—Rest ...
Oct 29, 2021 · We present a review of recent methods of objective measurement in psychiatry and psychology with a focus on home monitoring and its utility in guiding ...<|separator|>
[254]
a narrative review - JYMS : Journal of Yeungnam Medical Science
Sep 9, 2024 · The lack of useful psychiatric biomarkers is closely linked to the complex structures and functions of the brain. Additionally, a significant ...
[255]
A narrative review of digital biomarkers in the management of major ...
Nov 22, 2023 · Digital biomarkers show promise in predicting and assessing mood disorders. ... Smartphone data aids in tracking depression severity and treatment ...
[256]
Diagnostic error in mental health: a review - BMJ Quality & Safety
Diagnostic errors are associated with patient harm and suboptimal outcomes. Despite national scientific efforts to advance definition, measurement and ...
[257]
Challenges for Artificial Intelligence in Recognizing Mental Disorders
Dec 19, 2022 · Of the 840 primary care patients assessed in seven primary care clinics in three Canadian provinces, misdiagnosis rates reached 65.9% for major ...
[258]
Misdiagnosis, detection rate, and associated factors of severe ...
Feb 2, 2021 · This study revealed that more than a third of patients with severe psychiatric disorders were misdiagnosed (39.16%).
[259]
Metabolomic Biomarker Signatures for Bipolar and Unipolar ...
Oct 25, 2023 · Bipolar disorder (BD) affects approximately 1% of the population, yet it is frequently misdiagnosed, with nearly 40% of patients with BD ...<|control11|><|separator|>
[260]
Review Diagnostic inflation in the DSM: A meta-analysis of changes ...
In addition to criticisms about the increasing number of disorders (Houts, 2002), a common complaint is that new DSM editions have invalidly increased the ...
[261]
Overdiagnosis of mental disorders in children and adolescents ... - NIH
Jan 17, 2017 · We conducted a systematic literature search on the topic of overdiagnosis of mental disorders in children and adolescents.
[262]
Overdiagnosis in Psychiatry | 2021-09-10 - CARLAT PUBLISHING
Sep 10, 2021 · TCPR: Which disorders are the most overdiagnosed in psychiatry? Dr. Paris: At the top of the list are major depression, PTSD, bipolar II, adult ...Missing: empirical data
[263]
Millions of Dollars of Pharma Money Went to the DSM-5-TR Authors
Jan 15, 2024 · About 60% of the authors had financial ties to industry, not disclosed in the DSM. Studies show that FCOI leads to biased decision-making.
[264]
Overdiagnosis Problems in the DSM-IV and the New DSM-5
Criticisms of psychiatry for overdiagnosing, for pathologizing normality, are not new, dating at least from the antipsychiatry critiques in the 1960s.
[265]
Diagnostic Stability in Psychiatric Patients From Hospital Admission ...
May 25, 2023 · The rate of diagnostic consistency varied widely among readmissions which ranged from 91.0% for bipolar disorder to 9.5% for unspecified mental ...
[266]
Prevention of mental illness within public health - ScienceDirect.com
A well-established pathway to promote primary prevention of mental illness is via the mitigation of adverse childhood experiences (ACEs), which are a known risk ...
[267]
Mental Health Prevention and Promotion—A Narrative Review - PMC
Jul 26, 2022 · The onset of mental illnesses can be prevented by risk reduction interventions, which can involve reducing risk factors in an individual and ...
[268]
Risk and Protective Factors for the Onset of Mental Disorders - NCBI
The literature to date has netted three malleable factors—education, smoking, and head trauma—that are plausibly associated with AD. In all three cases, the ...
[269]
A meta‐review of “lifestyle psychiatry”: the role of exercise, smoking ...
A meta‐review of “lifestyle psychiatry”: the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders
[270]
Global population attributable fraction of potentially modifiable risk ...
Apr 28, 2022 · This study quantifies the Population Attributable Fraction (PAF) of potentially modifiable risk factors for mental disorders.
[271]
Screening in High Schools to Identify, Evaluate, and Lower ...
Nov 5, 2021 · In this randomized clinical trial, universal school-based MDD screening successfully increased identification of MDD symptoms and treatment initiation among ...
[272]
A Third of Public Schools Require Mental Health Screenings. Then ...
Aug 26, 2025 · A RAND study examines what behavioral health screening and services are available in K-12 public schools.
[273]
[PDF] Evidence-based Prevention and Early Intervention Programs
A randomized controlled studyfound strong evidence of success: Child First children were 42% less likely to have aggressive and defiant behaviors and Child ...
[274]
[PDF] Comparison of Early Intervention Services vs Treatment as Usual for ...
Oct 17, 2021 · Findings In this meta-analysis of 10 randomized clinical trials. (n = 2176 patients), early intervention services were associated with better ...
[275]
Results Over 5 Years From the RAISE-ETP Site-Randomized Trial
Jun 11, 2022 · Outcomes during and after early intervention services for first-episode psychosis: results over 5 years from the RAISE-ETP site-randomized trial.
[276]
Impact of Early Intervention for Early Psychosis on Suicidal Behavior ...
Nov 27, 2024 · Our meta-analysis shows that early intervention for psychosis is associated with a statistically significant reduction by a third in deaths by ...3 Methodology · 4 Results · 5 Discussion<|separator|>
[277]
School mental health early interventions and academic outcomes for ...
A meta-analysis found no statistically significant effect on the academic outcomes ... Table 1 School mental health (SMH) early intervention programs and ...Missing: intervention | Show results with:intervention
[278]
Youth Mental Health Screening and Linkage to Care - PMC - NIH
Jul 1, 2024 · As with other forms of illness, intervening early in the course of a mental health condition is associated with better outcomes. However, early ...
[279]
Evidence-Based Resources - Healthy People 2030 | odphp.health.gov
2030 includes objectives focused on the prevention, screening, assessment, and treatment of mental disorders and behavioral conditions.
[280]
Adapting Evidence-Based Early Psychosis Intervention Services for ...
Dec 7, 2021 · Background: Timely and comprehensive treatment in the form of early psychosis intervention (EPI) has become the standard of care for youth ...
[281]
The serotonin theory of depression: a systematic umbrella review of ...
Jul 20, 2022 · This review suggests that the huge research effort based on the serotonin hypothesis has not produced convincing evidence of a biochemical ...
[282]
Placebo Effect in the Treatment of Depression and Anxiety - Frontiers
Jun 12, 2019 · None of the meta-analyses have reported drug-placebo differences that come close to reaching the criterion for CGI-I ratings of minimal ...Abstract · Introduction · Placebo Effects versus... · Is There a Drug Effect at All?
[283]
Magnitude of the Placebo Response Across Treatment Modalities ...
Sep 24, 2021 · ... placebo-response rates of about 35% to 40%. However, this analysis included only RCTs of antidepressant drugs in patients without TRD.
[284]
Comparative efficacy of antidepressant medication for adolescent ...
May 10, 2025 · This meta-analysis is based on 15 RCTs, including 12,258 adolescents with depression, comparing the efficacy of fluoxetine, vilazodone, ...
[285]
Efficacy and dose–response relationships of antidepressants in the ...
This study aimed to analyze the efficacy of antidepressants and characterize their dose–response relationships in the treatments of major depressive disorders ...
[286]
No evidence that depression is caused by low serotonin levels, finds ...
Jul 20, 2022 · After decades of study, there remains no clear evidence that serotonin levels or serotonin activity are responsible for depression, according ...
[287]
Relative effectiveness of antidepressant treatments in ... - Nature
Dec 30, 2024 · This systematic review and network meta-analysis (NMA) sought to compare different antidepressant treatments for treatment-resistant depression (TRD)
[288]
Oral and long‐acting antipsychotics for relapse prevention in ...
May 7, 2022 · Based on these findings, olanzapine, aripiprazole and paliperidone are the best choices for the maintenance treatment of schizophrenia‐spectrum ...
[289]
Comparative Effectiveness of Antipsychotics in Patients With ...
Oct 9, 2024 · Our results also suggest that clozapine, which is the criterion standard for treatment-resistant schizophrenia, performed better on relapse ...
[290]
Study Finds Best Way to Prevent Schizophrenia Relapse
Jan 29, 2025 · A Finnish study suggests earlier use of clozapine after a first relapse in schizophrenia significantly reduces relapse risks.
[291]
Comparative effectiveness of antipsychotic treatment strategies for ...
The best pharmacological treatment practices for relapse prevention in patients with first-episode schizophrenia are unclear. We aimed to assess different ...
[292]
Long-Term Lithium Therapy for Bipolar Disorder: Systematic Review ...
We report a systematic review and meta-analysis of randomized controlled trials comparing lithium with placebo in the prevention of relapse in bipolar disorder.
[293]
Lithium: current state of the art and future directions
Nov 28, 2024 · Lithium is effective both in treating acute mania, as an adjunctive antidepressant, and as a maintenance treatment in bipolar disorder.
[294]
Lithium as a disease-modifying drug for bipolar disorder - The Lancet
Jun 9, 2025 · Clinical trial and cohort study evidence shows that lithium is effective and probably superior to other medications used to treat bipolar disorder.
[295]
a systematic review and component network meta-analysis
To conclude, stimulants and atomoxetine were the only interventions with evidence of effectively reducing core ADHD symptoms in the short term, based on both ...
[296]
Long-term efficacy and safety of treatment with stimulants ... - PubMed
Aug 20, 2012 · Here we review the long-term efficacy and safety of the stimulant drugs methylphenidate and amphetamine, as well as the related compound atomoxetine.
[297]
Efficacy of stimulants for preschool attention‐deficit/hyperactivity ...
Feb 25, 2023 · Evidence suggests that stimulants effect on height may be moderated by the level of stimulant exposure and may be attenuated by treatment ...
[298]
Risks Associated with Long-Term Benzodiazepine Use - AAFP
Aug 15, 2013 · Benzodiazepines increase the risk of addiction, withdrawal, cognitive decline, motor vehicle crashes, and hip fracture.
[299]
Benzodiazepines: Uses, Dangers, and Clinical Considerations - PMC
Nov 10, 2021 · Chronic use of BZD leads to a small but significant change in fluid intelligence, while long-term use of BZD correlates with worse cognitive ...
[300]
Study highlights consequences of chronic benzodiazepine use
Jul 19, 2023 · A recent study that found the depressant is linked to nervous system injury and negative life effects during and after use.
[301]
Effect of exercise for depression: systematic review and network ...
Feb 14, 2024 · Psychotherapies for depression: a network meta-analysis covering efficacy, acceptability and long-term outcomes of all main treatment types.Effect of exercise for... · Related content · Article metrics · Peer review<|separator|>
[302]
Pharmacologic Treatment of Depression - AAFP
A meta-analysis showed that discontinuation of antidepressants in patients with mild to moderate depression is not significantly associated with relapse.
[303]
Absolute and relative outcomes of psychotherapies for eight mental ...
May 10, 2024 · These results indicate that, although most psychotherapies lead to better outcomes compared to control conditions, response rates are modest.
[304]
The efficacy of psychotherapies and pharmacotherapies for mental ...
Jan 11, 2022 · Psychotherapies and pharmacotherapies are recommended as first line treatments. However, evidence has emerged that their efficacy may be overestimated.
[305]
Cognitive behavior therapy vs. control conditions, other ... - NIH
Jan 14, 2023 · CBT was significantly more effective than other psychotherapies, but the difference was small (g=0.06; 95% CI: 0‐0.12) and became non‐ ...
[306]
Is cognitive–behavioral therapy more effective than other therapies?
Comparisons between CBT and other therapies Examination of Table 3 indicates that CBT proved significantly more effective than psychodynamic therapy, but not ...
[307]
Why Cognitive Behavioral Therapy Is the Current Gold Standard of ...
(2)]: (1) CBT is the most researched form of psychotherapy. (2) No other form of psychotherapy has been shown to be systematically superior to CBT; if there are ...
[308]
Evidence-based psychological treatments for mental disorders - NIH
While evidence-based psychological treatments (EBPTs) are effective single or adjunctive treatments for mental disorders, there is also evidence that access to ...
[309]
Psychological treatment of depression: A systematic overview of a ...
Aug 15, 2023 · Over the years, we have conducted a series of meta-analyses examining the effects of specific psychotherapies, including CBT (Cuijpers et al., ...
[310]
The efficacy of psychotherapy, pharmacotherapy and their ...
The combination of psychotherapy and medication performed significantly better for both outcomes compared to each treatment alone yielding small effect sizes (g ...
[311]
a systematic review and meta-analysis of randomized controlled trials
Mar 18, 2024 · Moderate-certainty evidence showed little to no difference in the effectiveness of in-person and therapist-guided remote CBT across a range of mental health ...<|control11|><|separator|>
[312]
Exploring the efficacy of psychotherapies for depression
Mar 13, 2023 · We included all randomised controlled trials comparing psychotherapies with control conditions without restricting the type of psychotherapy, ...
[313]
Efficacy of neurostimulation across mental disorders - Nature
Apr 1, 2022 · We concluded that TMS and tDCS can benefit individuals with a variety of mental conditions, significantly improving clinical dimensions.
[314]
Clinical outcomes of deep brain stimulation for obsessive ... - NIH
Results. Six participants achieved clinical response (35% improvement in obsessions and compulsions on the Yale Brown Obsessive Compulsive Scale (YBOCS)) within ...
[315]
response rate to ECT - pi :: Psychiatry Investigation
Jan 19, 2021 · Electroconvulsive therapy (ECT) is considered as an effective therapeutic option for major depression with estimated response rates of 80–90% [1] ...
[316]
Efficacy of electroconvulsive therapy as a potential first-choice ... - NIH
A naturalistic study that analyzed 38 patients who showed severe resistant to treatment, concluded that ECT is highly effective and showed a higher than 50% ...
[317]
Modern Electroconvulsive Therapy: Vastly Improved yet Greatly ...
Jun 28, 2017 · It is now estimated that nearly 85% of patients relapse if ECT is followed by placebo and that approximately 50% will retain benefit for a year ...
[318]
Electroconvulsive therapy reduces suicidality and all-cause mortality ...
Thus, treatment with ECT demonstrated a significant 34 % decrease in the odds of suicide (OR 0.66, 95 % CI 0.50–0.88, p = 0.0047) and a 30 % reduction of death ...
[319]
Repetitive Transcranial Magnetic Stimulation for the Acute ...
Dec 28, 2016 · This systematic review and network meta-analysis examines the relative efficacy and tolerability of different types of repetitive ...
[320]
Durability of antidepressant response to repetitive transcranial ...
rTMS is a durable treatment for depression, with sustained responder rates of 50% up to 1 year after a successful induction course of treatment.
[321]
Short-term and long-term efficacy of accelerated transcranial ...
Short-term and long-term efficacy of accelerated transcranial magnetic stimulation for depression: A systematic review and meta-analysis. Citation.
[322]
Efficacy of repetitive transcranial magnetic stimulation (rTMS ...
Jul 27, 2023 · A systematic review and meta-analysis on placebo response to repetitive transcranial magnetic stimulation for depression trials. Prog ...
[323]
Efficacy and safety of transcranial magnetic stimulation for treating ...
Authors of all meta-analyses interpreted findings to suggest TMS is safe and effective for MDD. Our re-analysis showed that in 14 out of 15 meta-analyses, the ...
[324]
Deep Brain Stimulation for Obsessive-Compulsive Disorder - Frontiers
Mar 23, 2021 · DBS remains an efficacious tool for the treatment of OCD, even in patients with significant comorbidities in whom DBS has not previously been investigated.
[325]
Deep Brain Stimulation for Depression - ScienceDirect.com
DBS across different targets is associated with on average 60% response rates in previously refractory chronically depressed patients.
[326]
Six-Nine Year Follow-Up of Deep Brain Stimulation for Obsessive ...
These data indicate that DBS was safe and conferred a long-term benefit in reduction of obsessive-compulsive symptoms.
[327]
Vagus nerve stimulation - Mayo Clinic
Dec 20, 2024 · Devices for vagus nerve stimulation include one the Food and Drug Administration (FDA) approved that goes into the body, to treat epilepsy and depression.Overview · Why It's Done · What You Can Expect
[328]
Vagus nerve stimulation relieves severe depression
Dec 18, 2024 · People with severe, treatment-resistant depression who received vagus nerve stimulation therapy showed improvement in depressive symptoms.
[329]
Vagus Nerve Stimulation in Psychiatry: A Systematic Review of the ...
Nov 16, 2016 · We performed a systematic review aiming to give a detailed overview of the available evidence of the efficacy of VNS for the treatment of psychiatric disorders.
[330]
Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and ...
Mar 13, 2018 · VNS in PTSD Vagus nerve stimulation has shown promise as therapeutic option in treatment-resistant anxiety disorders, including PTSD (8). ...The Role Of Vagus In The... · Vagus Nerve As A Link... · Vagus Nerve Stimulation
[331]
[PDF] Efficacy and Safety of Neuromodulation Techniques in Depression ...
Sep 18, 2025 · Conclusion: Both iTBS and rTMS have similar efficacy and safety. Further validation of multimodal neuroimaging biomarkers is needed to enhance ...
[332]
Neuromodulation and neural networks in psychiatric disorders
Sep 26, 2025 · Though still in early research stages, FUS has shown promising results in preliminary trials for depression, SCZ, and anxiety (Shi & Wu, 2025).
[333]
Decoding the Mind: Basic Science Revolutionizes Treatment of ...
Mar 21, 2024 · For the treatments of tomorrow, NIMH is building a new research program called Pre-Clinical Research on Gene Therapies for Rare Genetic ...Missing: emerging | Show results with:emerging
[334]
New and emerging approaches to treat psychiatric disorders - PMC
In this review, we outline how brain-stimulation techniques are advancing our understanding of psychiatric disease. We discuss new and emerging approaches to ...
[335]
Self-management interventions for people with severe mental illness
Self-management interventions conferred benefits in terms of reducing symptoms and length of admission, and improving functioning and quality of life.
[336]
Lifestyle interventions for bipolar disorders: A systematic review and ...
Lifestyle interventions for BD mostly target diet, exercise, and sleep. Multidimensional interventions are more effective than single-domain interventions.
[337]
Association Between Physical Activity and Risk of Depression
Jun 1, 2022 · This systematic review and meta-analysis of associations between physical activity and depression suggests significant mental health benefits from being ...
[338]
Effectiveness of physical activity interventions for improving ...
Physical activity is highly beneficial for improving symptoms of depression, anxiety and distress across a wide range of adult populations.Article info · Citation Tools · Rapid Responses · Share
[339]
Association Between Physical Activity and Risk of Depression
Apr 13, 2022 · In this study, relatively small doses of physical activity were associated with substantially lower risks of depression.
[340]
Role of Physical Activity on Mental Health and Well-Being: A Review
Jan 7, 2023 · According to a meta-analysis of randomised controlled trials, exercise has shown a statistically significant effect on sleep quality in adults ...
[341]
How sleep affects mental health (and vice versa) - Stanford Medicine
Aug 11, 2025 · People with insomnia, for example, are 10 times more likely to have depression and 17 times more likely to have anxiety than the general ...
[342]
Improving sleep quality leads to better mental health - NIH
Improving sleep led to a significant medium-sized effect on composite mental health (g+ = −0.53), depression (g+ = −0.63), anxiety (g+ = −0.51), and rumination.
[343]
Sleep Hygiene Practices and Its Impact on Mental Health and ... - NIH
Worsening sleep hygiene may predispose to psychiatric disorders such as depression [24]. Hence, this study investigated the relationship between sleep hygiene ...
[344]
Nutrition and mental health: A review of current knowledge about the ...
Long-term observations confirm that adherence to the Mediterranean diet reduces the risk of developing neurological disorders by up to 28% compared to the use ...
[345]
How to Boost Mental Health Through Better Nutrition - Psychiatry.org
Apr 18, 2023 · The diet intervention group showed significant improvements in depressive symptoms, with a mean reduction of 20.6 points on the Beck Depression ...
[346]
Food and mood: how do diet and nutrition affect mental wellbeing?
Jun 29, 2020 · Poor nutrition may be a causal factor in the experience of low mood, and improving diet may help to protect not only the physical health but also the mental ...
[347]
Social support and recovery from mental health problems: a scoping ...
Jan 4, 2021 · This scope review maps out the literature on the association between social support and mental health by focusing on recovery from mental health problems.Social Support In Relation... · Social Support As Direct... · Discussion<|separator|>
[348]
Social support and mental health: the mediating role of perceived ...
Feb 20, 2024 · This study aimed to explore whether perceived stress mediate the relationship between social support and positive affect, anxiety, and depression.
[349]
PeerTECH: a randomized controlled trial of a peer-led mobile health ...
Integrated medical and psychiatric self-management interventions demonstrate strong potential in addressing medical and psychiatric symptoms and conditions in ...
[350]
Meditation Programs for Psychological Stress and Well-being
Mindfulness meditation programs, in particular, show small improvements in anxiety, depression, and pain with moderate evidence and small improvements in stress ...
[351]
The efficacy of mindfulness apps on symptoms of depression and ...
The efficacy of mindfulness meditation apps in enhancing users' well-being and mental health related outcomes: A meta-analysis of randomized controlled trials.
[352]
The efficacy of mindfulness-based interventions on mental health ...
Nov 30, 2023 · According to a recent meta-analysis, potential advantages of mindfulness therapy include lower levels of depression (7), anxiety (8) and stress ...
[353]
Special Report: Using Nutrition as a Therapeutic Modality
Dec 20, 2024 · Growing evidence indicates that nutritional interventions should play a central role in psychiatric care. This emerging body of research ...
[354]
Living with mental health issues: citizen science project on self ...
Oct 11, 2025 · Self-management strategies are intended to promote clinical recovery, including reduced symptomatology, improved functioning, and better relapse ...
[355]
Recovery From Serious Mental Illness: Trajectories, Characteristics ...
Dec 1, 2013 · A two-year study of recovery among 177 people with serious mental illnesses revealed four distinct patterns, none of which resembled the grim deterioration.
[356]
10-year outcome trajectories of people with mental illness and their ...
Aug 31, 2024 · This study explored the long-term outcome trajectories of individuals and families who received case management services provided by multidisciplinary outreach ...
[357]
Recurrence of major depressive disorder across different treatment ...
The risk of recurrence after a first major depressive episode is 50% and increases with subsequent episodes (Post, 1992, Kupfer et al., 1996, American ...
[358]
Prevention of Relapse and Recurrence in Adults with Major ... - NIH
Risk of relapse within several months of initial remission averaged 23.3% with antidepressant continued versus 49.4% after discontinuing treatment, a 2.1-fold ...
[359]
Predicting and preventing relapse of depression in primary care
After treatment of the first episode of depression, approximately half of all patients will relapse, and this risk increases for every subsequent episode (70% ...
[360]
Relapse and Clinical Characteristics of Patients with Bipolar ...
Sep 28, 2020 · From 312 patients with bipolar disorders, during follow-up, 65.9% of them experienced a relapse within 2.5 years (47.8% manic, 44.3% depressive ...
[361]
Predictors of Recurrence in Bipolar Disorder: Primary Outcomes ...
Feb 1, 2006 · During longitudinal treatment and monitoring, 416 participants (8.5%) experienced recurrence. Median time to recurrence of any mood episode was ...
[362]
Relapse Prevention in Schizophrenia: A Systematic Review and ...
This is the largest meta-analysis to date directly comparing relapse rates in schizophrenia patients treated with SGAs or FGAs followed for ≥6 months. We found ...
[363]
Expressed Emotion and Psychiatric Relapse: A Meta-analysis
Expressed emotion (EE) is a measure of the family environment that has been demonstrated to be a reliable psychosocial predictor of relapse in schizophrenia.
[364]
The nature of relapse in schizophrenia | BMC Psychiatry | Full Text
Feb 8, 2013 · Multiple relapses characterise the course of illness in most patients with schizophrenia, yet the nature of these episodes has not been ...<|separator|>
[365]
Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety ...
Nov 23, 2019 · This systematic review and meta-analysis of 69 randomized clinical trials assesses long-term outcomes after cognitive behavioral therapy for ...
[366]
Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety ...
Mar 1, 2020 · The findings of this meta-analysis suggest that cognitive behavioral therapy for anxiety-related disorders is associated with improved outcomes compared with ...
[367]
Recurrence of post-traumatic stress disorder: systematic review of ...
Jan 9, 2024 · Four studies reported data on the prevalence of recurrence in populations who had previously recovered from PTSD. Reported rates were 14% [52] ( ...
[368]
Diagnosis, Course, and Prevalence of PTSD - NCBI - NIH
In one study, of those who developed PTSD in the first year, about one-third remitted within 3 months without treatment, 39% had a chronic course, and only 3.5% ...DIAGNOSTIC CRITERIA FOR... · COURSE OF PTSD · PREVALENCE OF PTSD
[369]
Family interventions for relapse prevention in schizophrenia
Almost all family intervention models were efficacious in preventing relapse in schizophrenia. Family psychoeducation alone, without behavioural or skills ...
[370]
Relapse in clinically stable adult patients with schizophrenia or ...
Nov 30, 2023 · There is no consensus on defining relapse in schizophrenia, and scale-derived criteria with unclear clinical relevance are widely used.
[371]
Optimizing prediction of response to antidepressant medications ...
Jul 8, 2021 · Current practice for MDD treatment mainly relies on trial and error, with an estimated 42–53% response rates for antidepressant use. Here, we ...
[372]
An umbrella review of candidate predictors of response, remission ...
Nov 13, 2023 · Fewer symptoms of anxiety and depression predicted greater remission in each disorder, and more symptoms of depression predicted depression ...
[373]
Predicting antidepressant response by monitoring early ... - NIH
Jun 28, 2018 · Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: individual patient data meta-analysis.
[374]
Treatment resistance in psychiatry: state of the art and new directions
Treatment resistance affects 20–60% of patients with psychiatric disorders; and is associated with increased healthcare burden and costs up to ten-fold higher.
[375]
Electroencephalography for predicting antidepressant treatment ...
Jan 15, 2023 · Electroencephalography can predict the response to antidepressant treatment with high accuracy. However, future studies with more rigorous validation are ...
[376]
GENETIC AND ENVIRONMENTAL PREDICTORS OF TREATMENT ...
Preliminary analyses show that PGS for depression, bipolar disorder, ADHD and PTSD were all significantly associated with TRD (p < 0.001). CYP gene metaboliser ...Missing: illness | Show results with:illness
[377]
Predictors of treatment resistant schizophrenia: a systematic review ...
Younger age of onset was the most consistent predictor of treatment resistance. We discuss the gaps in the literature and how future prediction models can ...
[378]
The neurobiology of treatment-resistant schizophrenia - Nature
Jan 7, 2020 · TRS may develop via one of several neurobiological pathways. Several lines of evidence point to dopamine and glutamate dysfunction in the ...
[379]
The MAKE Biomarker Discovery for Enhancing anTidepressant ...
Apr 5, 2018 · Although this meta-analysis found that the restoration of BDNF levels was more prominent in responders than in non-responders [21], and although ...
[380]
Factors predicting the outcome of psychotherapy for borderline ...
The therapeutic alliance is an important common factor predicting outcome in patients with BPD, even in highly disorder-specific treatments.
[381]
Predictors of treatment outcome of psychological therapies for ...
The review identified 28 factors reported as significant predictors of treatment outcome in at least one study, across different domains: psychosocial (n = 9), ...
[382]
Predictors of response and remission in patients with treatment ...
Predictors of response to ESK+AD and AD+PBO were identified in patients with TRD. ESK+AD treatment, younger age, employment, and low anxiety predicted response.
[383]
Predictors and Risk Factors of Treatment-Resistant Depression
Nov 13, 2023 · The most frequently reported mental predictors/risk factors were greater symptom severity (9 studies), suicidality (8 studies), and recurrent depression (6 ...
[384]
Predictive Factors of Treatment Resistance in First Episode of ...
Feb 25, 2019 · Several factors were identified as predictors of treatment resistance: lower premorbid functioning; lower level of education; negative symptoms ...Introduction · Treatment non-response and... · Results · Discussions
[385]
Predictors of Treatment Resistance Across Different Clinical ...
May 14, 2020 · TRD and TRBD seem to be consistently predicted by broadly defined mixed features among different clinical subtypes of depression, either unipolar or bipolar ...Abstract · Introduction · Methods · Discussion
[386]
Multimodal Predictors of Treatment Response in Major Depressive ...
Mar 1, 2024 · Here, tier 1 predictors included measures with the strongest evidence supporting their role as predictors of treatment response in depression.
[387]
Mental Illness - National Institute of Mental Health (NIMH) - NIH
In 2022, there were an estimated 59.3 million adults aged 18 or older in the United States with AMI. This number represented 23.1% of all U.S. adults. The ...Definitions · Prevalence of Any Mental... · Prevalence of Serious Mental...
[388]
Socioeconomic inequality in mental health disorders - Nature
May 22, 2025 · In 2019, an estimated 970 million people globally were living with a mental disorder, with anxiety and depression being the most common. Mental ...
[389]
Association between socioeconomic inequality and the global ...
May 17, 2022 · This study showed that the prevalence of anxiety and depressive disorders is mainly concentrated in countries with a higher level of HDI, which ...
[390]
Common mental disorders, neighbourhood income inequality ... - NIH
In this analysis, the UK was eleventh worst on both measures, with the USA in twelfth place.
[391]
[PDF] Understanding and addressing inequalities in mental health - OECD
This disparity contributes to a 20% higher prevalence of mental disorders among women in. OECD countries, according to IHME estimates. In contrast, conditions ...<|separator|>
[392]
Global inequalities in mental health problems - ScienceDirect.com
Socio-economic inequalities in mental health problems are found in measures covering prevalence, treatment utilisation, and treatment helpfulness.
[393]
Where mental illness is increasing in the US - USAFacts
Nov 16, 2023 · Nearly 23% of adults had a mental illness in 2021. Percent of adults who had any mental illness in the past year, 2008-2021.
[394]
[PDF] National Survey of Children's Health Adolescent Mental and ...
The prevalence of diagnosed anxiety increased 61 percent (from 10.0% to 16.1%) and depression increased 45 percent (from 5.8% to 8.4%); the prevalence of ...
[395]
Data and Statistics on Children's Mental Health - CDC
Jun 5, 2025 · This page provides data about indicators of positive mental health in children and mental health conditions that are most common in children.
[396]
The Rise of Anxiety and Depression among Young Adults in the ...
Mar 2, 2025 · Additionally, depression and anxiety diagnoses have increased by 63% among young adults from 2005 to 2017.16 As of 2016, 23% of adult US ...
[397]
Global burden and trends of major mental disorders in individuals ...
Sep 16, 2025 · According to the World Health Organization (WHO) estimates, nearly 970 million people worldwide lived with a mental disorder in 2019. Globally, ...
[398]
Global burden and trends of major mental disorders in individuals ...
Sep 15, 2025 · Males experienced a higher burden than females, with variations in sex-specific patterns across age groups. ... mental disorders, sex, and age.
[399]
Youth Mental Health Statistics - The Annie E. Casey Foundation
Jul 25, 2025 · Another national survey found an 18% increase between 2020–2021 and 2022–2023 in the share of young people ages 3 to 17 who were told by a ...
[400]
Any Anxiety Disorder - National Institute of Mental Health (NIMH)
Past year prevalence of any anxiety disorder was higher for females (23.4%) than for males (14.3%). An estimated 31.1% of U.S. adults experience any anxiety ...Definitions · Prevalence of Any Anxiety... · Any Anxiety Disorder with...
[401]
Demons and mental illness in Ancient Mesopotamia
Mesopotamia's demon-centric view on mental health showcases an essential facet of human nature: the need to rationalise the unknown. Today, as science provides ...
[402]
Mental Health in Ancient Egypt | Kathleen M. Pike, PhD |
Oct 28, 2022 · The ancient Egyptian medical texts describe somatic, emotional, and psychological symptoms of depression with language that foreshadows clinical descriptions ...
[403]
Heartbreak and the History of Distress in Ancient Mesopotamia
Jul 27, 2023 · The concept of “heartbreak” appears multiple times in cuneiform texts as a metaphor to describe both mental and physical conditions.
[404]
Mental Health in Ancient Times: The Humors and Their Impact
Aug 14, 2021 · Hippocrates's humoral theory of illness proposed that the body consisted of four humors: black bile, yellow bile, blood and phlegm.
[405]
The Hippocratic account of Mental Health: Humors and Human ...
Sep 20, 2020 · The aim of the work is to highlight the contribution of Hippocrates to the study of mental illness based on his theory of humors.
[406]
Balancing Your Humors | Psychology Today
Nov 2, 2013 · Classical medicine was all about balancing these humors by changing diet, lifestyle, occupation, climate, or by administering medicine.<|separator|>
[407]
Mental Illness, Evil Spirits, and Scripture - Reflections - Yale University
An evil spirit from the Lord tormented Saul. To call this mental illness—or madness—is to make a set of implicit claims. It is to assume that mental illness is ...
[408]
Demons or Mental Health Problems? | Catholic Answers Magazine
Some people resist believing in demons, calling possessions in the Bible undiagonosed mental health problems. But Jesus knew the difference.Missing: insanity | Show results with:insanity
[409]
Madness and care in the community: a medieval perspective - PMC
From the late 13th century congenital idiots were protected by law. Care of lunatics, by contrast, was primarily the responsibility of the family.
[410]
Mental Illness in the Middle Ages: The Return of Supernatural Beliefs
Jul 22, 2024 · Exorcism became the primary treatment for what we now recognize as mental illness. These ritual practices aimed to drive out demons or evil ...
[411]
Sin and mental illness in the Middle Ages - PubMed
The authors examined 57 descriptions of mental illness (madness, possession, alcoholism, epilepsy, and combinations thereof) from pre-Crusade chronicles and ...<|separator|>
[412]
Philippe Pinel | Mental Illness, Asylum Reform & Psychiatry | Britannica
Sep 13, 2025 · Philippe Pinel was a French physician who pioneered in the humane treatment of the mentally ill. Arriving in Paris (1778), he supported ...
[413]
Moral Treatment - an overview | ScienceDirect Topics
Philippe Pinel is often credited as creating what is now known as moral treatment or “moral therapy”, emphasizing kindness and respect while speaking with each ...
[414]
The 19th Century Asylum - Hearing Voices
The 19th century saw tremendous change in the care and treatment of mental illness. Names still familiar to many influenced this transformation.
[415]
A Victorian Mental Asylum | Science Museum
Jun 13, 2018 · It was no longer acceptable to keep poor mentally ill people in workhouses and prisons, so state provision of asylums became mandatory. There ...The origins of the asylum · Physical restraints in asylums · New attitudes to mental...
[416]
Dorothea Dix (1802–1887) - PMC - NIH
Dorothea Dix played an instrumental role in the founding or expansion of more than 30 hospitals for the treatment of the mentally ill.
[417]
Moral Treatment - Social Welfare History Project
Oct 24, 2023 · Several decades after Rush's death, Dorothea Dix in 1841 began her quest to bring humane treatment to the insane. Dix insisted that hospitals ...
[418]
History of Psychiatric Hospitals - Penn Nursing
But the Friends Asylum, established by Philadelphia's Quaker community in 1814, was the first institution specially built to implement the full program of ...
[419]
Who Were the Alienists? | Psychology Today
Jan 26, 2018 · Starting around the mid-nineteenth century, psychiatrists were referred to as "alienists." It was the alienist's job to study, understand ...
[420]
From Alienism to the Birth of Modern Psychiatry: A Neurological Story?
Aug 19, 2009 · Étienne-Jean Georget (1795–1828), one of the most distinguished alienists in the beginning of the nineteenth century, had written that hysteria ...
[421]
Cycles of reform in the history of psychosis treatment in the United ...
The first reform cycle, the Moral Treatment Era, highlighted freestanding asylums in the early 19th century (Grob, 1983). Secondly, the Mental Hygiene movement, ...
[422]
The history of psychiatry revisited | Cairn.info
The history of psychiatry was initially the work of alienist doctors, soon to be renamed psychiatrists, but was subsequently taken over by philosophers such as ...
[423]
A Brief History of Psychiatry | Psychology Today
Oct 20, 2014 · Psychoanalysis was the dominant paradigm in outpatient psychiatry for the first half of the 20th century. In retrospect, it overreached, as ...
[424]
An evidence-based critique of contemporary psychoanalysis
This book assesses the state of psychoanalysis in the 21st century. It examines areas where analysis needs to develop a stronger scientific and clinical ...
[425]
People and Discoveries: Drug for treating schizophrenia identified
In 1954 chlorpromazine was approved by the U.S. Food and Drug Administration, and it took the country by storm. It had a calming effect without sedating ...
[426]
the discovery of chlorpromazine and the management of madness
Sep 3, 2021 · This article analyzes the shortcomings and problems of the thesis that a true revolution took place in the field of biological psychiatry between 1952 and 1954.
[427]
Fifty years chlorpromazine: a historical perspective - PubMed
Chlorpromazine was instrumental in the development of neuropsychopharmacology, a new discipline dedicated to the study of mental pathology with the employment ...
[428]
Mental Health's Stalled (Biological) Revolution: Its Origins, Aftermath ...
Nov 1, 2023 · By the 1930s, many of the psychiatrists involved in these programs had also discovered psychoanalysis and were incorporating Freudian ideas ...
[429]
DSM-III and the transformation of American psychiatry: a history
The publication of DSM-III in 1980 represented an answer to this crisis, as the essential focus of psychiatric knowledge shifted from the clinically-based ...
[430]
DSM History - Psychiatry.org
In 2007, APA formed the DSM–5 Task Force to begin revising the manual as well as 13 work groups focusing on various disorder areas. DSM–5 was published in 2013.DSM–5-TR · DSM–5 · DSM–III–R and DSM–IV · Development of DSM–III<|separator|>
[431]
https://oxfordre.com/psychology/display/10.1093/acrefore/9780190236557.001.0001/acrefore-9780190236557-e-631
[432]
A brief historicity of the Diagnostic and Statistical Manual of Mental ...
Jan 13, 2012 · Many of the modifications incorporated into the DSM-III constituted a veritable paradigm shift in psychiatry.
[433]
A brief historicity of the Diagnostic and Statistical Manual of Mental ...
Jan 13, 2012 · Specifically, we document major modifications in the definition, characterization, and classification of mental disorders throughout successive ...
[434]
A comparison of DSM and ICD classifications of mental disorder
Jan 2, 2018 · Both DSM and ICD classification systems in psychiatry have value and, in particular, the high profile of DSM since 1980 has stimulated much more ...
[435]
Changes from ICD-10 to ICD-11 and future directions in psychiatric ...
This article provides a brief overview of the changes from ICD-10 to ICD-11 regarding the classification of mental, behavioral, or neurodevelopmental disorders.
[436]
Diagnostic Issues and Controversies in DSM-5 - Annual Reviews
Jan 11, 2016 · Allen Frances, who had been chair of the DSM-IV (Am. ... An often-heard mantra was that DSM-5 would focus on validity rather than reliability.
[437]
The Evolution of the Classification of Psychiatric Disorders - PMC - NIH
Jan 18, 2016 · This article has reviewed the long history of diagnostic classification of psychiatric disorders. DSM-III heralded a paradigm shift in the ...
[438]
The Successes and Failures of the DSM Revolution
P14Research in the two decades after 1980, however, consistently found that diagnostic psychiatry failed to accomplish any of these objectives.18 The previous ...
[439]
The biomedical model of mental disorder: a critical analysis of its ...
The biomedical model posits that mental disorders are brain diseases and emphasizes pharmacological treatment to target presumed biological abnormalities.
[440]
Comparison of the Heritability of Schizophrenia and ... - NIH
Previous meta-analyses of twin studies have indicated a substantial heritability of this disorder ranging from 44% to 87% with a mean of 81%.
[441]
PRS and Twin Concordance for Schizophrenia and Bipolar Disorder
Aug 28, 2024 · Twin/pedigree studies have shown that they are highly heritable (60%-83%). Schizophrenia and bipolar disorder show substantial genetic overlap, ...
[442]
Differences in Hippocampal Volume Between Major Depression and ...
Jun 3, 2009 · The objectives of this study are to investigate whether hippocampal volumes are reduced in patients with schizophrenia and those with major depression.
[443]
What Is Constructionism in Psychiatry? From Social Causes to ... - NIH
Apr 18, 2016 · Social constructivism may involve both, a causal and a non-causal claim concerning the relation between mental disorders and social facts.Missing: evidence | Show results with:evidence
[444]
Revisiting the Myth of Mental Illness and Thomas Szasz
Sep 17, 2012 · One of Szasz's basic arguments is that mental illness is a myth. He was highly critical of the so-called medical model for understanding human ...
[445]
Third ISA Forum of Sociology (July 10-14, 2016)
We conclude that the social construction of mental disorders is no argument for their non-existence. The social construction of mental disorders, however, is a ...
[446]
“Mental illness is like any other medical illness”: a critical ...
The statement that “mental illness is like any other medical illness” implies that mental illness has a biological basis just like other medical illnesses.
[447]
Data and Statistics on ADHD - CDC
May 22, 2024 · An estimated 7 million (11.4%) US children aged 3–17 years have ever been diagnosed with ADHD, according to a national survey of parents using data from 2022.ADHD Throughout the Years... · ADHD Information and...
[448]
ADHD Diagnostic Trends: Increased Recognition or Overdiagnosis?
Attention Deficit Hyperactivity Disorder is thought to be caused by a combination of factors: genetic, neurobiologic, and environmental. Twin studies show that ...
[449]
Review: Saving Normal | Psychology Today
Jul 16, 2014 · Frances' arguments about the dangers of inflating psychiatric conditions and psychiatric diagnosis are persuasive – maybe more so because he ...Missing: key | Show results with:key
[450]
Saving Normal by Allen Frances | Summary, Quotes, FAQ, Audio
Rating 4.4 (150) Apr 1, 2025 · The book's main argument is that diagnostic inflation leads to unnecessary medication and pathologizing normal behavior. Frances advocates for ...
[451]
ADHD diagnoses are rising. 1 in 9 U.S. kids have gotten one ... - NPR
May 23, 2024 · The most common were behavioral or conduct problems, anxiety and developmental delays. Autism and depression were also frequently observed, ...
[452]
Testing the diagnostic expansion hypothesis with a population ...
Sep 9, 2025 · The study adds robust support for the hypothesis that expanded concepts of depression are common, particularly in younger people, and that these ...
[453]
Are mental health awareness efforts contributing to the rise in ...
In this paper, we present the hypothesis that, paradoxically, awareness efforts are contributing to this reported increase in mental health problems.
[454]
Saving Normal | Psychology Today
A step-by-step comparison illustrates that the United States is the worst place in the world to be mentally ill and that Trieste is the best.Missing: key arguments
[455]
(PDF) Expansion of the concept of mental disorder in the DSM-5
Aug 9, 2025 · In this study, 83 disorders revised between the DSM-IV-TR and DSM-5 received codes based on whether the diagnostic criteria conceptually became more inclusive.
[456]
The influence of pharmaceutical companies - PMC - NIH
Jul 13, 2017 · Pharmaceutical companies finance most – if not all – Randomized Controlled Trials (RCT) on the efficacy of medications, and this has obvious consequences on ...
[457]
Industry Funding Biases Antidepressant Efficacy Findings
Oct 14, 2024 · A new study confirms that industry funding inflates the apparent efficacy of psychiatric drugs. Tamar Oostrom at Ohio State University ...
[458]
Bias found when drug manufacturers fund clinical trials
Oct 7, 2024 · Psychiatric drugs are reported to be about 50% more effective in clinical trials funded by the drug's manufacturer than when trials of the same drug are ...
[459]
Diagnosing Conflict-of-Interest Disorder - AAUP
Our research showed that nearly 70 percent of the DSM-V task-force members report having ties to the pharmaceutical industry. This represents a relative ...
[460]
Undue Pharmaceutical Influence on Psychiatric Practice
DSM and Clinical Practice Guidelines are not immune to industry influence. DSM is often mischaracterized as the bible of psychiatric disorders because of its ...
[461]
[PDF] Drug Firms, the Codification of Diagnostic Categories, and Bias in ...
In fact, some critics have referred to the relationship amongst the DSM, the FDA, and Big Pharma as an “unholy alliance.” Thus, it is not surprising that, ...
[462]
Preying on Prescribers (and Their Patients) — Pharmaceutical ...
detailing, free samples, free food and drink, flashy ...
[463]
Pharma Marketing May Contribute to Stimulant Oversupply
Jan 17, 2020 · Pharma marketing to doctors may fuel stimulant oversupply and overprescribing, raising concerns about misuse and patient safety.
[464]
Antidepressants and Advertising: Psychopharmaceuticals in Crisis
We explore how such drug marketing portrays idealized scientific relationships between psychopharmaceuticals and depression.
[465]
Industry sponsorship and financial conflict of interest in the reporting ...
The extent and implications of industry sponsorship and financial conflict of interest in psychiatric clinical trials have not been investigated, to the authors ...
[466]
Psychotropic Marketing Practices and Problems
In this article, we discuss psychotropic drug prescribing, problematic marketing practices relevant to the DSM-5, and problematic diagnostic practices.
[467]
Comparative efficacy and acceptability of 21 antidepressant drugs ...
Feb 21, 2018 · We found that all antidepressants included in the meta-analysis were more efficacious than placebo in adults with major depressive disorder and ...
[468]
Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data ...
Feb 26, 2008 · On average, the SSRIs improved the HRSD score of patients by 1.8 points more than the placebo, whereas NICE has defined a significant clinical ...
[469]
Comparative efficacy of placebos in short-term antidepressant trials ...
Sep 7, 2020 · Consistent with our hypothesis that unblinding of outcome-assessors in trials of older drugs biases the average drug-placebo difference, a meta- ...<|separator|>
[470]
Individual Differences in Response to Antidepressants: A Meta ...
Feb 17, 2021 · No evidence was found of more variability in response to antidepressants than to placebo. Variability was not associated with baseline depression severity or ...
[471]
Articles Efficacy and effectiveness of antipsychotics in schizophrenia ...
We therefore compared the efficacy and effectiveness of antipsychotics for relapse prevention in schizophrenia and estimated overall treatment effects.
[472]
Long-term efficacy of antipsychotic drugs in initially acutely ill adults ...
Most acute phase antipsychotic drug trials in schizophrenia last only a few weeks, but patients must usually take these drugs much longer.
[473]
The Long-Term Effects of Antipsychotic Medication on Clinical ...
May 5, 2017 · However, studies of first-episode psychosis consistently find improvement of cognition with antipsychotic treatment, consistent with symptom ...
[474]
Long-Term Antipsychotic Effectiveness and Comparison ... - Frontiers
Jun 12, 2022 · At present, atypical antipsychotic drugs have become the first line drug treatment for people with schizophrenia (Lehman et al., 2004).Introduction · Methods · Results · Discussion
[475]
Discontinuing psychotropic drug treatment - PMC - NIH
Feb 19, 2020 · Long-term exposure to antidepressant, antipsychotic, anxiolytic, mood stabilising and other psychotropic drugs leads to neuropharmacological ...
[476]
Discontinuing Psychiatric Medications: A Survey of Long-Term Users
Jul 17, 2017 · Among those who completely discontinued their medication, 67 (52%) reported having been off medications a year or more, 43 (33%) reported less ...
[477]
Antidepressants withdrawal effects and duration of use: a survey of ...
Notably, a relationship between duration of use and increased risk of withdrawal effects is a common principle across psychotropic medications likely related to ...
[478]
Statistically Significant Antidepressant-Placebo Differences on ...
The most recent meta-analysis indeed concludes that antidepressants are more effective than placebo but also acknowledges that risk of bias was substantial and ...
[479]
Out of DSM: Depathologizing Homosexuality - PMC - NIH
Dec 4, 2015 · DSM-I classified “homosexuality” as a “sociopathic personality disturbance.” In DSM-II, published in 1968 [8], homosexuality was reclassified ...
[480]
https://psychologytoday.com/us/blog/hide-and-seek/201509/when-homosexuality-stopped-being-a-mental-disorder
[481]
How LGBTQ+ Activists Got “Homosexuality” out of the DSM
May 26, 2021 · The campaign to remove the “homosexuality” diagnosis from the DSM began in earnest in the 1960s, backed by a growing civil rights, women's rights, and gay ...
[482]
“Gay Is Good”: History of Homosexuality in the DSM and Modern ...
Sep 8, 2022 · The DSM-III-R in 1987 categorized marked distress about one's sexual orientation under “sexual disorder, not otherwise specified” (11). This ...Missing: controversies | Show results with:controversies
[483]
The diagnostic status of homosexuality in DSM-III - PubMed
In 1973 homosexuality per se was removed from the DSM-II classification of mental disorders and replaced by the category Sexual Orientation Disturbance.
[484]
Prolonged Grief Disorder - American Psychiatric Association
The inclusion of the diagnostic criteria for prolonged grief disorder in DSM-5-TR allows clinicians to use a common standard to differentiate between normal ...Missing: controversy | Show results with:controversy<|separator|>
[485]
A public health perspective on Prolonged Grief Disorder | Pursuit
Nov 17, 2023 · One criticism of the inclusion of PGD in the DSM-5-TR is that it may pathologize the normal grieving process and stigmatize bereaved individuals ...
[486]
Prolonged grief disorder in ICD-11 and DSM-5-TR - PubMed
Feb 6, 2023 · Prolonged grief disorder in ICD-11 and DSM-5-TR: Challenges and controversies. Aust N Z J Psychiatry. 2023 Jul;57(7):944-951. doi: 10.1177 ...
[487]
Gender Dysphoria Diagnosis - American Psychiatric Association
With the publication of DSM–5 in 2013, “gender identity disorder” was eliminated and replaced with “gender dysphoria.” This change further focused the ...
[488]
Autism Spectrum Disorder and Gender Dysphoria/Incongruence. A ...
May 20, 2022 · This review showed a relationship between ASD traits and GD feelings in the general population and a high prevalence of GD/GI in ASD.
[489]
Review Gender Dysphoria and Autism Spectrum Disorder
There is a growing clinical recognition that a significant proportion of patients with gender dysphoria have concurrent autism spectrum disorder (ASD).
[490]
Diagnostic Fads (Chapter 4) - Fads and Fallacies in Psychiatry
Mar 16, 2023 · The process of diagnostic inflation and concept creep applies particularly to major depression, bipolar disorders, ADHD, autism spectrum ...Missing: declassification | Show results with:declassification
[491]
The New Crisis of Confidence in Psychiatric Diagnosis - ACP Journals
Aug 6, 2013 · Psychiatric diagnosis is facing a renewed crisis of confidence caused by diagnostic inflation. The boundaries of psychiatry are easily expanded ...
[492]
Stigma, Prejudice and Discrimination Against People with Mental ...
Stigma, prejudice and discrimination against people with mental illness can be subtle or obvious—but no matter the magnitude, they can lead to harm. People ...
[493]
Survey: Americans becoming more open about mental health
May 1, 2019 · A third of respondents (33%) agreed with the statement, "people with mental health disorders scare me," and 39% said they would view someone ...
[494]
Public perceptions of risk in criminality: The effects of mental illness ...
Oct 30, 2013 · Our study set out to examine varying levels of stereotypical and discriminatory attitudes towards a variety of mental illnesses and to compare ...
[495]
The mark of mental health problems. A field experiment on hiring ...
The results show that applicants who disclose mental health problems are discriminated against in hiring processes. Applicants with mental health problems have ...
[496]
Employment Barriers for Persons With Psychiatric Disabilities
Employment rates for people who met criteria for disabling mental illness were even lower, ranging from 32 to 61 percent, and lower still—22 to 40 percent—among ...
[497]
Study Finds that People with Mental Disabilities Experience Rental ...
Sep 11, 2017 · Results of Pilot Testing finds that individuals with mental disabilities experience discrimination during their search for rental housing.
[498]
Social Determinants of Health: Housing
... mental illness experience housing discrimination throughout the rental process. People with mental illness are overrepresented in the unhoused population ...
[499]
Do the Effects of Inadequate Housing/Community and Inadequate ...
Jan 20, 2025 · Research has concluded decades over that IMHD are more at-risk of finding themselves in situations of inadequate employment and inadequate housing/community.
[500]
Trends in Public Stigma of Mental Illness in the US, 1996-2018
Dec 21, 2021 · This survey study examines changes in the levels of stigma regarding mental illness in the US over the past 2 decades.
[501]
Worldwide changes in self-stigma among people with mental illness ...
Jun 25, 2025 · 179 articles involving 33,046 people were identified. Self-stigma levels increased across all ISMI dimensions from 2005 to 2023 (β = 0.086–0.283) ...
[502]
Changes in mental illness stigma over 30 years - NIH
Uneasiness decreased by −0.17 between 2001 and 2011. Between 2011 and 2020, anger decreased by −0.14, and lack of understanding by −0.19 (Supplementary Table S9) ...
[503]
Interventions to Reduce Mental Health Stigma in Young People
Jan 15, 2025 · These findings suggest that interventions to reduce mental health stigma among youth are beneficial in the short term.
[504]
Interventions to Reduce Discrimination and Stigma - Psychiatry Online
Jan 15, 2025 · There is evidence for small to moderate positive impacts of both mass media campaigns and interventions for target groups in terms of stigma-related knowledge, ...
[505]
Adverse unintended effects of antistigma campaigns ... - APA PsycNet
Antistigma campaigns and intervention messages have the potential to reduce the harmful stigmatization of various conditions (e.g., HIV/AIDS, ...<|control11|><|separator|>
[506]
The effectiveness of anti-stigma interventions for reducing mental ...
A focus on anti-stigma interventions in young people has the potential to significantly improve the quality of life of people living with poor mental health as ...
[507]
O'Connor v. Donaldson | 422 U.S. 563 (1975)
O'Connor described Donaldson's treatment as "milieu therapy." But witnesses from the hospital staff conceded that, in the context of this case, "milieu therapy" ...
[508]
An International Perspective on the Law of Involuntary Commitment
The leading alternative has been the 1983 Mental Health Act in England and Wales, with its focus on the "health and safety" of the patient, as well as.
[509]
Mental Health Act 1983 - Legislation.gov.uk
An Act to consolidate the law relating to mentally disordered persons.Changes over time for: Section 3 · Mental disorder · Part I Application of Act · 107.
[510]
Compulsory treatment of physical illness under MHA 1983 - PMC
Sep 11, 2021 · Sections 145 & 63 of the Mental Health Act 1983 (MHA) provide for treatment without consent of physical illness ancillary to the mental disorder with which a ...Missing: involuntary | Show results with:involuntary
[511]
Variations in patterns of involuntary hospitalisation and in legal ...
We aimed to describe the extent of variations in involuntary annual hospitalisation rates between countries, to compare trends over time,
[512]
WHO-OHCHR launch new guidance to improve laws addressing ...
Oct 9, 2023 · The guidance proposes legislative provisions to end coercion in mental health services and enshrine free and informed consent as the basis of ...
[513]
UN Rights experts call on Council of Europe to stop legislation for ...
May 28, 2021 · “The coercive approach to mental health is doing harm to people with disabilities and we should not go backwards to authorize this outdated ...
[514]
The benefits and harms of inpatient involuntary psychiatric treatment
Sep 17, 2024 · The review found that involuntary inpatient admission was associated with harms including increased subjective and objective coercion, increased cost and ...
[515]
Coercive Measures in Psychiatry: A Review of Ethical Arguments
Dec 14, 2021 · Coercive measures infringe on several fundamental rights based on ethical principles (autonomy, freedom of movement and will, bodily integrity).
[516]
Reasons behind the rising rate of involuntary admissions under the ...
There has been a significant rise in the use of the Mental Health Act (1983) in England over the last 10 years. This includes both health-based Place of ...
[517]
Criteria, Procedures, and Future Prospects of Involuntary Treatment ...
The criteria for involuntary hospitalization are as follows: patients must exhibit dangerous behavior toward themselves or others, they must be helpless and ...
[518]
Cross-cultural variations in the prevalence and presentation of ...
This article indicates that certain anxiety disorders (e.g., generalized anxiety disorder and panic disorder) may vary greatly in rate across cultural groups.
[519]
Influences of Cultural Differences in the Diagnosis and Treatment of ...
May 15, 2019 · One of the main differences seen across cultures is the way anxiety and depression is expressed. Someone from a culture where it is common to ...
[520]
Factor analysis of depression symptoms across five broad cultural ...
Mar 1, 2021 · The purpose of this study was to examine differences and similarities of depression symptom groupings between broad cultural groups.
[521]
Cultural inroads in DSM-5 - PMC - NIH
Oct 1, 2014 · A lot has been said and written about the relevance of well-conceived cultural concepts in the diagnostic assessment of all kinds of patients.
[522]
[PDF] Cultural Concepts in DSM-5 - American Psychiatric Association
Rather than a simple list of culture-bound syndromes, DSM-5 updates criteria to reflect cross-cultural variations in presentations, gives more detailed and ...
[523]
Culture and Context in Mental Health Diagnosing: Scrutinizing the ...
Dec 28, 2017 · This article examines the revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and its claim of incorporating a “greater cultural ...<|separator|>
[524]
Cultural Aspects of Major Mental Disorders: A Critical Review from ...
We attempted to critically review the cultural factors in relation to the epidemiology, phenomenology, treatment, and outcome of major mental disorders from an ...
[525]
Cultural differences in stigma surrounding schizophrenia
Jan 2, 2018 · Not only theory but also empirical research on stigma shows a strong bias in favour of Western culture. A review of all population-based ...<|control11|><|separator|>
[526]
Full article: Culture and mental illnesses - Taylor & Francis Online
Feb 18, 2021 · Cultures may influence and contribute to the causation of mental illnesses, mould symptoms, render certain sub-groups more vulnerable as well as modify beliefs ...<|separator|>
[527]
Cultural considerations in the classification of mental disorders
Jan 27, 2020 · The origins and manifestations of mental disorders are complex, reflecting biological, psychological, and socio-cultural influences [1].
[528]
Mental health literacy: a cross-cultural approach to knowledge and ...
Cultural differences are evident in the public's recognition of mental disorders, with European individuals being significantly better at recognizing symptoms ...
[529]
Cross cultural variations in psychiatrists' perception of mental illness
Studies show that the prevalence of the most common mental disorders as well as risk and protective factors varies across cultures but comorbid patterns and ...
[530]
Mental Health | Strategic Intelligence - The World Economic Forum
The cost of mental health conditions (and related consequences) is projected to rise to $6 trillion globally by 2030, from $2.5 trillion in 2010.
[531]
Novel study quantifies immense economic costs of mental illness in ...
Apr 22, 2024 · Mental illness costs the U.S. economy $282 billion annually, which is equivalent to the average economic recession, according to a new study ...
[532]
The Economic Toll of America's Mental Health Crisis
Apr 4, 2025 · Recent research has shown that untreated mental illness among Americans, namely workers, will cost the US economy approximately $477.5 billion ...
[533]
The economic burden of mental health inequities | Deloitte Insights
May 15, 2024 · If left unaddressed, mental health inequities could lead to about US$14 trillion in excess costs between now and 2040, according to our analysis.
[534]
Fast Facts: Health and Economic Costs of Chronic Conditions - CDC
Aug 8, 2025 · Ninety percent of the nation's $4.9 trillion in annual health care expenditures are for people with chronic and mental health conditions.12 ...
[535]
The Mental Health Parity and Addiction Equity Act (MHPAEA) - CMS
Sep 10, 2024 · In addition, MHPAEA prohibits separate financial requirements and treatment limitations that apply only to MH/SUD benefits. MHPAEA also imposes ...
[536]
Impact of Mental Health Parity and Addiction Equity Act - Milliman
This paper presents an analysis of healthcare utilization and cost patterns during the six-year period from 2008 to 2013 and suggests that the Mental Health ...
[537]
Economic Effects of Legislations and Policies to Expand Mental ...
The history of their predictions is traced36 from the initial estimated increase in premiums of 4.0% predicted to follow the Mental Health Parity Act (MHPA) of ...
[538]
Unintended Consequences of Mental Health Parity Rule Jeopardize ...
Sep 9, 2024 · Rule will increase costs and risks while lowering standards of care.
[539]
Reducing the Economic Burden of Unmet Mental Health Needs | CEA
May 31, 2022 · The Federal Government covers some of the costs of treating mental health disorders. Around $280 billion were spent on mental health services ...Missing: responses | Show results with:responses
[540]
Strengthening State-Level Mental Health Policy During Uncertain ...
Jul 16, 2025 · Governors continue to work to ensure that mental and behavioral health services are available to individuals and families.
[541]
Federal Parity and Spending for Mental Illness - PMC - NIH
MHPAEA enforcement was associated with improvements in financial protection for the overall population of children with mental health conditions and among those ...
[542]
Animal Models of Neuropsychiatric Disorders - PMC - NIH
Here we review the current state of animal models of mental illness, with a focus on schizophrenia, depression, and bipolar disorder.
[543]
Meeting Report: Can We Make Animal Models of Human Mental ...
The importance of using animal models is that they make it possible to establish the underlying biology—which is not possible in humans—by manipulating specific ...
[544]
Criteria of validity for animal models of psychiatric disorders: focus ...
Nov 7, 2011 · Animal models of psychiatric disorders are usually discussed with regard to three criteria first elaborated by Willner; face, predictive and construct validity.<|separator|>
[545]
Criteria of validity for animal models of psychiatric disorders
Animal models of psychiatric disorders are usually discussed with regard to three criteria first elaborated by Willner; face, predictive and construct validity.
[546]
Encore: Behavioural animal models of stress, depression and mood ...
Animal studies over the past two decades have led to extensive advances in our understanding of pathogenesis of depressive and mood disorders.
[547]
Animal Models of Psychiatric Disorders and Their Relevance to ...
This section describes animal models for schizophrenia, depression, and fear and anxiety. The use of animal models to study alcoholism and co-occurring ...
[548]
An updated review on animal models to study attention-deficit ...
Apr 11, 2024 · Absence of BRINP1 in mice causes increase of hippocampal neurogenesis and behavioral alterations relevant to human psychiatric disorders.Animal Model And Criteria... · Coloboma Mice · Alpha-Synuclein Lacking Mice
[549]
Rodent models for psychiatric disorders: problems and promises
Apr 15, 2020 · In this mini-review, we highlight current challenges and promises of using rodent models in advancing science and drug development.
[550]
Are Animal Models Relevant in Modern Psychiatry? | Psychiatric Times
Animal models, in general, have not been subjected to the rigors of evidence-based medicine. Few systematic reviews or meta-analyses have been conducted to ...
[551]
Evaluating the validity of animal models of mental disorder
Nov 10, 2022 · This paper provides a historical analysis of a shift in the way animal models of mental disorders were conceptualized.
[552]
The smoke detector principle: Signal detection and optimal defense ...
The SDP can help guide clinical decisions about the use of medications to block responses such as anxiety, cough, vomiting, and fever. Such graded responses ...
[553]
Smoke detector - Randolph Nesse
The smoke detector principle provides a crucial guide for all clinical thinking about when it is safe to block defensive responses.Missing: depression | Show results with:depression
[554]
The smoke detector principle. Natural selection and the regulation of ...
The smoke detector principle is an essential foundation for making decisions about when drugs can be used safely to relieve suffering and block defenses.
[555]
Evolutionary psychiatry: foundations, progress and challenges - PMC
May 9, 2023 · Evolutionary medicine goes further to ask why natural selection left some traits vulnerable to malfunction. Evolutionary psychiatry answers that ...
[556]
Two Different Mismatches: Integrating the Developmental and ... - NIH
The evolutionary-mismatch hypothesis states that differences in stressors between the environment in which humans evolved and the current environment are ...Missing: illness | Show results with:illness
[557]
Full article: The matching problem for evolutionary psychiatry
May 15, 2024 · Mismatch – Mental disorders are naturally selected psychological mechanisms whose effects were adaptive for our ancestors but are no longer ...
[558]
Evolutionary psychiatry: foundations, progress and challenges - Nesse
May 9, 2023 · Evolutionary psychiatry may offer a new paradigm. It asks different questions, provides different kinds of explanations, and views disorders in a new way.What Evolution Can And Can't... · Anxiety And Its Disorders · Depression And Low Mood<|separator|>
[559]
[PDF] Nesse - 2015 - Evolutionary Psychology and Mental Health.pdf
An evolutionary per- spective does not compete with other theories that try to explain why some people have mental disorders and others do not. Instead, it asks ...
[560]
Psychosis as an Evolutionary Adaptive Mechanism to Changing ...
Jun 4, 2018 · One can therefore wonder why genes that make us vulnerable for psychotic disorders, occurring during fertile age, and decreasing fecundity (2), ...
[561]
An evolutionary life history approach to understanding mental health
Oct 1, 2020 · This article reviews the life history theory and its integration with mental disorders and then introduces representative research methods and ...Life History Theory · Longitudinal Design · Experimental Design